---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description. Covers Product description and Place of product in therapy. 377 evidence topics quoted from 152 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; BLA planned for 2027

> “BLA submission for barzolvolimab in CSU anticipated in 2027”
> “Treatment in both EMBARQ-CSU trials will continue to 52 weeks, and the Company anticipates a BLA submission in 2027.”

Source: [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)

> “Treatment will continue in both trials to 52 weeks, and a Biologics License Application (BLA) submission to the FDA is anticipated in 2027.”
> “We plan to present EMBARQ-CSU data at an upcoming medical meeting and submit a BLA to the FDA in 2027.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “The Company intends to present the EMBARQ-CSU data at an upcoming medical meeting and plans to submit a Biologics License Application (BLA) to the FDA in 2027.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Results support planned BLA submission in 2027”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Development phase: phase 3, with phase 3 treatment continuing to 52 weeks

> “Barzolvolimab is in Phase 3 development.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “The EMBARQ-CSU trials are ongoing, with treatment continuing through 52 weeks.”
> “The Phase 3 EMBARQ-CSU1 and CSU2 studies are ongoing. A BLA submission is planned for 2027.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.1-4"></a>

##### Additional phase 3 results anticipated in February 2027

> “Additional 24-week Phase 3 results anticipated in February 2027”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.1-5"></a>

##### Phase 3 topline results reported in September 2026

> “HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.”
> “Data cutoff: September 9, 2026”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.1-6"></a>

##### Phase 3 enrollment completed in February 2026

> “HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2.”
> “Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU”

Source: [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)

<a id="topic-2.1.1-7"></a>

##### Phase 3 trials initiated in July 2024

> “In July 2024, we initiated two Phase 3 studies of barzolvolimab in CSU.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-2.1.1-8"></a>

##### Phase 2 study: first participant dosed in June 2022

> “HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU).”

Source: [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)

<a id="topic-2.1.1-9"></a>

##### Subcutaneous formulation phase 1 study in healthy volunteers: first cohort dosed in September 2021

> “HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers.”

Source: [Celldex subcutaneous formulation study release (2021)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-initiation-cdx-0159-subcutaneous-formulation)

<a id="topic-2.1.1-10"></a>

##### Phase 1b study in chronic spontaneous urticaria: first participant dosed in October 2020

> “HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU).”
> “As previously presented, CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, indicative of systemic mast cell ablation in a Phase 1a single dose, healthy volunteer study.”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

<a id="topic-2.1.1-11"></a>

##### Development in other indications: cold urticaria, symptomatic dermographism, atopic dermatitis, prurigo nodularis, and eosinophilic esophagitis

> “Enrollment is ongoing in Celldex’s global Phase 3 study in cold urticaria (ColdU) and symptomatic dermographism (SD)—EMBARQ-ColdU and -SD.”
> “Enrollment is complete in the Phase 2 study in atopic dermatitis (AD).”
> “Topline data from this study are expected to be presented in late 2026.”
> “Topline data from the Phase 2 study in prurigo nodularis (PN) were presented in July 2026 and suggested that mast cells may not be the key pathogenic driver in PN. Based on these results, Celldex is discontinuing the Phase 2 PN study.”
> “Additional indications for barzolvolimab will be announced by year end.”

Source: [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)

> “today reported topline results from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.”
> “Based on these results, Celldex will not advance development in EoE.”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.1-12"></a>

##### FDA expedited program designations for chronic spontaneous urticaria

No evidence found.

<a id="topic-2.1.1-13"></a>

##### Patent protection: U.S. composition of matter patent with estimated expiry in 2034

> “A composition of matter patent has been issued in the U.S. which would have an estimated patent expiry date in 2034 (this includes additional term due to PTA, but does not include any PTE if this may be secured in due course) and further U.S. patent applications are pending.”
> “Where issued the foregoing would have estimated normal patent expiry dates ranging from 2032 to 2033.”
> “Further (later filed) patent applications (relating to Fc sequences used in barzolvolimab and certain uses of barzolvolimab) are pending in the U.S., the European Patent Office, Japan, Canada, China, Australia, New Zealand, Israel, India, the Republic of Korea, the Eurasian Patent Office, Singapore, Brazil, Mexico and South Africa. If, when and where issued the latter would have estimated normal patent expiry dates in 2042.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.1-14"></a>

##### Phase 3 topline timing, July 2026 to August 2026, superseded in September 2026

> “Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

> “Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027”

Source: [Celldex second quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-financial-results-and-provides)

<a id="topic-2.1.1-15"></a>

##### Phase 3 topline timing, February 2026 to June 2026, superseded in July 2026

> “Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027”

Source: [Celldex fourth quarter 2025 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-year-end-2025-financial)

> “Topline data expected Q4 2026”
> “BLA submission planned for 2027”

Source: [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)

> “Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027”

Source: [Celldex first quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-first-quarter-financial-results-and-provides)

> “Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026”
> “Topline data are anticipated in Q4 2026, supporting a planned BLA submission in 2027.”

Source: [Celldex EAACI 2026 angioedema release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-long-term-barzolvolimab-results-demonstrating)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Celldex Therapeutics

> “CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Celldex Therapeutics” |
| Official title | “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)” |

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.1-2"></a>

###### International nonproprietary name and description

| Field | Quoted record |
| --- | --- |
| INN list | “Proposed INN: List 125” |
| Latin name | “barzolvolimabum” |
| English name | “barzolvolimab” |
| Description | “extracellular domain], monoclonal antibody” |
| Expression system | “produced in Chinese hamster ovary (CHO) cells, glycoform alfa” |
| Functional class | “immunomodulator” |

Source: [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Development code: CDX-0159

> “Barzolvolimab (also referred to as CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is currently being studied across multiple mast cell driven diseases including:”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.1-4"></a>

###### Proprietary name

No evidence found.

<a id="topic-2.1.2.1-5"></a>

###### Therapeutic class: humanized IgG1 kappa anti-KIT monoclonal antibody

> “Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT and potently inhibits its activity.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Barzolvolimab (CDX-0159) is a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody (mAb) that binds the extracellular domain of KIT with high specificity and sub-nanomolar affinity, and allosterically inhibits activation by SCF.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

> “CDX‐0159 is a humanized IgG1/κ monoclonal antibody with a modified Fc domain that was derived from CDX‐0158, a predecessor anti‐KIT antibody with an unmodified IgG1/κ backbone.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “Barzolvolimab - KIT Inhibitor Program”

Source: [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Dosage form: 1 mL pre-filled syringes for subcutaneous administration

> “Drug product manufacturing into 1 mL pre-filled syringes has been completed and pre-filled syringes are actively being used in Phase 3 trials.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Our barzolvolimab drug product is currently administered subcutaneously.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.2-2"></a>

###### Strength and concentration per pre-filled syringe

No evidence found.

<a id="topic-2.1.2.2-3"></a>

###### Intravenous formulation in phase 1 studies and subcutaneous formulation for phase 2

> “The Company intends to utilize the subcutaneous formulation of CDX-0159 in its Phase 2 program in chronic urticarias, planned for initiation in the first half of 2022. Celldex is currently studying an intravenous formulation of CDX-0159 in Phase 1 studies in chronic spontaneous and chronic inducible urticarias and will initiate a third intravenous study in prurigo nodularis later this year.”

Source: [Celldex subcutaneous formulation study release (2021)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-initiation-cdx-0159-subcutaneous-formulation)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication studied in phase 3: adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment

> “The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”
> “The EMBARQ-CSU1 and EMBARQ-CSU2 studies are the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “The studies, EMBARQ-CSU1 and EMBARQ-CSU2, are designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.5-2"></a>

###### Prior biologic experience permitted in the phase 3 trials

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment”
> “Participants with and without prior biologic experience are eligible.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

> “The studies will also include patients who remain symptomatic after treatment with biologics.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Humanized monoclonal antibody that binds KIT and blocks SCF binding and KIT dimerization

> “Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT and potently inhibits its activity.”
> “KIT is expressed in a variety of cells, including mast cells, and its activation by its ligand SCF regulates mast cell growth, differentiation, survival, chemotaxis and degranulation.”
> “Barzolvolimab is designed to block KIT activation by disrupting both SCF binding and KIT dimerization.”
> “By targeting KIT, barzolvolimab has been shown to inhibit mast cell activity and decrease mast cell numbers, which we believe could provide potential clinical benefit in mast cell related diseases.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Barzolvolimab is a humanized monoclonal antibody with a novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity.”
> “The KIT receptor is abundantly expressed by mast cells and critical for their function and survival.”
> “Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.6.1-2"></a>

###### Allosteric inhibition through the membrane-proximal dimerization domains of KIT

> “CDX‐0159 is a humanized IgG1/κ monoclonal antibody with a modified Fc domain that was derived from CDX‐0158, a predecessor anti‐KIT antibody with an unmodified IgG1/κ backbone.”
> “The antibody was developed from mice immunized with the membrane proximal dimerization domains (Ig 4 and 5) of human KIT (huKIT‐D4D5), which are required for KIT activation by SCF but are not directly involved in ligand binding.”
> “CDX‐0159 bound to KIT naturally expressed in the surface of megakaryoblastic leukemia M‐07e cells with an EC50 of 153 ± 22 pM (Figure 1B), and completely blocked binding of fluorescently labeled SCF to M‐07e cells with an IC50 value of 118 ± 6 pM (Figure 1C).”
> “CDX‐0159 allosterically blocks binding of SCF to KIT, which may result in an elevation of SCF plasma levels from accumulating unbound SCF.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “Barzolvolimab (CDX-0159) is a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody (mAb) that binds the extracellular domain of KIT with high specificity and sub-nanomolar affinity, and allosterically inhibits activation by SCF.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-3"></a>

###### Selectivity and inhibition of SCF-dependent KIT phosphorylation and mast cell degranulation

> “Furthermore, CDX‐0159 bound specifically to KIT but not to other related type‐III receptor tyrosine kinases (Figure S2).”
> “Similarly, titration of CDX‐0159 on CHO cells stably transfected to express human KIT (CHO‐KIT) inhibited SCF‐dependent KIT phosphorylation (Figure 1D) with an IC50 of 232 ± 4 pM, or 2–3 orders of magnitude more potently than FDA‐approved KIT‐targeting TKIs imatinib, pexidartinib, and avapritinib (IC50 = 931 ± 78 nM, 87 ± 7 nM, and 175 ± 59 nM, respectively).”
> “In this assay, CDX‐0159 titration fully inhibited SCF‐dependent MC degranulation (IC50 = 650 ± 88 pM) (Figure 1F).”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.6.1-4"></a>

###### Fc substitutions that abolish effector function and reduce clearance

> “To eliminate the potential for FcγR crosslinking and effector functions, we engineered 3 amino acid substitutions (L234A/L235Q/K322Q) in the Fc region of CDX‐0158 predicted to abolish FcγR binding and expected to similarly impact C1q receptor binding.”
> “In addition, we also incorporated a set of modifications (M252Y/S254T/T256E)—herein named YTE—that increase the binding affinity for the neonatal Fc receptor (FcRn) which enhances the pharmacokinetic (PK) properties of the mAb by reducing the rate of in vivo clearance.”
> “Taken together, these data demonstrate that the Fc modifications in CDX‐0159 effectively abolish Fc‐dependent effector function and agonist activity leading to MC degranulation.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “Modifications to the Fc fragment of barzolvolimab eliminated FcγR binding and the potential for significant infusion-related reactions through Fc-mediated MC activation, and enhanced antibody serum exposure in non-human primates.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-5"></a>

###### KIT expression on mast cells and on other cell types

> “The KIT (c‐KIT/CD117) receptor tyrosine kinase and its only ligand stem cell factor (SCF) are master regulators of MC biology.”
> “KIT is highly expressed throughout the life of a MC and is also expressed in hematopoietic stem cells, melanocytes, interstitial cells of Cajal, germ cells, and a subset of taste receptor cells.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “KIT activation by SCF in follicular melanocytes participates in their terminal differentiation and maturation but is not expressed in melanocyte stem cells.”
> “Similarly, KIT expression has been reported in mature T1R3-positive type II taste cells”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-6"></a>

###### Mast cell depletion as the hypothesized basis of benefit in CSU

> “Barzolvolimab—a monoclonal anti‐KIT antibody—depletes MCs by inhibiting activation of KIT by stem cell factor.”
> “Barzolvolimab, as a potent inhibitor of SCF‐dependent KIT activation in cells, is hypothesized to provide therapeutic benefit in patients with CSU by decreasing the number of MCs and their activity.”
> “These results support the anti‐KIT mechanism of action for treating CSU.”
> “Patients had similar symptom improvement irrespective of prior omalizumab use, suggesting that barzolvolimab can help improve urticaria symptoms regardless of whether IgE is the underlying trigger.”
> “The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.1-7"></a>

###### Wild-type and KITD816V mast cell models: apoptosis and SCF-enhanced IgE-mediated activation

> “We established and characterized primary-like human MC models, including isogenic human induced pluripotent stem cell-derived WT and heterozygous KITD816V MCs, peripheral CD34+ stem cell-derived MCs, and HMC-1.2 cell line.”
> “Barzolvolimab induced dose-dependent apoptosis and inhibited stem cell factor-induced KIT signaling in WT MCs, but it had no effect on mutant MC viability or signaling.”
> “Notably, barzolvolimab effectively suppressed stem cell factor-enhanced IgE-mediated MC activation across all primary-like models, including KITD816V MCs, as evidenced by reduced β-hexosaminidase release and CD63 expression.”
> “This inhibitory effect occurred at low nanomolar concentrations and was independent of cytotoxicity.”

Source: [Hu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42697278/)

<a id="topic-2.1.2.6.1-8"></a>

###### Cold urticaria and symptomatic dermographism: skin mast cells as the effector cells

> “This study also highlights the striking reliance of skin mast cells on KIT/SCF signaling and provides the first direct demonstration that skin MCs are the key effector cells in ColdU and SD.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.1-9"></a>

###### Eosinophilic esophagitis: mast cell depletion without improved clinical outcomes

> “Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract”
> “Profound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.2.6.1-10"></a>

###### Prurigo nodularis: mast cell depletion without improvement in itch or skin lesions

> “Profound mast cell depletion as evidenced by significant reduction in serum tryptase was observed and did not result in improvement in itch or skin lesions in patients with PN compared to placebo, indicating mast cells may not be a key pathogenic driver of symptoms in PN.”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Serum tryptase and plasma SCF in CSU: phase 1b, intravenous dosing every 4 or 8 weeks

> “Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9).”
> “Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B).”
> “Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation.”
> “Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).”
> “The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.”
> “All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.2-2"></a>

###### Serum tryptase depletion in the phase 2 CSU trial

> “In a Phase 2 study in patients with H1-antihistamine-refractory CSU (NCT05368285), barzolvolimab, a highly potent, first-in-class anti-KIT monoclonal antibody, demonstrated rapid, profound, and durable depletion of serum tryptase, with corresponding improvements in clinical symptoms”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### Baseline serum tryptase in CSU compared with healthy participants, and response by baseline tryptase: phase 2 post hoc analysis

> “Mean baseline serum tryptase levels were compared between pooled barzolvolimab studies in patients with CSU (n=239) and healthy participants (n=94)”
> “Exploratory, post hoc efficacy analyses from the Phase 2, double-blind, placebo-controlled study (NCT05368285) assessed the association of baseline serum tryptase with baseline disease severity and response to barzolvolimab at Week 12 and Week 52 in patients with H1-antihistamine-refractory CSU”
> “Patients with CSU had higher mean (range) baseline serum tryptase than HV (5.8 [<1-36.2] vs 4.2 [1.1-21.2] ng/mL)”
> “Baseline serum tryptase levels were higher among patients with CSU than healthy participants, consistent with increased MC burden or activation as a driver of disease”
> “Baseline serum tryptase was not associated with baseline disease severity nor was predictive of barzolvolimab response”
> “Barzolvolimab demonstrated clinical benefits for patients with CSU regardless of their baseline serum tryptase levels”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

| Timepoint | Response definition | Area under the ROC curve for baseline serum tryptase |
| --- | --- | --- |
| Week 12 | UAS7 = 0 | “0.49” |
| Week 12 | UAS7 ≤6 | “0.53” |
| Week 52 | UAS7 = 0 | “0.51” |
| Week 52 | UAS7 ≤6 | “0.56” |

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Tryptase recovery during the 24-week follow-up period of the phase 2 CSU trial

> “In a Phase 2 trial of patients with antihistamine-refractory CSU treated with barzolvolimab (150 mg Q4W or 300 mg Q8W for 1 year), 71% had well controlled disease at the end of the treatment period”
> “Following a 52-week total treatment period, patients entered a 24-week follow-up period”
> “Analyses on barzolvolimab concentrations versus urticaria activity scores and circulating tryptase, a soluble mast cell marker, were conducted.”
> “Tryptase recovers towards range of healthy subjects by week 76 indicating normal mast cell numbers”
> “Despite gradual decreasing concentration of barzolvolimab and tryptase recovery, mean UAS7 scores remained low”
> “Sustained off-treatment efficacy was observed despite barzolvolimab clearance and normalization of tryptase”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Serum tryptase and plasma SCF in healthy volunteers: single intravenous doses

> “A single ascending dose (0.3, 1, 3, and 9 mg/kg), double‐blinded placebo‐controlled phase 1a human healthy volunteer study (n = 32) was conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX‐0159.”
> “A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).”
> “Tryptase reduction was manifest in all subjects dosed with CDX‐0159 at 24 h after the infusion.”
> “At the lowest dose of 0.3 mg/kg, plasma tryptase was reduced by approximately 50%, including the subject with high baseline tryptase.”
> “At higher doses, tryptase levels were reduced below the lower limit of assay quantitation (LLoQ) (1 ng/ml) in all CDX‐0159 treated subjects for at least 3 weeks at 1 mg/kg, 6–14 weeks at 3 mg/kg and over 18 weeks at 9 mg/kg (Figure 4B and Figure S10).”
> “No significant change in tryptase was observed in the placebo group.”
> “We observed dose‐proportional increases in SCF levels that mirrored the effects of CDX‐0159 on plasma tryptase.”
> “Together with the effect of the antibody on tryptase levels, these data provide additional evidence of systemic KIT saturation with CDX‐0159 at doses of 1 mg/kg and above.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.6.2-6"></a>

###### Serum tryptase in healthy volunteers: single subcutaneous doses

> “A randomized, double-blind, placebo-controlled, Phase 1 study designed to evaluate the safety of single ascending doses of the subcutaneous formulation of CDX-0159 has been conducted in healthy volunteers.”
> “Importantly, subcutaneous delivery of CDX-0159 resulted in dose-dependent, rapid and sustained decreases in serum tryptase compared with placebo and achieved sufficient exposure to produce tryptase suppression levels comparable with the levels that generated impressive clinical activity observed in the Phase 1 chronic inducible urticaria IV study.”

Source: [Celldex fourth quarter 2021 results release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-full-year-2021-financial)

<a id="topic-2.1.2.6.2-7"></a>

###### Cold urticaria and symptomatic dermographism: skin mast cell depletion, tryptase, and SCF after one 3 mg/kg intravenous dose

> “This is an open-label, trial in patients with antihistamine refractory ColdU or SD, receiving one IV dose of barzolvolimab (3 mg/kg), with a 12-week follow-up.”
> “Treatment resulted in significant depletion of skin MCs, decreased tryptase (<limit of detection), and increased soluble SCF through Week 12.”
> “The concomitant increase in circulating SCF as a result of KIT blockade by barzolvolimab is indicative of KIT engagement in tissues (Figure 1B,C).”
> “Skin MC reduction was observed and independently assessed by staining for tryptase (89% decrease at Week 12) and CD117 (KIT; 87% decrease at Week 12; Figure 1G,H).”
> “The kinetics of serum tryptase reduction correlated with that of CD117-positive and tryptase-positive skin MC numbers, demonstrating circulating tryptase is a surrogate marker for skin MC number (Figure S2).”
> “There was no change from baseline in epidermal CD117 (KIT+) melanocytes at any timepoint (Figure 1F).”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.6.2-8"></a>

###### Chronic inducible urticaria: kinetics of skin mast cell depletion and repopulation to Week 36

> “Patients with two forms of CIndU (SD; n = 10 and ColdU; n = 10) received a single 3 mg/kg intravenous dose of barzolvolimab.”
> “As early as 1 week following drug administration, MC numbers rapidly decreased, reaching approximately 90% reduction after 8 weeks and with similar kinetics as reductions in serum tryptase and clinical symptoms (Figure S3).”
> “MCs only recovered partially 36 weeks after dosing (31% for tryptase and 38% for CD117 from baseline), suggesting that MCs can repopulate skin, albeit very slowly.”
> “In contrast to IHC data, MC transcripts completely recovered by Week 36 (Figure 2A) and the kinetics closely mirrored that of clinical symptoms and serum tryptase (Figure 2B–D).”
> “Our data demonstrate that KIT‐dependent MC reduction is fully reversible and that mature and reactive MCs repopulate skin from MC progenitors within several weeks following their depletion.”

Source: [Alvarado et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12862557/)

> “A single dose of barzolvolimab led to marked decreases in tryptase and in skin mast cells.”
> “This confirmed that serum tryptase level is a robust pharmacodynamic biomarker for assessing mast cell burden and clinical activity in inducible urticaria and potentially in other diseases with mast cell driven involvement.”
> “Serum tryptase exhibits a similar rate of recovery as clinical symptoms, while skin mast cells return at a slower rate.”
> “Tissue KIT signaling, as approximated by SCF levels, was rapidly inhibited after dose administration and fully reactivated approximately 18 weeks after dosing.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.6.2-9"></a>

###### Eosinophilic esophagitis: esophageal intraepithelial mast cell counts at Week 12, phase 2

> “This randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE.”
> “65 patients were randomly assigned on a 1:1 ratio to receive subcutaneous injections of barzolvolimab at 300 mg every 4 weeks or placebo during a 16-week placebo-controlled treatment phase.”
> “Peak mast cell counts (CD117 positive cells) per high power field (hpf) at baseline were 50.3 in the placebo arm and 55.4 in the barzolvolimab 300mg Q4W arm.”
> “At Week 12 the absolute change from baseline was -2.7 for placebo compared to -36.0 for barzolvolimab [Diff (95%CI): -33.3 (-44.1, -22.6); p=<0.0001)].”
> “Mast cells defined by tryptase staining also showed profound decreases at week 12 in barzolvolimab treated patients with sustained and deepening decreases observed at Week 28.”
> “Despite profound mast cell depletion, no definitive evidence of clinical improvement in EoE symptoms, as measured by the Dysphagia Symptom Questionnaire (DSQ) (p=0.33), or endoscopic scoring of EoE-related inflammation & fibrosis (EREFS) (p=0.95) were observed compared to placebo.”
> “There was also no difference observed in histological reduction in esophageal intraepithelial infiltration of eosinophils (p=0.57).”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.2.6.2-10"></a>

###### Prurigo nodularis: serum tryptase with a 450 mg loading dose, phase 2

> “This Phase 2 randomized, double-blind, placebo-controlled, parallel group study evaluated barzolvolimab compared to placebo in patients with moderate to severe PN who had inadequate response to prescription topical medications, or for whom topical medications were medically inadvisable.”
> “140 patients were randomly assigned to receive barzolvolimab 150mgQ4W after an initial loading dose of 450mg, 300mgQ4W after an initial loading dose of 450mg, or placebo during a 24-week Treatment Phase.”
> “The study did not meet primary or key secondary endpoints at Week 12 at either dose level evaluated.”
> “Rapid and profound suppression of circulating tryptase, indicative of systemic mast cell depletion, was observed.”
> “The addition of the 450mg loading dose led to early, profound tryptase reduction that was sustained over the duration of the treatment period.”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

<a id="topic-2.1.2.6.2-11"></a>

###### Prurigo nodularis: serum tryptase and plasma SCF after a single intravenous dose

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “Serum tryptase levels declined rapidly in a dose-dependent manner in barzolvolimab-treated participants”
> “Most 3.0 mg/kg barzolvolimab-treated participants experienced tryptase suppression below the levels of assay detection by week 8, with plasma stem cell factor increases mirroring tryptase suppression kinetics”
> “Greater efficacy observed with the 3.0 mg/kg dose suggests that profound and sustained tryptase reduction may be needed to maximize clinical benefit in PN.”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.6.2-12"></a>

###### Nonclinical toxicology in cynomolgus monkeys: bone marrow, red blood cell mass, and hair color

> “To support human trials, a GLP‐compliant toxicology study was performed with CDX‐0159 in cynomolgus monkeys with dose levels of 1, 10, and 75 mg/kg administered every two weeks for 13 weeks.”
> “CDX‐0159 was well tolerated with no significant changes in body weight, coagulation, clinical chemistry, ophthalmology, electrocardiography, respiratory, or neurological function during the treatment and recovery period.”
> “Observations attributed to CDX‐0159‐included minimal increases in the myeloid to erythroid ratio in bone marrow smears in the animals dosed at 10 and 75 mg/kg at the end of dosing (day 85), with evidence of recovery by day 141 despite continued drug exposure in the recovery period (Figure 2B).”
> “In addition, recoverable minimal/mild decreases in red blood cell mass parameters were observed (Figure 2C).”
> “Hair color changes were noted in some high‐dose‐treated animals, consistent with inhibition of KIT activity in follicular melanocytes.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

Additional sources: [Moñino-Romero et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439351/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Healthy volunteers, single intravenous doses: dose-proportional exposure and terminal half-life

> “A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).”
> “CDX‐0159 serum levels were dose proportional and indicative of a PK profile with high exposure and long half‐life at higher doses, consistent with the expected effects of the YTE substitutions (Figure 4A and Table S2).”
> “Mean terminal phase half‐life increased from 15 days at 0.3 mg/kg to 32 days at 9 mg/kg, which exceeds the average expected half‐life of 10–21 days for human IgG”
> “Results indicate a PK profile and volume of distribution consistent with those of a monoclonal antibody through this dosing range with evidence of target mediated clearance below approximately 5 μg/ml.”
> “For example, the terminal half‐life of CDX‐0159 at a single 3 mg/kg dose was 23 days and was accompanied with tryptase suppression for >6 weeks.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “This study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159 in healthy subjects.”

Source: [ClinicalTrials.gov NCT04146129](https://clinicaltrials.gov/study/NCT04146129)

<a id="topic-2.1.2.6.3-2"></a>

###### Healthy volunteers, single subcutaneous doses of 50 to 600 mg

> “The randomized, double-blind, placebo-controlled Phase 1 study will evaluate single ascending doses of CDX-0159 administered subcutaneously in healthy volunteers.”
> “Thirty two subjects will be enrolled across four dosing cohorts (50 mg, 150 mg, 300 mg and 600 mg) with 8 subjects in each cohort (6 active; 2 placebo).”
> “The primary endpoints of the study are safety and tolerability; secondary endpoints include pharmacokinetics, pharmacodynamics (circulating tryptase and stem cell factor) and immunogenicity.”

Source: [Celldex subcutaneous formulation study release (2021)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-initiation-cdx-0159-subcutaneous-formulation)

> “CDX-0159 serum concentrations will be measured at specified visits”
> “Patients will be monitored for the development of anti-drug antibodies.”

Source: [ClinicalTrials.gov NCT05031624](https://clinicaltrials.gov/study/NCT05031624)

> “Multiple dose levels have been identified that possess promising pharmacokinetic and pharmacodynamic properties.”
> “Celldex anticipates the upcoming Phase 2 multi-dose studies in urticaria will evaluate 75mg and 150mg administered q4weeks and 300mg administered q8weeks.”
> “The planned doses support a 0.5 to 2 ml injection volume, allowing for a single injection as CDX-0159 advances towards potential commercialization.”

Source: [Celldex fourth quarter 2021 results release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-full-year-2021-financial)

<a id="topic-2.1.2.6.3-3"></a>

###### Subcutaneous bioavailability, time to peak concentration, and half-life

No evidence found.

<a id="topic-2.1.2.6.3-4"></a>

###### Nonclinical pharmacokinetics in cynomolgus macaques: effect of the YTE substitutions

> “Consistent with previously published data with antibodies harboring YTE mutations, the pharmacokinetic properties of CDX‐0159 in cynomolgus macaques were indeed enhanced relative to CDX‐0158”
> “terminal half‐life (22 ± 5.8 vs. 4.8 ± 3.5 days)”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.6.3-5"></a>

###### CSU, multiple doses: dose-linear exposure, accumulation, and target saturation

> “Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).”
> “PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings.”
> “Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A).”
> “Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1).”
> “Increased clearance and lower volumes of distribution were observed in patients who received lower doses.”
> “Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.”
> “Target saturation was observed with a durable clinical response and tryptase suppression with doses ≥ 1.5 mg/kg.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.3-6"></a>

###### Chronic inducible urticaria, single 3 mg/kg intravenous dose: clearance, half-life, volume of distribution, and time to clearance

> “Single-dose barzolvolimab administration exhibited a slow rate of clearance (2.7 ± 0.9 ml/day/kg) and a terminal half-life of 20.1 ± 7.1 days, consistent with engineered half-life extending mutations.”
> “The volume of distribution in the terminal phase was 70.9 ± 7.1 ml/kg or approximately 4.9 L in a 70 kg human.”
> “There were no differences in PK parameters between CU and SD patients and exposure was very similar to that observed in healthy volunteers (Figure 1A).”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

> “Barzolvolimab pharmacokinetics in patients with CIndU (N = 20) following a single 3 mg/kg intravenous dose.”
> “Drug levels reach approximately 1 μg/mL by Week 12, as MC markers and clinical symptoms start to recover.”
> “Barzolvolimab is fully cleared after Week 18.”

Source: [Alvarado et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12862557/)

<a id="topic-2.1.2.6.3-7"></a>

###### Prurigo nodularis, single intravenous dose: terminal half-life and exposure by sex, weight, and antidrug antibody status

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “The mean terminal phase half-life was 10.2 ± 3.0 days in 1.5 mg/kg and 18.0 ± 6.9 days in 3.0 mg/kg barzolvolimab-treated participants”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.6.3-8"></a>

###### CSU: barzolvolimab concentrations during the 24-week follow-up period of the phase 2 trial

> “In a Phase 2 trial of patients with antihistamine-refractory CSU treated with barzolvolimab (150 mg Q4W or 300 mg Q8W for 1 year), 71% had well controlled disease at the end of the treatment period”
> “Following a 52-week total treatment period, patients entered a 24-week follow-up period”
> “Concentration of barzolvolimab falls below therapeutic levels by week 64”
> “Maintenance of well-controlled disease despite subtherapeutic concentrations of barzolvolimab”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-2.1.2.6.3-9"></a>

###### Immunogenicity: treatment-emergent antidrug antibodies and their effect on exposure and safety

> “The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively.”
> “Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.”
> “Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.”
> “Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.6.3-10"></a>

###### Immunogenicity in the phase 2 and phase 3 CSU trials

No evidence found.

Additional sources: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information for Barzolvolimab

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

###### Adverse events through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “Adverse Events Through 24 Week Placebo Controlled Period (AEs observed in > 3% of patients)”
> “Pooled EMBARQ-CSU1 and EMBARQ-CSU2”
> “On barzolvolimab, the vast majority of AEs are mild to moderate”
> “Rate of SAEs similar across treatment groups”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Adverse event, n (%) | Placebo Q4W | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W |
| --- | --- | --- | --- |
| Participants (N) | “N=645” | “N=648” | “N=641” |
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

> “Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior experience through the end of the placebo controlled period at Week 24.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.7.1-3"></a>

###### Anaphylaxis adjudication through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2

> “Adverse Events Through 24 Week Placebo Controlled Period (AEs observed in > 3% of patients)”
> “Pooled EMBARQ-CSU1 and EMBARQ-CSU2”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

| Anaphylaxis | Placebo Q4W | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W |
| --- | --- | --- | --- |
| Participants (N) | “N=645” | “N=648” | “N=641” |
| Adjudicated as probable (G4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Other (events in the footnotes below) | “1” | “1” | “3” |

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

> “G3 anaphylaxis adjudicated as unlikely”
> “G2 angioedema/throat tightness/urticaria”
> “G3 anemia/neutropenia;”
> “G2 malaise/dyspnea/chest pain;”
> “G3 anaphylaxis after placebo administration”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.7.1-4"></a>

###### Anaphylaxis adjudication: phase 2 in cold urticaria and symptomatic dermographism

> “Here we report the primary analysis (Week 12) of a Phase 2 study evaluating the efficacy and safety of barzolvolimab compared with placebo in patients with cold urticaria and symptomatic dermographism whose disease is inadequately controlled by antihistamines (NCT05405660)”
> “Single treatment related SAE (anaphylaxis) reviewed by independent expert adjudication panel who concluded there was no evidence of anaphylaxis”

Source: [Maurer et al. (2024e)](https://celldex.com/wp-content/uploads/2025/06/Barzolvolimab_Phase-2-ClndU_ACAAI_FINAL.pdf)

<a id="topic-2.1.2.7.1-5"></a>

###### Anaphylactic reaction: prurigo nodularis phase 1b, 3.0 mg/kg intravenous dose

> “We have expanded clinical development of barzolvolimab into prurigo nodularis (PN).”
> “We have completed a Phase 1b multi-center, randomized, double-blind, placebo-controlled intravenous study in PN.”
> “During the initial 8 week observation period in the 3.0 mg/kg dosing arm, an anaphylactic reaction occurred in a complicated patient with multiple comorbidities; the event fully resolved without sequelae.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.7.1-6"></a>

###### Neutropenia and infection rates: phase 3

> “Barzolvolimab Did Not Lead to Increased Rate of Infections”
> “No increased rates of infection in barzolvolimab vs placebo treatment groups”
> “Placebo: 23.9%”
> “150 mg Q4W: 24.4%”
> “300 mg Q8W: 23.6%”
> “Rates of neutropenia in Phase 3 were consistent with Phase 2”
> “Placebo: 0.6%”
> “150 mg Q4W: 9.1%”
> “300 mg Q8W: 11.7%”
> “Neutropenia Not Associated with Increased Incidence of Infections”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.7.1-7"></a>

###### Hematologic laboratory decreases: phase 1b intravenous dosing in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks”
> “Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.”
> “The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections. Decreases in hematologic parameters were consistent with observations in healthy volunteers [10] and patients with chronic inducible urticaria [7] who received a single barzolvolimab dose.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-8"></a>

###### Hair color and skin pigmentation changes: phase 2 through Week 76

> “The objective of this analysis was to assess the rate and reversibility of pigmentation changes over 76 weeks in patients with CSU treated with barzolvolimab”
> “204 patients received ≥1 dose of barzolvolimab (any dose) and were included in this analysis”
> “Hair color changes (hypopigmentation) occurred in 49 (24%) patients; 96% of hair color changes were mild (Grade 1). Mean time to onset was ≈4 months, with 91% of evaluable patients reporting resolution of hair color change by the end of study participation”
> “Skin hypopigmentation occurred in 36 (18%) patients and events were mostly mild (94%; Grade 1); mean onset was ≈9 months, with 68% of evaluable patients reporting resolution by data cutoff”
> “Skin hyperpigmentation occurred in 6 (3%) patients, all of whom reported the events as mild (Grade 1); mean time to onset was ≈5 months, with 67% of evaluable patients reporting resolution by data cutoff”
> “Overall, 19 (9%) of patients reported concomitant hair color changes and skin hypopigmentation; 4 (2%) reported hair color changes and concomitant skin hyperpigmentation”
> “KIT-mediated hair color and skin pigmentation changes were observed in a subset of patients and were generally mild and reversible”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

| Characteristic | Hair color changes | Skin hypopigmentation | Skin hyperpigmentation |
| --- | --- | --- | --- |
| Participants with the event | “n=49” | “n=36” | “n=6” |
| Grade 1, n (%) | “47 (96)” | “34 (94)” | “6 (100)” |
| Time to onset from start of barzolvolimab, days, mean (range) | “137 (7-397)” | “271 (107-424)” | “156 (11-283)” |
| Resolved at the time of data cutoff, n (%) | “40 (91)” | “19 (68)” | “4 (67)” |
| Time to resolution on treatment, days, median (95% CI) | “209 (119, 231)” | “110 (60, 120)” | “25 (7, NE)” |
| Time to resolution off treatment, days, median (95% CI) | “168 (138,189)” | “214 (196, 285)” | “NE” |
| Discontinued study treatment due to event, n (%) | “6 (3)” | “0 (0)” | “1 (<0.5)” |

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-2.1.2.7.1-9"></a>

###### Hair color changes: chronic inducible urticaria phase 1b

> “This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.”
> “First appearance of hair color change was reported 4–6 weeks post-treatment. Affected areas were mainly head hair, eyebrows, eyelashes and in men beard hair as well as body hair in some patients. The hair color change was transient and improved over time with new hair growth at about 10–12 weeks post-treatment, with complete resolution over time during a follow-up. Overall, the hair color changes were considered mild and not burdensome to patients.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.7.1-10"></a>

###### Taste changes: chronic inducible urticaria phase 1b

> “This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.”
> “Taste changes include ageusia and hypogeusia.”
> “Taste changes were reported by patients as being selective for umami and salty flavor. All patients experiencing taste changes reported the ability to taste, but less intensively and the loss of intensity varied between patients. Changes were all transient and improved gradually with complete resolution within 12 weeks after treatment in most patients. Given the quick resolution, patients did not report impairment of quality of life by the taste changes.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.7.1-11"></a>

###### Taste changes: phase 1b in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Taste changes, as noted in prior barzolvolimab studies, were reported by three patients (< 10%).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-12"></a>

###### Infections: phase 1b in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-13"></a>

###### Treatment discontinuations for adverse events: phase 2 through Week 52

> “Patient Disposition Through 52 Weeks”
> “Placebo and 75mg Q4W re-randomized to 150mg Q4W or 300mg Q8W at Week 16”
> “Adverse event discontinuations in more than one patient: hair color changes (6), urticaria (5), macrocytic anemia (2)”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

| Disposition, n (%) | Barzolvolimab 75 mg Q4W, then 150 mg or 300 mg | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | Placebo, then barzolvolimab 150 mg or 300 mg |
| --- | --- | --- | --- | --- |
| Randomized | “n=53” | “n=52” | “n=52” | “n=51” |
| Discontinued treatment | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Discontinued for an adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Discontinuation due to pigmentation changes was low (hair color changes: 3%, n=6; skin hypopigmentation, n=0; skin hyperpigmentation: <0.5%, n=1 )”
> “Discontinuations due to pigmentation changes were uncommon, suggesting these changes were tolerable for patients”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-2.1.2.7.1-14"></a>

###### Reversibility off treatment: phase 2 follow-up to Week 76

> “Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. No new safety signals were identified during the follow-up period. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Here we present the efficacy and safety of barzolvolimab during the 24-week follow up period”
> “Barzolvolimab was well tolerated with no new safety findings identified during follow up period”
> “These events were generally mild (grade 1), KIT-mediated and reversible”
> “Neutropenia/neutrophil count events resolved while on treatment and were not associated with infection”
> “Resolution of hair color changes and skin hypopigmentation observed following discontinuation of treatment”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-2.1.2.7.1-15"></a>

###### Reversibility off treatment: chronic inducible urticaria phase 1b follow-up through Week 36

> “Long term follow up data was collected from the 3.0 mg/kg cohorts in cold urticaria and symptomatic dermographism.”
> “Data were collected at one or more timepoints beyond Week 12 through Week 36.”
> “Drug related adverse events noted during the study all resolved.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.7.1-16"></a>

###### Phase 2 adverse events through Week 12

> “We have completed a Phase 2 study in patients with CSU who remained symptomatic despite antihistamine therapy.”
> “Barzolvolimab was well tolerated with a favorable safety profile. Most adverse events were mild to moderate in severity; through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were urticaria/CSU (10%), hair color changes (9%), and neutropenia/ANC decrease (8%). The rate of infections was similar between barzolvolimab treated patients and placebo with no association between neutropenia and infections.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.7.1-17"></a>

###### Phase 2 most common adverse events across doses

> “Adults with antihistamine-refractory CSU (urticaria activity score over 7 days [UAS7] ≥ 16) in a phase 2 double-blind placebo-controlled trial were randomized 1:1:1:1 to receive barzolvolimab 75 mg every 4 weeks (n = 53); 150 mg every 4 weeks (n = 52); 300 mg every 8 weeks (n = 51); or placebo (n = 51).”
> “All doses of barzolvolimab were well tolerated, with urticaria and hair color change as the most common adverse events in barzolvolimab-treated patients.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-2.1.2.7.1-18"></a>

###### Phase 2 adverse events: placebo-controlled period to Week 16 and treatment period to Week 52

> “Barzolvolimab was well tolerated through 52 weeks of treatment”
> “Placebo Controlled Period (16 weeks)”
> “All dose levels (75mgQ4W, 150mgQ4W, 300mgQ8W) combined”
> “All dose levels combined; patients randomized to 75mgQ4W were re-randomized to 150mgQ4W or 300mgQ8W at week 16”
> “Patients received 36 weeks of barzolvolimab 150mgQ4W or 300mgQ8W after 16 weeks of placebo; data are shown for 36 week barzolvolimab experience”
> “SAEs of worsening urticaria symptoms”
> “Most events were grade 1 (mild), mechanism-related (KIT) and expected to be reversible”
> “Adverse events were not dose dependent”
> “No association between infections and neutropenia/decreased neutrophil counts”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

| Participants, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 | Placebo, Weeks 0 to 16 | Barzolvolimab, all doses, Weeks 0 to 52 | Placebo then barzolvolimab, 36 weeks of barzolvolimab |
| --- | --- | --- | --- | --- |
| Participants (N) | “N= 156” | “N= 51” | “N= 156” | “N=48” |
| At least one adverse event | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment-related serious adverse events | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia or neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Barzolvolimab was well tolerated with a favorable safety profile through 52 weeks of treatment. Most adverse events were grade 1 (mild), mechanism related (KIT) and expected to be reversible. The most common treatment emergent adverse events occurring in greater than 10% of barzolvolimab treated patients were hair color changes, neutropenia, urticaria, skin hypopigmentation (areas of skin lightening) and nasopharyngitis (common cold). Neutrophil counts did not decline further with continued dosing and there was no association between infections and neutropenia. The hypopigmentation was observed with longer term exposure and did not lead to treatment discontinuation. Adverse events were not dose dependent.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.7.1-19"></a>

###### Phase 1b adverse events at 24 weeks: intravenous dosing in chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks”
> “TEAEs reported by system organ class and preferred term in ≥ 10% barzolvolimab‐treated patients at 24 weeks.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

| Treatment-emergent adverse event, n (%) | All barzolvolimab | Pooled placebo |
| --- | --- | --- |
| Participants (N) | “N = 35” | “N = 10” |
| Any treatment-emergent adverse event | “30 (86)” | “6 (60)” |
| Neutropenia | “5 (14)” | “0 (0)” |
| Leukopenia | “3 (9)” | “0 (0)” |
| Headache | “5 (14)” | “2 (20)” |
| Hair color changes | “9 (26)” | “0 (0)” |

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.”
> “Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.”
> “Most AEs were mild or moderate in severity and resolved while on study. One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-20"></a>

###### Immunogenicity: antidrug antibodies in phase 1b chronic spontaneous urticaria

> “This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.”
> “Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.”
> “Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.”
> “Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.7.1-21"></a>

###### Immunogenicity: antidrug antibody status and exposure after a single intravenous dose in prurigo nodularis

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.7.1-22"></a>

###### Immunogenicity: risk factor text on antibodies against biologics

> “In addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by our product candidates, the administration of biologics frequently causes an immune response, sometimes resulting in the creation of antibodies against the drug candidate which can impact the safety and/or efficacy associated with the treatment.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.7.1-23"></a>

###### Chronic inducible urticaria phase 1b: single 3 mg/kg intravenous dose

> “This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.”
> “Single dose of barzolvolimab is administered intravenously on Day 1, and patients are followed for 12 weeks for safety, PD, and clinical activity assessments.”
> “Here, we report data from two cohorts of patients with ColdU and SD treated with a single dose of barzolvolimab (3 mg/kg) followed for 12 weeks as detailed below.”
> “Barzolvolimab was well tolerated (Table 2). All 21 patients reported AE. Most AEs were mild, and the most common (≥3 patients) were hair color changes (areas of hair lightening) (76%; n = 16/21), infusion reactions (43%; n = 9/21), taste changes (38%; n = 8/21), nasopharyngitis (24%; n = 5/21), malaise (24%; n = 5/21), and headache (19%; n = 4/21).”
> “Infusion reactions, which manifested as localized hives and itching as well as erythema and feeling hot, resolved spontaneously. One patient with a history of fainting experienced loss of consciousness during infusion; this event was not associated with MC activation based on decreasing tryptase values shortly after the event.”
> “Overall, mean hematology parameters remained within the normal ranges. Mild, transient, and asymptomatic decreases in hemoglobin and white blood cell parameters occurred for some patients (Figure S1).”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

<a id="topic-2.1.2.7.1-24"></a>

###### Chronic inducible urticaria phase 2: Week 12 and Week 20 treatment periods

> “We completed a Phase 2 study in patients with CIndU who remain symptomatic despite antihistamine therapy.”
> “Barzolvolimab was well tolerated with a favorable safety profile consistent with prior studies. Most adverse events were grade 1 (mild). Through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were hair color changes (13%; Grade 1, n=15 / Grade 2, n=2) and neutropenia (10%; Grade 1, n=7 / Grade 2, n=6), which are mechanism related (KIT) and expected to be reversible. The rate of infections was similar between barzolvolimab-treated patients and placebo with no association between neutropenia and infections.”
> “Barzolvolimab was well tolerated with a favorable safety profile over the 20 week treatment period consistent with previous studies. There was no difference between active treatment (2%) and placebo groups (3%) in rate of discontinuations due to adverse events. Most adverse events for patients on study drug were grade 1 (mild), mechanism related (KIT) and, as demonstrated in previous studies, expected to be reversible. The most common adverse events occurring in greater than 10% of patients in any treatment group through Week 20 were hair color changes (18%; Grade 1, n=22 / Grade 2, n=2) and neutropenia (12%; Grade 1, n=9 / Grade 2, n=6). Neutropenia was transient and there was no association with infections.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Here we report the primary analysis (Week 12) of a Phase 2 study evaluating the efficacy and safety of barzolvolimab compared with placebo in patients with cold urticaria and symptomatic dermographism whose disease is inadequately controlled by antihistamines (NCT05405660)”
> “98% of treatment emergent adverse events were Grade 1 or 2 (mild (66.7%), moderate (31.7%))”
> “Other discontinuations due to AEs: urticaria/lip edema (150mg), neutropenia (300mg), cystic acne/aphthous ulcer (placebo) and paraesthesia oral/swollen tongue (placebo)”

Source: [Maurer et al. (2024e)](https://celldex.com/wp-content/uploads/2025/06/Barzolvolimab_Phase-2-ClndU_ACAAI_FINAL.pdf)

| Participants, n (%) | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | All barzolvolimab | Placebo |
| --- | --- | --- | --- | --- |
| Participants (n) | “n=65” | “n=65” | “n=130” | “n=63” |
| Any adverse event | “40 (62%)” | “39 (60%)” | “79 (61%)” | “33 (52%)” |
| Treatment-related serious adverse events | “0” | “1 (2%)” | “1 (1%)” | “0” |
| Discontinued study treatment for adverse events | “1 (2%)” | “2 (3%)” | “3 (2%)” | “2 (3%)” |
| Hair color changes | “9 (14%)” | “8 (12%)” | “17 (13%)” | “0” |
| Neutropenia | “4 (6%)” | “9 (14%)” | “13 (10%)” | “0” |

Source: [Maurer et al. (2024e)](https://celldex.com/wp-content/uploads/2025/06/Barzolvolimab_Phase-2-ClndU_ACAAI_FINAL.pdf)

<a id="topic-2.1.2.7.1-25"></a>

###### Prurigo nodularis: adverse events after a single intravenous dose

> “Adults with moderate-to-severe PN were randomly assigned in a 1:1:1 ratio to placebo or barzolvolimab at 1.5 or 3.0 mg/kg as an intravenous infusion and were followed for 24 weeks.”
> “Treatment-emergent adverse events were reported in 5/8 (62.5%) placebo-treated participants and 6/15 (40.0%) barzolvolimab-treated participants. Treatment-emergent adverse events were mild or moderate and resolved while on study”
> “A single intravenous dose of barzolvolimab 3.0 mg/kg was well tolerated and led to a meaningful reduction in itch, improved lesion healing, and decreased serum tryptase in patients with moderate-to-severe PN.”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.7.1-26"></a>

###### Prurigo nodularis phase 2: 450 mg loading dose then 150 or 300 mg every 4 weeks

> “This Phase 2 randomized, double-blind, placebo-controlled, parallel group study evaluated barzolvolimab compared to placebo in patients with moderate to severe PN who had inadequate response to prescription topical medications, or for whom topical medications were medically inadvisable.”
> “140 patients were randomly assigned to receive barzolvolimab 150mgQ4W after an initial loading dose of 450mg, 300mgQ4W after an initial loading dose of 450mg, or placebo during a 24-week Treatment Phase.”
> “Barzolvolimab was well tolerated. Loading dose (450mg) followed by Q4W dosing (150 or 300mg) demonstrated favorable safety profile consistent with prior studies.”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

<a id="topic-2.1.2.7.1-27"></a>

###### Eosinophilic esophagitis phase 2: 300 mg every 4 weeks through Week 44

> “today reported topline results from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.”
> “65 patients were randomly assigned on a 1:1 ratio to receive subcutaneous injections of barzolvolimab at 300 mg every 4 weeks or placebo during a 16-week placebo-controlled treatment phase.”
> “Barzolvolimab demonstrated a favorable safety profile at the 300 mg Q4 weekly dosing regimen, consistent with prior studies where barzolvolimab was dosed less frequently.”
> “An unblinded review of all available data through the full treatment period (28 weeks) and full study (44 weeks) was conducted and clinical and safety outcomes were consistent at these timepoints.”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.2.7.1-28"></a>

###### Healthy volunteers: single intravenous doses of 0.3 to 9 mg/kg

> “placebo‐controlled phase 1a healthy volunteer study of CDX‐0159”
> “A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1). A CDX‐0159 intravenous infusion was well tolerated at all doses. The most common adverse event (AE)s observed in thirteen out of twenty‐four subjects who received CDX‐0159 were mild, self‐limited infusion reactions that were consistently described as areas of local itching associated with erythema, and induration/hives, which started during the infusions (Table 2).”
> “Mild decreases in hemoglobin levels generally within the normal range were observed, which rapidly stabilized despite the presence of high plasma drug levels (Figure 3A).”
> “In addition, all CDX‐0159 treatment groups showed variable, asymptomatic decreases relative to placebo on circulating neutrophils, which were also reflected in the total leukocyte count and did not further decline during the course of the study (Figure 3B,C).”
> “In our healthy volunteer study, there were no reports of hair color changes.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

| Treatment-emergent adverse event, n (%) | CDX-0159, all doses | Placebo |
| --- | --- | --- |
| Participants (n) | “Total (n = 24)” | “Placebo (n = 8)” |
| Any event | “19 (79%)” | “5 (63%)” |
| Infusion-related reaction | “13 (54%)” | “0 (0%)” |
| White blood cell count decreased | “4 (17%)” | “1 (13%)” |
| Neutrophil count decreased | “4 (17%)” | “1 (13%)” |
| Sensation of foreign body in the throat | “3 (13%)” | “0 (0%)” |

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.7.1-29"></a>

###### Healthy volunteers: single ascending subcutaneous doses

> “A randomized, double-blind, placebo-controlled, Phase 1 study designed to evaluate the safety of single ascending doses of the subcutaneous formulation of CDX-0159 has been conducted in healthy volunteers. Subcutaneous administration of CDX-0159 demonstrated a well tolerated safety profile; no injection site reactions were reported.”

Source: [Celldex fourth quarter 2021 results release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-full-year-2021-financial)

<a id="topic-2.1.2.7.1-30"></a>

###### Risk factor text on hypersensitivity, anaphylaxis, and injection-site reactions

> “Our drug candidates, including barzolvolimab, are monoclonal antibodies, which are biologics. Side effects from biologics may include but are not limited to hypersensitivity; severe reactions such as anaphylaxis or cytokine release syndrome; immune-mediated adverse reactions that may occur in any organ system or tissue, such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions; as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea.”
> “There are risks inherent in subcutaneous injections, such as injection-site reactions (including redness, itching, swelling, pain, and tenderness) and other side effects.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

Additional sources: [Muñoz et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42206950/)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age: adult participants in the phase 3 trial

> “This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.8-2"></a>

###### Age: eligibility from 18 to 75 years

> “Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.8-3"></a>

###### Pediatric participants

No evidence found.

<a id="topic-2.1.2.8-4"></a>

###### Pregnancy, nursing, and contraception for 150 days after treatment

> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.”
> “Women who are pregnant or nursing.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.8-5"></a>

###### Male fertility: spermatogenesis in the six-month non-human primate toxicology study

> “In February 2022, we reported interim data after completing the in-life dosing portion of our six-month chronic toxicology study in non-human primates.”
> “The only clinically adverse finding at the completion of dosing was a profound impact on spermatogenesis, an expected and well understood effect of KIT inhibition.”
> “Due to the very high concentrations of barzolvolimab at the end of dosing, the recovery period was approximately one year.”
> “As we expected, and consistent with previous findings with KIT blocking antibodies, we were pleased to report in December 2022, that during this recovery period spermatogenesis fully recovered in all male animals as measured by both sperm count and motility.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “In addition to its role in hematopoiesis, KIT signaling is important in other processes and has been described to have a role in hair pigmentation and spermatogenesis.”
> “The effect of CDX‐0159 on fertility parameters will be studied in relevant preclinical models.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.8-6"></a>

###### Sex and body weight: effect on exposure in prurigo nodularis

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.8-7"></a>

###### Hepatic impairment: normal liver function tests required for enrollment

> “Normal blood counts and liver function tests.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.8-8"></a>

###### Renal impairment

No evidence found.

<a id="topic-2.1.2.8-9"></a>

###### History of anaphylaxis and HIV, hepatitis B, or hepatitis C infection: exclusion criteria

> “History of anaphylaxis.”
> “Known HIV, hepatitis B or hepatitis C infection.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Barzolvolimab

<a id="topic-2.1.2.9.1-1"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="topic-2.1.2.9.1-2"></a>

###### Extrinsic participant-specific parameters and exposure: prurigo nodularis

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.9.1-3"></a>

###### Prior biologics, immunosuppressives, and oral doxepin: exclusion criteria

> “Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Barzolvolimab on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="topic-2.1.2.9.2-2"></a>

###### Live vaccines avoided and inactivated vaccines allowed during the study

> “Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Phase 3 regimens: 150 mg every 4 weeks after a 300 mg loading dose, or 300 mg every 8 weeks after a 450 mg loading dose

> “Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies. 1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2) evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) for 52 weeks or placebo for 24 weeks. At 24 weeks, patients on placebo were re-randomized to active treatment across both dosing groups.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | Quoted arm description |
| --- | --- |
| Barzolvolimab 150 mg | “barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.” |

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023); [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

<a id="topic-2.1.2.10.1-2"></a>

###### Dosing regimen named in the company summary of phase 3 data: every 4 weeks

> “Based on results from completed Phase 1 and Phase 2 studies and the topline data from both ongoing Phase 3 trials in CSU (Q4W dosing), barzolvolimab has the potential to offer symptom free complete control (absence of itch and hives, UAS7=0) and clinically meaningful improvements in quality of life and angioedema in a majority of patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.10.1-3"></a>

###### Dose regimen proposed for licensure

No evidence found.

<a id="topic-2.1.2.10.1-4"></a>

###### Phase 3b long-term extension retreatment regimen

| Group | Quoted arm description |
| --- | --- |
| Official title | “A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13” |
| Group 2 Barzolvolimab Retreatment Group | “Barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Group 1 Observation Group, worsening disease | “barzolvolimab will be administered once as a 300 mg subcutaneous injection followed by 150 mg every 4 weeks for up to 52 weeks.” |

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-2.1.2.10.1-5"></a>

###### Phase 2 regimens

> “The randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy.”
> “Approximately 168 patients will be randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment phase.”

Source: [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)

> “randomized 1:1:1:1 to receive barzolvolimab 75 mg every 4 weeks (n = 53); 150 mg every 4 weeks (n = 52); 300 mg every 8 weeks (n = 51); or placebo (n = 51).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

| Arm | Quoted arm description |
| --- | --- |
| Barzolvolimab 75 mg then 150 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Barzolvolimab 75 mg then 300 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
| Barzolvolimab 150 mg | “barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks” |

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-2.1.2.10.1-6"></a>

###### Phase 1b intravenous regimens in mg/kg

> “Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up”
> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.10.1-7"></a>

###### Regimens with a 450 mg loading dose in cold urticaria, symptomatic dermographism, atopic dermatitis, and prurigo nodularis

> “In December 2025, we initiated a Phase 3 study of barzolvolimab in adult patients with ColdU and SD who remain symptomatic despite H1 antihistamine treatment.”
> “Participants in each cohort will be randomized in a 1:1 ratio to one of two treatment arms: cohort 1: barzolvolimab 150 mg every 4 weeks (Q4W) following a loading dose of 450 mg on Day 1 or cohort 2: matching placebo for 24 weeks.”
> “The randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of subcutaneous barzolvolimab in patients with moderate to severe AD.”
> “131 patients were randomly assigned on a 1:1:1 ratio to receive subcutaneous injections of barzolvolimab at either 150 or 300 mg or placebo every 4 weeks after an initial loading dose of 450 mg or placebo during a 16-week placebo-controlled treatment phase.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN)”
> “Barzolvolimab was well tolerated. Loading dose (450mg) followed by Q4W dosing (150 or 300mg) demonstrated favorable safety profile consistent with prior studies.”
> “The addition of the 450mg loading dose led to early, profound tryptase reduction that was sustained over the duration of the treatment period.”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Subcutaneous administration with potential self-administration at home

> “Our barzolvolimab drug product is currently administered subcutaneously. The subcutaneous formulation allows for potential self-administration at home, eliminating the need for intravenous dosing in a hospital or clinic setting.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.10.2-2"></a>

###### Pre-filled syringes used in the phase 3 trials

> “Drug product manufacturing into 1 mL pre-filled syringes has been completed and pre-filled syringes are actively being used in Phase 3 trials.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.10.2-3"></a>

###### Intravenous infusion over 60 minutes in the phase 1b study

> “Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up”
> “Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial-scale manufacturing at contract manufacturers and process performance qualification

> “The barzolvolimab manufacturing process has been successfully transferred and scaled up to produce larger cGMP batches at both Drug Substance (DS) and Drug Product (DP) commercial Contract Development and Manufacturing Organizations in support of late-stage trials and to prepare for potential commercialization.”
> “In 2025, we initiated the Process Performance Qualification (PPQ) manufacturing runs for DS and anticipate the completion of those activities in 2026. DP PPQ activities were successfully completed.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.11-2"></a>

###### Reliance on contract manufacturers for commercial supply, filling, packaging, storage, and shipping

> “The Company relies on contract development & manufacturing organizations (CDMOs) to manufacture drug substance and drug product as well as for future commercial supplies. The Company also relies on CDMOs for supply of raw materials as well as filling, packaging, storing and shipping our drug products. Some of the Company’s CDMOs are currently single source manufacturers.”
> “We currently operate our own cGMP manufacturing facility in Fall River, Massachusetts, to produce drug substance for our current and planned early-stage clinical trials.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.11-3"></a>

###### Commercial organization and commercial planning

> “On November 10, 2025, we announced the appointment of a new Chief Commercial Officer.”
> “We currently lack sufficient sales, marketing, market access, patient services and distribution capabilities to carry out this strategy.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

> “We look forward to continuing to grow our leadership in mast cell biology as we advance to our next stage of development—establishing a commercial-stage organization committed to delivering barzolvolimab to patients and physicians in need as quickly as possible.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “The increase in G&A expenses was primarily due to an increase in barzolvolimab commercial planning expenses and an increase in employee headcount to support the commercialization of barzolvolimab.”

Source: [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)

> “We expect general and administrative expenses to increase over the next twelve months primarily due to increased costs to support commercial planning efforts and the continued growth of our organization in preparation for potential commercialization of barzolvolimab, although there may be fluctuations on a quarterly basis.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.11-4"></a>

###### Distribution channel and patient support model

No evidence found.

<a id="topic-2.1.2.11-5"></a>

###### Drug product process performance qualification timing, February 2026, superseded in November 2026

> “We are currently preparing for the DP PPQ activities and expect to complete these activities in 2026.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Background second-generation H1 antihistamine at a stable regimen in the phase 3 trials

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment”
> “CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:”
> “Must be on a stable regimen of second generation non-sedating H1-antihistamine for”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023); [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)

> “Antihistamine refractory CSU, (1-4x approved dose) including patients with advanced therapy experienced/refractory CSU”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.12-2"></a>

###### Live vaccines excluded within 30 days before screening in the phase 3 trials; inactivated vaccines allowed

> “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment”
> “Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.12-3"></a>

###### Phase 3b long-term extension observation group: standard of care with at least second-generation H1 antihistamines

> “A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13”
> “Group 1 Observation Group”
> “Standard of care treatment (at least 2nd generation Type 1 antihistamines”
> “with or without other permitted background medications) for 52 weeks.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-2.1.2.12-4"></a>

###### Phase 2 background H1 antihistamine and live vaccine exclusion within 2 months

> “A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria”
> “Diagnosis of CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:”
> “Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-2.1.2.12-5"></a>

###### Phase 1b add-on to H1 antihistamine alone or with H2 antihistamine or leukotriene receptor antagonist, with rescue antihistamines

> “Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up”
> “over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion). Rescue treatments were allowed up to maximum allowable doses: diphenhydramine 100 mg 4× daily (QID), hydroxyzine 50 mg QID, or H2 antihistamine 4× the recommended dose.”
> “This study was limited by the small sample size and variation in drugs used for background urticaria treatment; however, patients had to be on a stable regimen prior to barzolvolimab administration.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

> “A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria”

Source: [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Barzolvolimab on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### AAAAI and ACAAI urticaria measures: laboratory test overuse and antihistamine updosing underuse

| Measure | Quoted measure title | Quoted measure description |
| --- | --- | --- |
| Urticaria Measure 1 | “Overuse: Laboratory Tests for Connective Tissue Disease” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent diagnostic testing for connective tissue disease in the absence of a history or symptoms consistent with or suggestive of a connective tissue disease.” |
| Urticaria Measure 2 | “Overuse: Laboratory Tests for Food Allergy” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for food allergies.” |
| Urticaria Measure 3 | “Overuse: Laboratory Tests for Inhalant Allergy” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for inhalant allergens.” |
| Urticaria Measure 4 | “Overuse: Laboratory Tests for Hereditary or Acquired Angioedema” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria with or without angioedema, who underwent diagnostic testing for a C1 inhibitor deficiency syndrome.” |
| Urticaria Measure 5 | “Underuse: Higher doses of Antihistamines” | “The proportion of patients with chronic urticaria that is uncontrolled on monotherapy with approved doses of 2nd generation antihistamines, who are advanced as tolerated to one or more of the following: higher doses of second generation antihistamines; addition of another 2nd generation antihistamine, addition of a leukotriene antagonist, addition of an H2 blocker, or addition of a 1st generation antihistamine to be taken at bedtime.” |

Source: [AAAAI Urticaria Measures Set (2015)](https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Practice%20Management/Practice%20Tools/Urticaria-Measures-Set_Final-2015_2026-7-20.pdf)

> “consensus by the AAAAI and ACAAI Joint Task Force on Quality Measures has determined that an error rate of no more than 25% is acceptable for this measure to allow for clinician discretion to evaluate atypical cases.”
> “Maintenance of Certification® Programs”

Source: [AAAAI Urticaria Measures Set (2015)](https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Practice%20Management/Practice%20Tools/Urticaria-Measures-Set_Final-2015_2026-7-20.pdf)

<a id="topic-2.1.2.13-2"></a>

###### Recommendation against routine extensive testing in chronic urticaria

> “In the overwhelming majority of patients with chronic urticaria, a definite etiology is not identified.”
> “Routine extensive testing is neither cost-effective nor associated with improved clinical outcomes.”

Source: [AAAAI Choosing Wisely list](https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Media/Choosing-WiselyT.pdf)

<a id="topic-2.1.2.13-3"></a>

###### Physician adherence to CSU guidelines in a multinational online survey of dermatologists and allergists, Novartis-funded

> “This is a multinational cross-sectional online survey involving patients with CSU and CSU-treating physicians from seven countries (USA, Canada, UK, Germany, France, Italy, and Japan).”
> “Overall, 862 physicians (517 dermatologists; 345 allergists) participated in the study.”
> “Globally, 56% of physicians adhered to guidelines, 19% followed therapeutic protocols, and approximately 30% did not adhere to any guideline.”
> “This study and the journal’s Rapid Service Fees were funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Weller et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12454223/)

<a id="topic-2.1.2.13-4"></a>

###### Physician awareness of and adherence to CSU guidelines, Genentech-funded study

> “Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU.”
> “This study was funded by Genentech, Inc, a member of the Roche Group.”

Source: [Mosnaim et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12814061/)

<a id="topic-2.1.2.13-5"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Absence of head-to-head trials: company statement on cross-study comparisons

> “Across reported studies, not based on head-to-head comparisons.”
> “Cross study comparisons are limited given differences in the design of the included trials, such as variations in statistical methods, patient populations, and dosing schedules, among other factors.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.14-2"></a>

###### Absence of head-to-head trials of omalizumab and dupilumab

> “However, the lack of head-to-head randomized trials makes it challenging to compare treatment outcomes between omalizumab and dupilumab.”

Source: [Mosnaim et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990347/)

<a id="topic-2.1.2.14-3"></a>

###### Barzolvolimab: phase 3 dosing regimens and planned BLA submission

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2) evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) for 52 weeks or placebo for 24 weeks.”
> “plans to submit a Biologics License Application (BLA) to the FDA in 2027.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.14-4"></a>

###### Barzolvolimab: subcutaneous pre-filled syringe and potential self-administration at home

> “Our barzolvolimab drug product is currently administered subcutaneously.”
> “The subcutaneous formulation allows for potential self-administration at home, eliminating the need for intravenous dosing in a hospital or clinic setting.”
> “Drug product manufacturing into 1 mL pre-filled syringes has been completed and pre-filled syringes are actively being used in Phase 3 trials.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.14-5"></a>

###### Barzolvolimab: Week 12 UAS7 change and UAS7=0 in EMBARQ-CSU1 and EMBARQ-CSU2

> “Both Phase 3 trials met the primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at Week 12, and all key secondary endpoints”
> “Proportion of Patients with Complete Response (UAS7=0) at Weeks 12 and 24”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | EMBARQ-CSU1 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU2 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU1 UAS7=0 at Week 12 | EMBARQ-CSU2 UAS7=0 at Week 12 |
| --- | --- | --- | --- | --- |
| Placebo | “-10.7 (0.65)” | “-11.4 (0.64)” | “9.3%” | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “-20.2 (0.64)” | “-20.2 (0.63)” | “42.4%” | “45.7%” |
| Barzolvolimab 300 mg every 8 weeks | “-20.5 (0.65)” | “-19.7 (0.64)” | “42.1%” | “44.0%” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.14-6"></a>

###### Omalizumab: CSU indication, subcutaneous dosing every 4 weeks, and administration setting

> “Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment (1.4)”
> “The recommended dosage for chronic spontaneous urticaria (CSU) is XOLAIR 150 mg or 300 mg by subcutaneous injection every 4 weeks.”
> “Dosing of XOLAIR in CSU patients is not dependent on serum IgE (free or total) level or body weight.”
> “Initiate therapy in a healthcare setting and once therapy has been safely established, the healthcare provider may determine whether self-administration of XOLAIR prefilled syringe or autoinjector by the patient or caregiver is appropriate, based on careful assessment of risk for anaphylaxis and mitigation strategies.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Omalizumab: anaphylaxis boxed warning

> “WARNING: ANAPHYLAXIS”
> “Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Omalizumab: UAS7=0 at Week 12 in CSU Trial 1

> “In CSU Trial 1, a larger proportion of patients treated with XOLAIR 300 mg (36%) reported no itch and no hives (UAS7=0) at Week 12 compared to patients treated with XOLAIR 150 mg (15%), XOLAIR 75 mg (12%), and placebo group (9%). Similar results were observed in CSU Trial 2.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Omalizumab list price

> “of XOLAIR is approximately $30,000 - $60,000 annually, but most people will not pay this amount.”
> “Current list price refers to the wholesale acquisition cost (WAC).”

Source: [Genentech Xolair cost page (2026)](https://www.xolair.com/cost.html)

<a id="topic-2.1.2.14-10"></a>

###### Dupilumab: CSU indication and subcutaneous dosing every 2 weeks in adults

> “DUPIXENT is indicated for the treatment of adult and pediatric patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.”
> “The recommended dosage of DUPIXENT for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Dupilumab: CUPID Study A and Study C results at Week 24, and Study B

> “The key secondary endpoint was change from baseline in urticaria activity score over 7 days (UAS7) at Week 24.”
> “The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Outcome at Week 24 | CUPID Study A dupilumab (N=68) | CUPID Study A placebo (N=68) | CUPID Study C dupilumab (N=73) | CUPID Study C placebo (N=75) |
| --- | --- | --- | --- | --- |
| LS mean change (SE) in UAS7 | “-20.99 (1.77)” | “-11.95 (1.81)” | “-15.61 (2.62)” | “-11.27 (2.61)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “29 (39.7)” | “17 (22.7)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “22 (30.1)” | “13 (17.3)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

###### Dupilumab list price

> “$4,193.03 per 4-week supply”
> “A four-week supply of DUPIXENT (200mg or 300 mg) is defined as two injections. Pricing as of January 1, 2026.”

Source: [Regeneron Dupixent Colorado price disclosure (2026)](https://www.regeneron.com/downloads/codrugcosteducation_dupixent.pdf)

<a id="topic-2.1.2.14-13"></a>

###### Remibrutinib: CSU indication in adults and oral dosing twice daily

> “RHAPSIDO® is indicated for adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of:”
> “chronic spontaneous urticaria (1)”
> “The recommended dosage is 25 mg taken orally twice daily with or without food.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.1.2.14-14"></a>

###### Remibrutinib: UAS7 change, UAS7 ≤6, and UAS7 = 0 at Week 12 in REMIX-1 and REMIX-2

> “The key secondary endpoint was absolute change from baseline in UAS7 at Week 12.”
> “Secondary endpoints included proportion of patients who achieved UAS7 ≤6 at Weeks 2 and 12, and the proportion of patients who achieved complete absence of itch and hives (UAS7 = 0) at Week 12.”
> “Multiple imputation techniques were implemented for missing data.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
| --- | --- | --- | --- | --- |
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.1.2.14-15"></a>

###### Remibrutinib list price

> “The list (or wholesale) price for RHAPSIDO, as of January 7, 2026, is $4,521 per package (30-day supply, 60 tablets).”

Source: [Novartis Rhapsido savings and support page (2026)](https://www.rhapsido.com/savings-support)

<a id="topic-2.1.2.14-16"></a>

###### Draft joint task force guideline: direct and retail prices of omalizumab, dupilumab, and remibrutinib as of December 2025

| Medication | Example packages | Direct price | Retail price |
| --- | --- | --- | --- |
| Omalizumab | “1 syringe/pen per box” | “$1475 per month” | “$1,525.61 per 150mg” |
| Dupilumab | “Carton” | “$4,193.03 per carton” | “$3100.84-5132.09 per carton” |
| Remibrutinib | “60 tablets” | “$4,424.01 per bottle” | “$4,521 per bottle” |

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

> “Prices in US dollars from GoodRx, CostPlusDrugs, and manufacturer”
> “websites as of December 2025.”

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="topic-2.1.2.14-17"></a>

###### International guideline: dupilumab effect relative to omalizumab, oral remibrutinib, and cost restrictions

> “Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab”
> “In September 2025 remibrutinib was approved by the FDA as an oral treatment for adult patients with CSU who remain symptomatic despite H1‐antihistamine treatment and does not require injections or lab monitoring”
> “but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.1.2.14-18"></a>

###### Network meta-analysis for the joint task force guideline: omalizumab and remibrutinib among the most effective

> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “We included 93 studies (n = 11,398; mostly adult and adolescent participants across 83 randomized trials and 10 nonrandomized studies) that evaluated 42 interventions.”
> “With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes. The safety profile of remibrutinib, however, is less certain. Dupilumab improved urticaria activity, but its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.1.2.14-19"></a>

###### Network meta-analysis of biologic and targeted synthetic treatments for antihistamine-refractory CSU

> “Most biological and synthetic target‐specific drugs for antihistamine‐refractory chronic spontaneous urticaria (CSU) have not been compared head‐to‐head.”
> “23 randomized clinical trials with 6933 participants that compared 26 different interventions or dosages and placebos were included.”
> “Omalizumab 300 mg [MD −10.07, 95% CI (−11.35; −8.82)] continues to demonstrate superior efficacy compared with placebo. Remibrutinib, at doses of 35 mg once daily [MD −7.80, 95% CI (−12.76; −2.51)], 25 mg twice daily [MD −7.69, 95% CI (−9.85; −5.76)], and 10 mg twice daily [MD −7.61, 95% CI (−12.59; −2.47)], had the best overall performance for efficacy and safety. Dupilumab, fenebrutinib, and rilzabrutinib also showed greater efficacy than placebo.”
> “No significant differences were found among all treatment comparisons for AEs and SAEs.”

Source: [Zhao et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12053928/)

<a id="topic-2.1.2.14-20"></a>

###### Network meta-analysis of omalizumab, dupilumab, and remibrutinib at Weeks 12 and 24

> “Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24.”
> “Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks.”

Source: [Xiong et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41186128/)

<a id="topic-2.1.2.14-21"></a>

###### Time to minimal clinically important difference in UAS7 across approved and investigational therapies

> “This study aims to provide indirect evidence on the relative time to meaningful clinical response across approved and investigational therapies using a Bayesian network meta-analysis.”
> “The primary outcome was the mean time in weeks to minimal clinically important difference (MCID), defined as a UAS7 reduction of 10 points.”
> “Only omalizumab 300 mg every 4 weeks, dupilumab 300 mg every 2 weeks, and ligelizumab 72 mg and 120 mg every 4 weeks achieved statistically significant reductions compared with placebo. All treatments had wide credible intervals reflecting limited direct comparisons.”

Source: [Balachandar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13301777/)

<a id="topic-2.1.2.14-22"></a>

###### Matching-adjusted indirect comparison of omalizumab versus dupilumab at Week 12

> “Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial”
> “Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).”
> “Change from baseline in UAS7 at week 12 for omalizumab versus placebo was −12.6 (−15.7, −9.5) and for dupilumab versus placebo was −5.0 (−9.3, −0.7).”

Source: [Mosnaim et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990347/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition of urticaria, wheals, and angioedema in the international guideline

> “Urticaria is a condition characterized by the development of wheals (hives), angioedema, or both.”
> “A wheal has three typical features: a sharply circumscribed superficial central swelling of variable size and shape, almost invariably surrounded by reflex erythema, an itching or sometimes burning sensation, a fleeting nature, with the skin returning to its normal appearance, usually within 30 min to 24 h.”
> “Angioedema is characterized by: a sudden, pronounced erythematous or skin colored deep swelling in the lower dermis and subcutis or mucous membranes, tingling, burning, tightness, and sometimes pain rather than itch, a resolution slower than that of wheals (can take up to 72 h).”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-2"></a>

###### Classification by duration and by eliciting factors: acute versus chronic at 6 weeks, spontaneous versus inducible

> “Urticaria is classified based on two main criteria: (i) its duration, as acute or chronic, and (ii) the role of definite triggers, categorized as inducible or spontaneous.”
> “Acute urticaria is defined as the occurrence of wheals, angioedema or both for 6 weeks or less.”
> “Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks.”
> “When the clinical course has no definite physical eliciting factor involved and shows a spontaneous course, it is described as chronic spontaneous urticaria”
> “Inducible urticaria is characterized by the presence of definite and subtype‐specific triggers leading to the development of wheals, angioedema, or both”
> “We recommend that urticaria is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks)”
> “We recommend that urticaria is classified as spontaneous (no definite eliciting factor involved) or inducible (specific definite factor involved)”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-3"></a>

###### Chronic spontaneous urticaria with known and unknown causes in the guideline classification

> “Spontaneous appearance of wheals, angioedema or both for > 6 weeks due to known”
> “CSU comes as CSU with known cause and CSU with unknown cause.”
> “For example, Type I autoimmunity (autoallergy) and type IIb autoimmunity, with mast cell‐activating autoantibodies.”
> “CU patients can concomitantly show more than one form of CU including more than one form of CIndU and they often do.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-4"></a>

###### Chronic spontaneous urticaria as a share of chronic urticaria in the draft AAAAI/ACAAI JTF guideline

> “60% of CU have CSU alone”

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="topic-2.2.1.1-5"></a>

###### Former name: chronic idiopathic urticaria

> “CU can be classified as chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria and marked by the spontaneous appearance of hives and angioedema due to unknown causes) and chronic inducible urticaria”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.1-6"></a>

###### United States: definitions in the Joint Task Force practice parameter

> “These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology.”
> “CU is defined as urticaria that has been continuously or intermittently present for at least 6 weeks.”
> “When no underlying cause is found, CU has been referred to as CIU”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.1-7"></a>

###### Etiology: autoimmunity as the identified cause of chronic spontaneous urticaria

> “Although CSU pathogenesis is not yet fully understood, it is well established that its signs and symptoms are due to the activation of skin mast cells and the subsequent release and effects of their mediators.”
> “In more than 50% of CSU patients, the pathophysiology is driven by two main autoimmune mechanisms: Type I (autoallergy) involving IgE autoantibodies against autoallergens, and type IIb involving IgG autoantibodies; a subpopulation of patients with CSU has both types”
> “It is also important to explain to the patient that CU is predominantly an autoimmune condition”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “In conclusion, autoimmunity, either of Type 1 viz. IgE antibodies to local autoallergens, or Type 2b, viz. IgG autoantibodies to IgE or its receptor, are considered to be the most frequent causes of CSU.”

Source: [Church et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29431202/)

<a id="topic-2.2.1.1-8"></a>

###### Etiology: infections, malignancy, thyroid disease, food, and drugs

> “Acute urticaria frequently follows upper airways infections”
> “In rare instances, chronic (silent) infections may contribute to CSU, and very rarely, an underlying malignancy has been reported”
> “Other potential underlying causes include active thyroid disease, infections, cancer, inflammatory processes, food, and drugs, though these factors can be both causative as well as aggravating”
> “Intensive and costly general screening programs for causes of urticaria are not advised.”
> “IgE‐mediated food allergy is extremely rarely the underlying cause of CSU”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-9"></a>

###### Etiology: type 1 allergen sensitization not causal in a Berlin population survey

> “A questionnaire survey was sent to a representative cross-sectional sample of 13,300 inhabitants of Berlin, Germany, of whom 4093 responded.”
> “Prick tests found sensitization of ≥ 1 for type 1 allergens in 39.1% of patients.”
> “These were related to comorbidities such as allergic rhinitis or oral allergy syndrome, but were never the underlying cause of CU, as proven by double-blind, placebo-controlled provocation tests.”

Source: [Zuberbier et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456386/)

<a id="topic-2.2.1.1-10"></a>

###### Aggravating factors: NSAIDs, stress, and infections

> “Some patients suffering from CSU experience trigger‐induced augmentation of wheals, angioedema, or both.”
> “Among others, these triggers include stress and infections.”
> “Non‐IgE‐mediated reactions to drugs can also augment the activity of preexisting CSU.”
> “NSAIDs are the most common drugs to do so in up to one‐fourth of patients, except for paracetamol (acetaminophen) and/or COX‐2 inhibitors which are considered to be safer options in patients with CSU.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-11"></a>

###### Risk factors in an Italian general practitioner database: obesity, anxiety disorders, malignancy, immunosuppressants, and smoking

> “The risk of CSU was statistically significantly higher in the presence of the following variables: obesity; anxiety, dissociative and somatoform disorders; malignancies; use of immunosuppressive drugs; and chronic use of systemic corticosteroids.”
> “History of autoimmune thyroiditis showed a trend towards an increased risk of CSU, though it was not statistically significant.”
> “Smoking was associated with a significantly reduced risk of CSU.”

Source: [Lapi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26872037/)

<a id="topic-2.2.1.1-12"></a>

###### Children: causes and characteristics similar to adults

> “Recent reports indicate that, in children, the prevalence of CIndUs and CSU, as well as disease characteristics, underlying causes of CSU, and response to treatment, are very similar to those observed in adults”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Chronic spontaneous urticaria

<a id="topic-2.2.1.2.1-1"></a>

###### United States: incidence of diagnosed CSU in three US databases, 2012 to 2018, Novartis-funded

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017.”
> “The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan.”
> “Incident cohorts included newly identified patients with the first urticaria or angioedema code within the year of interest and no codes 12 months prior to that year.”
> “In Optum EHR, the age- and sex-standardized incidence rate (95% CI) among adults and pediatric patients during the identification period was 0.039 (0.039–0.039) and 0.066 (0.065–0.067) per 100 person-years, respectively”
> “The age-standardized incidence rate (95% CI) of CSU among the adult and pediatric populations during the identification period in Optum CDM was 0.094 (0.093–0.095) and 0.109 (0.107–0.111) per 100 person-years, respectively”
> “In MarketScan, the age-standardized incidence rate (95% CI) of CSU among adults and pediatric patients during the identification period was 0.102 (0.097–0.107) and 0.097 (0.096–0.098) per 100 person-years, respectively”
> “The study also reports for the first time, to the best of our knowledge, standard incidence rate of diagnosed CSU in the USA, with period estimates among adults ranging from 0.039 to 0.102 per 100 person-years in the three databases.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States: combined adult and pediatric incidence of diagnosed CSU and annual trend, Novartis-funded study

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.096 (0.096–0.097) per 100 person-years and 0.283% (0.281–0.284), respectively.”
> “The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.088 (0.087–0.088) per 100 person-years and 0.244% (0.243–0.245), respectively.”
> “The annual incidence rate ranged from 0.031 in 2012 to 0.069 per 100 person-years in 2018 across the three databases.”
> “Comparatively, the incidence and prevalence were higher among pediatric patients than adults.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.1-3"></a>

###### United States: average annual incidence of diagnosed CSU of 0.08% in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.”
> “The average annual incidence rate was 0.08%.”
> “US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.1.2.1-4"></a>

###### United States: chronic urticaria incidence estimate in the Joint Task Force practice parameter

> “These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology.”
> “The incidence of CU has been estimated at 1.4% per year.”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.2.1-5"></a>

###### Italy: incidence of CSU in a general practitioner database, 2002 to 2013

> “The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.”
> “The annual prevalence and incidence rates of CSU over a 12-year period (2002-2013) were estimated, along with demographic and clinical determinants.”
> “The incidence was 0·10-1·50 per 1000 person-years.”
> “For both prevalence and incidence rates, female patients outnumbered male.”

Source: [Lapi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26872037/)

<a id="topic-2.2.1.2.1-6"></a>

###### Italy: incidence of newly diagnosed CSU in primary care, 2002 to 2022

> “A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.”
> “The incidence was 2.07-1.93 per 1000 person-years.”
> “A cohort of 7,018 patients with CSU was identified during the study period.”

Source: [Lapi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702025/)

<a id="topic-2.2.1.2.1-7"></a>

###### Global: urticaria incidence in the Global Burden of Disease 2021 study

> “We utilized data from the Global Burden of Disease (GBD) Results (2021) to obtain prevalence, incidence, and disability-adjusted life years (DALYs) for urticaria from 1990 to 2021, categorized by age, gender, and region.”
> “Regarding incidence, the total number of urticaria cases rose from 84,870,288 (74,471,430 − 96,206,256) in 1990 to 117,014,587 (104,106,688 − 131,017,656) in 2021.”
> “The incidence rate declined from 1591.23 (1396.26-1803.77) per 100,000 population in 1990 to 1482.82 (1319.25-1660.27) in 2021, with an EAPC value of 0.01 (0.01–0.02).”
> “As shown in Fig. 1 , across all age groups, females generally have higher incidence and DALYs compared to males.”
> “Projections indicate a continued rise through 2046.”

Source: [Tan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333250/)

| Region | Age-standardized incidence rate, 1990 | Age-standardized incidence rate, 2021 |
| --- | --- | --- |
| High-income North America | “1569.62 (1461.56-1669.2)” | “1602.35 (1507.35-1697.23)” |
| Global | “1529.24 (1355.9-1720.36)” | “1533.71 (1358.35-1726.07)” |

Source: [Tan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333250/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Chronic spontaneous urticaria

<a id="topic-2.2.1.2.2-1"></a>

###### United States: diagnosed CSU period prevalence in three US databases, 2012 to 2018, Novartis-funded

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart.”
> “The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively.”
> “The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively.”
> “The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively.”
> “Our study reports the standardized period prevalence of diagnosed CSU among adults from 0.120% to 0.277% across three databases”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States: annual prevalence trend of diagnosed CSU, 2012 to 2018, Novartis-funded study

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The annual standardized prevalence of diagnosed CSU among adults across three databases increased from 0.052% in 2012 to 0.191% in 2018.”
> “The standardized period prevalence of diagnosed CSU among pediatric patients ranged from 0.193% to 0.304% across the three databases.”
> “The findings of this study highlight a general increasing trend in the incidence and prevalence of diagnosed CSU over time among the US population.”
> “most of the patients (≥ 80%) were diagnosed with unspecified urticaria, followed by idiopathic urticaria and other urticaria”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States: cumulative prevalence of diagnosed CSU of 0.57% in adults in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.”
> “Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.”
> “Estimated cumulative prevalence of diagnosed CSU was 0.57% (women: 0.80%; men: 0.32%).”
> “Chronic spontaneous urticaria (CSU) is an unpredictable inflammatory skin condition with substantial clinical burden that affects 0.23% to 0.78% of the US population.”
> “US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.1.2.2-4"></a>

###### United States: 12-month prevalence of self-reported physician-diagnosed CSU of 0.78% in adults, 2019 National Health and Wellness Survey, Novartis-funded

> “This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.”
> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “Adults who self-reported receiving a diagnosis of CSU from a healthcare provider in the past 12 months were included in the analysis for all outcomes and for the calculation of the weighted 12-month prevalence of diagnosed CSU.”
> “Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.”
> “The weighted prevalence (95% confidence interval) of diagnosed CSU was 0.78% (0.78%–0.78%).”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.2.2-5"></a>

###### United States: chronic urticaria prevalence of 0.23% in adults, cross-sectional electronic health records analysis

> “To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.”
> “A cross-sectional analysis with electronic health records data for a demographically heterogeneous population-based sample of >55 million patients across all 4 census regions.”
> “The overall CU prevalence was 0.23%, or 230 CU cases/100,000 adults.”
> “There are >500,000 people estimated to have CU in the United States, most of whom are women or adults ≥40 years of age.”
> “Use of administrative data has the potential to underestimate burden.”

Source: [Wertenteil et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30872154/)

<a id="topic-2.2.1.2.2-6"></a>

###### North America: chronic urticaria point prevalence of 0.1% in a global meta-analysis

> “The objective of this study was to systematically evaluate and summarize the prevalence of chronic urticaria by evaluating population-based studies worldwide.”
> “We performed a systematic search in PUBMED and EMBASE for population-based studies of cross-sectional or cohort design and studies based on health insurance/system databases.”
> “Eighteen studies were included in the systematic evaluation and 11 in the meta-analysis including data from over 86 000 000 participants.”
> “Asian studies combined showed a higher point prevalence of chronic urticaria (1.4%, 95%-CI 0.5-2.9) than those from Europe (0.5%, 0.2-1.0) and Northern American (0.1%, 0.1-0.1).”
> “The four studies that examined time trends indicated an increasing prevalence of chronic urticaria over time.”

Source: [Fricke et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31494963/)

<a id="topic-2.2.1.2.2-7"></a>

###### United States: chronic urticaria prevalence range and female to male ratio in the Joint Task Force practice parameter

> “These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology.”
> “The prevalence of CU in the general population has been estimated to range from 0.5% to 5%; however, the true point prevalence, cumulative prevalence, and lifetime prevalence of CU have not been established.”
> “Studies have generally shown an increased prevalence in female subjects, with the female/male ratio of patients with CU ranging from 7:3 to as high as 4:1”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.2.2-8"></a>

###### United States: chronic urticaria prevalence in adults by sex, age, and race

> “To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.”
> “The adjusted prevalence in women was 310 (95% confidence interval [CI] 307-312) cases/100,000 adults, more than twice that of men (146 [95% CI 143-148] cases/100,000 adults, P < .001).”
> “CU prevalence was highest among patients aged 40-49 years (256 [95% CI 252-261] cases/100,000 adults) and 50-59 years (246 [95% CI 242-251] cases/100,000 adults) compared with all other age groups (P < .0001).”
> “Adjusted prevalences for black (292 [95% CI 285-298] cases/100,000 adults) and other (331 [95% CI 323-338] cases/100,000 adults) patients were higher than that for white patients (262 [95% CI 260-264] cases/100,000 adults; P < .001).”

Source: [Wertenteil et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30872154/)

<a id="topic-2.2.1.2.2-9"></a>

###### United States by age: higher diagnosed CSU prevalence in pediatric than adult populations, Novartis-funded study

| Database and period | Adults (aged 18 years or older), prevalence (95% CI) | Pediatric patients (aged under 18 years), prevalence (95% CI) |
| --- | --- | --- |
| Optum EHR, 2012 to 2018 | “0.120% (0.119–0.120)” | “0.193% (0.191–0.195)” |
| Optum CDM, 2012 to 2018 | “0.277% (0.275–0.279)” | “0.304% (0.300–0.308)” |
| MarketScan, 2012 to 2017 | “0.256% (0.248–0.265)” | “0.264% (0.261–0.266)” |

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The prevalence of CSU in the present study was higher among pediatric patients than among adults across all databases.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.2-10"></a>

###### United States: age at diagnosis and sex of adults with self-reported diagnosed CSU, Novartis-funded survey

> “This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.”
> “The mean (standard deviation [SD]) age at diagnosis was 37.0 (17.1) years, and 51.7% of respondents were female.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.2.2-11"></a>

###### Female predominance from age 31 years in the international CURE registry

> “We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria.”
> “Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female.”
> “Statistically significant female predominance started at age 31 (<0.001).”
> “CSU demonstrates a pronounced sex disparity, with females being disproportionately affected—evidenced by at least twofold higher incidences in females compared with males.”

Source: [Kocatürk et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12723574/)

<a id="topic-2.2.1.2.2-12"></a>

###### Children: no sex difference in chronic urticaria prevalence under age 15 years

> “Women were slightly more affected than men, whereas in children < 15 years we did not find a sex-specific difference in the prevalence.”

Source: [Fricke et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31494963/)

<a id="topic-2.2.1.2.2-13"></a>

###### Children in five European countries: one-year diagnosed CSU prevalence of 0.75% from a physician survey

> “A physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population.”
> “Across 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively.”

Source: [Balp et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29679413/)

<a id="topic-2.2.1.2.2-14"></a>

###### Germany: lifetime and 12-month prevalence of chronic urticaria in a representative Berlin population survey

> “A questionnaire survey was sent to a representative cross-sectional sample of 13,300 inhabitants of Berlin, Germany, of whom 4093 responded.”
> “Lifetime prevalence rate of urticaria was 8.8% (95% CI 7.9-9.7%) for all types of urticaria.”
> “Lifetime prevalence for CU was 1.8% (95% CI 1.4-2.3%), and prevalence for the 12 months before assessment was 0.8% (95% CI 0.6-1.1%), and 70.3% were female.”

Source: [Zuberbier et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456386/)

<a id="topic-2.2.1.2.2-15"></a>

###### Italy: annual prevalence of CSU in a general practitioner database, 2002 to 2013

> “The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.”
> “The annual prevalence of CSU ranged from 0·02% in 2002 to 0·38% in 2013.”
> “For both prevalence and incidence rates, female patients outnumbered male.”

Source: [Lapi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26872037/)

<a id="topic-2.2.1.2.2-16"></a>

###### Italy: annual prevalence of CSU in primary care, 2002 to 2022

> “A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.”
> “Annual CSU prevalence ranged from 0.41% in 2002 to 0.35% in 2022.”

Source: [Lapi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702025/)

<a id="topic-2.2.1.2.2-17"></a>

###### Global: urticaria prevalence and female share in the Global Burden of Disease 2021 study

> “Globally, the total number of urticaria cases increased from 47,949,600 (42,267,752 − 54,859,773) in 1990 to 66,483,473 (59,240,738 − 74,912,351) in 2021.”
> “Meanwhile, the prevalence rate decreased from 899.01 (792.48-1028.56) per 100,000 population in 1990 to 842.49 (750.70-949.30) per 100,000 population.”
> “In 2021, females accounted for 58.94% of the total urticaria cases, with a female/male ratio of 1.44.”

Source: [Tan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333250/)

<a id="topic-2.2.1.2.2-18"></a>

###### Global: lifetime prevalence of urticaria

> “The lifetime prevalence of acute urticaria is estimated to be approximately 20%.”
> “Urticaria is a frequent disease affecting up to 20% of the world population at some point during their lifetime, with over half of those patients reporting angioedema, and the global prevalence continues to increase”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Chronic course and recurrence after remission: 2026 international guideline

> “Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks. CU can come with daily, or almost daily, signs and symptoms, or an intermittent/recurrent course.”
> “CSU episodes may recur after months or years of full remission”
> “Since the severity of urticaria may fluctuate, and spontaneous remission may occur at any time, it is also recommended to re‐evaluate the necessity for continued or alternative drug treatment every three to 6 months.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.3-2"></a>

###### Predictors of prolonged disease duration: 2026 international guideline

> “In CSU, disease duration, disease activity, and response to treatment are linked to clinical characteristics and laboratory markers.”
> “For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.3-3"></a>

###### Remission rates at years 1, 5, and 20: targeted literature review

> “The objectives of this targeted literature review were to identify evidence on the clinical course of CSU, including remission rates, and to estimate cumulative remission rates for different time points.”
> “Ten publications were included in this review. The proportion of patients achieving remission within year 1 ranged from 21 to 47%, while reported remission rate estimates at year 5 were 34% and 45%. Based on calculated 4-weekly remission rates, cumulative remission estimates ranged from 9 to 38% at year 1, from 29 to 71% at year 5 and from 52 to 93% at year 20. Cumulative weighted average estimates for the proportion of patients remitting at years 1, 5 and 20 were 17%, 45% and 73%, respectively.”
> “However, data sources differed in terms of definitions of disease severity and remission, as well as in conclusions on influencing factors.”
> “The average disease duration in CSU has been estimated to be 5 years, although it may persist longer in severe cases”

Source: [Balp et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8776966/)

<a id="topic-2.2.1.3-4"></a>

###### Remission and relapse clusters in chronic urticaria: electronic health record cohort of 112,443 adults

> “Adults with a CU diagnosis and confirmation CU diagnosis/CU-related treatment at least 6 weeks later were identified in the Optum® de-identified Electronic Health Record dataset (2007–2018). Active CU was a period during which a patient was not in clinical remission. Clinical remission was defined as at least 12 months without CU diagnosis and/or treatment. Relapse was defined as having a CU diagnosis and/or treatment following clinical remission.”
> “The 112,443 patients were grouped into four clusters. Cluster 1 ( N = 36,690 [32.6%]) had the shortest median time to clinical remission (4.1 months) and lowest relapse rate (38.0%). Cluster 2 ( N = 29,834 [26.5%]) reached clinical remission later (10.0 months), with a higher relapse rate (52.3%). Clusters 3 ( N = 24,093 [21.4%]) and 4 ( N = 21,826 [19.4%]) had the longest median times to clinical remission (33.8 and 44.6 months) and highest relapse rates (75%).”

Source: [Balp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11971071/)

<a id="topic-2.2.1.3-5"></a>

###### Remission of chronic urticaria: national sample cohort with 10-year follow-up

> “Patients with new-onset urticaria were identified from the National Health Insurance Service-National Sample Cohort data.”
> “The 10-year cumulative incidence rate of urticaria for the general population was 4.9% and that of chronic urticaria among patients with new-onset urticaria was 7.8%. Remission rates of chronic urticaria were 52.6% at 1 year and 88.9% at 5 years.”
> “Remission was achieved in the majority of patients with chronic urticaria regardless of demographic characteristics or accompanying thyroid disease.”

Source: [Eun et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29945815/)

<a id="topic-2.2.1.3-6"></a>

###### Remission of chronic urticaria: 329 Korean participants in three university hospitals

> “Total 329 Korean patients with CU, who had follow-ups more than 6 months after diagnosis during a 7-year period in the department of dermatology in three university hospitals were enrolled.”
> “The proportion recovered in 1, 3, and 5 years after the onset of CU was 10.8%, 18.8%, and 32.9%, respectively. The mean duration of CU was 6.3 years.”

Source: [Chung et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7992631/)

<a id="topic-2.2.1.3-7"></a>

###### Remission in children with chronic urticaria: 77 children followed for at least 48 months

> “We evaluated 77 children diagnosed with CU, who were monitored for at least 48 months.”
> “Remission was defined as having no symptoms without treatment for more than 1 year.”
> “The remission rates at 6 months, 1 year, 2 years, 3 years, and 4 years after symptom onset were 22.1%, 40.3%, 52.0%, 63.7%, and 70.2%, respectively, for children with CU. For children with CSU, these values were 23.4%, 43.7%, 56.2%, 68.7%, and 75.0%, respectively.”

Source: [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8724829/)

<a id="topic-2.2.1.3-8"></a>

###### Remission in children with chronic urticaria: 92 children aged 4 to 15 years

> “Children 4 to 15 years of age with CU were investigated with a complete blood cell count, erythrocyte sedimentation rate, antinuclear antibody titer, complement CH50 level, thyroid studies, autologous serum skin test, skin-prick tests, food challenges, and stool examination for parasites.”
> “In all, 92 children (53.3% female) with CU were recruited and followed up for a median duration of 4.3 years (range 2.5-5.8 years).”
> “Remission rates at 1, 3, and 5 years after the onset of CU symptoms were 18.5%, 54%, and 67.7%, respectively.”

Source: [Chansakulporn et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25023899/)

<a id="topic-2.2.1.3-9"></a>

###### Disease duration: physician-diagnosed CSU in a 2019 United States survey

> “To estimate the burden, clinical profile, and prevalence of diagnosed CSU in the United States.”
> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “The mean (SD) disease duration was 11.0 (12.6) years.”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.3-10"></a>

###### All-cause mortality: propensity score-matched electronic health record cohort, TriNetX

> “Chronic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life limiting, but the mortality of CSU has not been investigated.”
> “This was a retrospective population-based cohort study of electronic health records of 272,190 adult patients with CSU and 12,728,913 controls without urticaria from the US collaborative network TriNetX.”
> “The study included 264,680 propensity score–matched patients with CSU (mean [SD] age = 47.5 [19.8] years; 71.5% female) and a corresponding number of controls without urticaria. Patients with CSU had higher 3-month (hazard ratio [HR] 2.10, 95% CI 1.97-2.22), 1-year (HR 1.77, 95% CI 1.71-1.83), and 5-year (HR 1.69, 95% CI 1.65-1.73) all-cause mortality (all P < .0001).”
> “The risk of mortality appeared to be more pronounced in White and younger patients with CSU.”
> “CSU is associated with increased mortality likely due to comorbidities, especially suicide, and effective CSU treatment may reduce mortality. These findings should be investigated in additional studies and in other populations.”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.3-11"></a>

###### All-cause mortality by treatment exposure, including oral corticosteroids

> “All-cause mortality rates at 5 years were significantly lower in patients treated with second-generation H1 antihistamines versus untreated patients (1.0% vs 2.3%; HR 1.84, P < .0001) and omalizumab-treated patients versus antihistamine-treated patients (0.7% vs 2.6%; HR 3.99, P = .0003).”
> “In a descriptive analysis, CSU treatment with oral corticosteroids and cyclosporine A was linked to the highest mortality rates across all time points, ie, 3 months, 12 months, and 60 months (0.90%, 2.43%, and 7.73% and 3.01%, 3.01%, and 4.52%, respectively), followed by sgAHs (0.48%, 1.13%, and 3.24%) and omalizumab (0.66% at all time points).”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.3-12"></a>

###### Mortality analysis limitations stated by the authors

> “Limitations of our study, inherent to the retrospective observational design and studies based on patient EHRs, include underdiagnosis, overdiagnosis, misdiagnosis, unmeasured or uncontrolled confounders, self-selection, and reverse causality.”
> “Also, no causal inferences can be drawn as TriNetX does not provide the capability to identify the specific cause of death recorded in the EHRs.”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.3-13"></a>

###### Mortality association in the 2026 international guideline

> “Recent studies suggested an association between CSU and increased mortality, especially due to suicide, likely linked to its comorbidities”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Mast cell activation as the central mechanism

> “Urticaria is predominantly a mast cell‐driven disease but the triggers that activate mast cells are heterogeneous, diverse, and vary from patient to patient”
> “Overall, the result of mast cell activation is the release of mediators such as histamine and platelet activation factor (PAF), among others, which are responsible for sensory nerve stimuli (pruritus), vasodilatation (erythema), and inflammatory cells chemoattraction.”
> “Histologically, wheals are characterized by degranulated mast cells, with edema of the upper‐ and mid‐dermis, with dilatation and augmented permeability of the postcapillary venules as well as lymphatic vessels of the upper dermis.”
> “In angioedema, similar changes occur primarily in the lower dermis and the subcutis.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “It presents with wheals, angioedema or both due to activation and degranulation of skin mast cells and the release of histamine and other mediators.”

Source: [Kolkhir et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/36109590/)

<a id="topic-2.2.1.4-2"></a>

###### Skin mast cells as the primary effector cell, with increased numbers in lesional and non-lesional skin

> “This review presents evidence that the skin mast cell, in particular the MCTC subtype, is the primary effector cell in urticaria.”
> “Increased numbers of mast cells are found in both lesional and non-lesional skin in CSU and inducible urticaria.”
> “Histamine, PGD2 and tryptase are found in the venous blood draining wheal formation.”
> “The last 2 are specific for mast cells rather than basophils.”

Source: [Church et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29431202/)

> “Pathogenically, the skin mast cells are the most important cell in patients with CU, and histamine is the predominant mediator, although other cells and mediators also play a key role.”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.4-3"></a>

###### Other cells, receptors, and pathways: T cells, B cells, eosinophils, basophils, MRGPRX2, complement, and coagulation

> “Other than the histamine receptor, there are other receptors on mast cells that are also involved, such as the Mas‐related G‐protein coupled receptor member X2 (MRGPRX2)”
> “In addition to mast cells, several other cells and mediators can contribute to the pathology of CSU.”
> “These include T cells (i.e., interaction via OX40/OX40L, T cell cytokines), B cells (autoantibody production), eosinophils (i.e., release of MRGPRX2 agonists), neutrophils or basophils, macrophages, sensory nerves (i.e., release of neuropeptides), and others”
> “The non‐lesional skin of CSU patients has been shown to exhibit an upregulation of adhesion molecules, infiltrating eosinophils, altered cytokine expression”
> “Also, a significant number of CSU patients show signs of type 2 inflammation‐driven comorbidities”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “The pathogenesis of CSU consists of several interlinked events involving autoantibodies, complement and coagulation.”

Source: [Kolkhir et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/36109590/)

<a id="topic-2.2.1.4-4"></a>

###### Autoimmune endotypes: type I (autoallergic) and type IIb autoimmune CSU

> “In more than 50% of CSU patients, the pathophysiology is driven by two main autoimmune mechanisms: Type I (autoallergy) involving IgE autoantibodies against autoallergens, and type IIb involving IgG autoantibodies; a subpopulation of patients with CSU has both types”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “Type I autoimmune (autoallergic) CSU is associated with IgE antibodies against autoantigens, for example, thyroid peroxidase and IL-24.”
> “Type IIb autoimmune CSU is mediated by autoantibodies that activate mast cells, for example, via IgE and FcεRI, and is present in less than 10% of patients with CSU when strict criteria are used, that is, triple positivity of autologous serum skin test, immunoassays for IgG autoantibodies, and basophil activation tests.”
> “Mast cells are activated by IgE autoantibodies to autoallergens (type I autoallergy) or IgG-anti-IgE/IgG-anti-FcεRI autoantibodies (type IIb autoimmunity).”
> “Type I aiCSU is thought to be more common than type IIb aiCSU”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.1.4-5"></a>

###### Type I autoallergic CSU: IgE autoantibodies to thyroid peroxidase and other autoantigens

> “elevated IgE-anti-TPO levels in 54% (259) and 61% (191) of 478 patients with CSU, respectively.”
> “In total, patients with CSU have IgE to more than 200 autoantigens, which is more prevalent and different than seen in healthy controls”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.1.4-6"></a>

###### Type IIb autoimmune CSU: 8% meeting all three criteria in a multinational study of 182 participants

> “This was a multinational, multicenter study of 182 CSU patients.”
> “Of the 182 patients, 107 (59%) were ASST+, 46 (25%) were BASO+, and 105 (58%) were IgG anti-FcεRI+/IgE+.”
> “Fifteen patients (8%) fulfilled all three criteria of aiCSU.”
> “aiCSU patients appeared more severe (UAS7 21 vs 9 P < 0.016) but showed no other clinical or demographic differences from non-aiCSU patients.”
> “aiCSU patients also had markedly lower total IgE levels (P < 0.0001) and higher IgG anti-TPO levels (P < 0.001).”
> “Of biomarkers, positive BAT and BHRA tests were 69% and 88% predictive of aiCSU, respectively.”

Source: [Schoepke et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31228881/)

<a id="topic-2.2.1.4-7"></a>

###### Type IIb autoimmune CSU: prevalence by number of positive markers

> “IgG-anti-FcεRI and/or IgG-anti-IgE were reported in 0% to 69% of patients with CSU, with most studies reporting rates of more than 20% and less than 50%”
> “Although these rates are higher as compared with less than 10% in the PURIST study, definition of type IIb aiCSU in these older studies was based on 1 to 2 markers only as compared with the PURIST study (all 3 markers, ie, ASST, basophil tests, and IgG autoantibodies immunoassay).”
> “However, the strict criteria for type IIb aiCSU used in the PURIST study do not imply that the rest of the patients with just 1 positive biomarker or 2 cannot have a type IIb response.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

> “Chronic spontaneous urticaria (CSU) is believed to be Autoimmune (aiCSU) (type IIb CSU) in at least 8% of patients, associated with mast cell-activating IgG autoantibodies.”

Source: [Moñino-Romero et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37286132/)

<a id="topic-2.2.1.4-8"></a>

###### Biomarkers of type IIb autoimmune CSU: low total IgE, elevated IgG-anti-TPO, basopenia, eosinopenia, and basophil tests

> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti–thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab, and a good response to cyclosporine.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

> “We analyzed records of patients with CSU from 2 independent cohorts (n = 1120) for demographic, clinical, and laboratory parameters and treatment responses.”
> “Cutoff values were greater than or equal to 34 kU/L (high aTPO) and less than 40 IU/mL (low total IgE).”
> “One of 10 patients with CSU had both high aTPO and low IgE (aTPO↑IgE↓, 11%, n = 123).”
> “Almost half the patients with aTPO↑IgE↓ (44%, 19 of 43) had a positive BAT result, the best single marker for aiCSU, versus 12% (43 of 344) of patients without aTPO↑IgE↓ (P < .001).”
> “Patients with aTPO↑IgE↓ showed low response rates to antihistamine treatment as compared with patients without aTPO↑IgE↓ (30% vs 47%; P = .01).”

Source: [Kolkhir et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34363991/)

> “Of 1,058 records found in the search, 94 studies were reviewed by experts in urticaria and 42 were included in the analysis.”
> “In CSU patients, BAT/BHRA+ showed a strong level of evidence for an association with high disease activity and low levels of total IgE.”
> “A weak level of evidence was shown for the association of BAT/BHRA+ and the presence of angioedema, and basopenia.”

Source: [Moñino-Romero et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37286132/)

<a id="topic-2.2.1.4-9"></a>

###### Biomarkers in clinical practice: total IgE and IgG-anti-TPO, with limited diagnostic accuracy

> “In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited”
> “However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy.”
> “Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification”
> “Validated biomarkers assays are currently under development and are needed to better assist in decision‐making.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.4-10"></a>

###### KIT and stem cell factor: mast cell dependence on SCF/KIT signaling for survival and maturation

> “Mast cells show exceptional dependence on SCF/c-Kit signaling for tissue survival, proliferation, migration, and terminal maturation.”
> “Loss of function mutations in c-Kit or c-Kitl produce profound tissue mast-cell deficiency, and administration of SCF expands mast-cell populations in vivo”
> “SCF is widely regarded as the main growth factor for mast cells, controlling nearly every stage of mast cell biology, including progenitor differentiation, proliferation of immature and mature cells, survival through inhibition of apoptosis, chemotaxis, adhesion, and effector activation, such as degranulation and cytokine release”
> “SCF amplifies IgE/FcϵRI-dependent mast cell activation mainly by lowering the activation threshold and enhancing downstream signaling, rather than triggering strong degranulation on its own.”

Source: [Ocadiz-Ruiz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13755836/)

> “MCs express the tyrosine kinase receptor c-Kit, which binds stem cell factor (SCF), a key regulator of MC differentiation, maturation, proliferation and survival.”
> “SCF has also been implicated in MC activation, both as a direct trigger of degranulation and as an amplifier”
> “However, the reported effects of SCF on MC mediator release are variable with some studies describing comparable levels of mediator release following SCF and anti-IgE stimulation, whereas others report a weaker response to SCF.”

Source: [Jahn et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729876/)

<a id="topic-2.2.1.4-11"></a>

###### KIT expression beyond mast cells: melanocytes, hematopoietic progenitors, germ cells, and taste cells

> “These include hematopoietic progenitors, melanocytes, germ cells, and mast cells, which all are significantly affected by loss-of-function mutations of KIT or SCF”
> “Many other cells can express KIT constitutively or during immune responses, including dendritic cells, eosinophils, ILC2 cells, and taste cells.”

Source: [Tsai et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177781/)

> “c-Kit is expressed by hematopoietic stem cells, melanocytes, progenitor cells, mast cells, eosinophils, dendritic cells, basophils, and innate lymphoid cells.”

Source: [Ocadiz-Ruiz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13755836/)

<a id="topic-2.2.1.4-12"></a>

###### Mast cell depletion through KIT as a therapeutic mechanism

> “These include monoclonal antibodies and small molecules that can specifically inhibit mast cell degranulation via key receptors (such as FcεRI), that block specific signal transduction pathways involved in mast cell activation (for example, BTK), that silence mast cells via inhibitory receptors (such as Siglec-8) or that reduce mast cell numbers and prevent their differentiation by acting on the mast/stem cell growth factor receptor KIT.”

Source: [Kolkhir et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34611316/)

> “Chronic urticaria (CU) is a mast cell (MC)-dependent disease with limited therapeutic options.”
> “Current management strategies are directed at inhibiting IgE-mediated activation of MCs and antagonizing effects of released mediators.”

Source: [Metz et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37605867/)

> “Current recommended and effective treatment options for urticaria aim to target mast cell mediators at the receptors on nerves and endothelia, mast cell releasability, or mast cell activation by autoimmune triggers among others.”
> “Novel treatments currently under development aim to better regulate Type 2 immunity, or silence mast cells via inhibitory receptors, or to reduce mast cell numbers.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.4-13"></a>

###### Gut microbiome: emerging and unresolved role

> “There is emerging evidence that changes in the gut microbiome may play a role in the pathophysiology of urticaria”
> “However, as with the chicken or the egg dilemma, it is not clear if these changes are the cause or the consequence of the disease.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic steps: medical history, physical examination, photographs, and basic tests

> “A detailed medical history is essential in the diagnosis of urticaria”
> “is the first step in the diagnostic workup of all urticaria patients. This clinical anamnesis should include concomitant and comorbid diseases. The second step is the physical examination of the patient.”
> “Since wheals and angioedema are transient and may not be present at the time of physical examination, it is important to review prior documentation, including patient‐provided photographs of wheals and/or angioedema”
> “In CU, the third step involves a basic diagnostic workup which includes a limited set of recommended diagnostic tests”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-2"></a>

###### Aims of the diagnostic workup in CSU: 2026 international guideline

> “In CSU, the diagnostic workup has seven major aims: (i) to confirm the diagnosis and exclude differential diagnoses, especially for angioedema‐only patients; (ii) to look for the underlying causes; (iii) to identify relevant conditions that modify disease activity; (iv) to check for comorbidities; (v) to identify the consequences of CSU; (vi) to assess predictors of the course of disease and response to treatment; and (vii) to monitor disease activity, impact, and control”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-3"></a>

###### Routine laboratory tests: differential blood count, CRP or ESR, total IgE, and IgG anti-TPO

> “We recommend limited investigations. Basic tests include differential blood count, CRP and/or ESR, and in specialized care total IgE and IgG anti‐TPO, and more biomarkers as appropriate. We recommend performing further diagnostic measures based on the patient history and examination, especially in patients with long standing and/or uncontrolled disease.”
> “The basic tests include a differential blood count, CRP and/or ESR (to rule out severe systemic disease, as an indicator for parasitic disease, eosinophilic count, autoimmune disease such as systemic lupus), in all patients. In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy. Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification”
> “Intensive and costly general screening programs for causes of urticaria are not advised.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-4"></a>

###### Differential diagnosis: urticarial vasculitis, autoinflammatory disorders, and bradykinin-mediated angioedema

> “In patients who exclusively develop wheals (but not angioedema), urticarial vasculitis”
> “such as Schnitzler syndrome or cryopyrin‐associated periodic syndromes (CAPS), need to be ruled out.”
> “On the other hand, in patients who suffer exclusively from recurrent angioedema (but not from wheals), differential diagnosis should include bradykinin‐mediated angioedema, including those induced by angiotensin‐converting enzyme (ACE)‐inhibitor or gliptins, or hereditary angioedema (HAE)”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-5"></a>

###### Limited laboratory testing: 2014 AAAAI practice parameter and international guideline tests

> “However, empiric elimination diets (not guided by history and testing) and extensive laboratory evaluation are not recommended in the diagnosis of urticaria.”
> “The limited testing that has been suggested by the international guidelines and the AAAAI Practice Parameter Update 2014 (A-PP) includes a CBC with diff, ESR or CRP, liver enzymes and TSH.”

Source: [Bernstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180992/)

<a id="topic-2.2.1.5-6"></a>

###### Diagnostic delay: CURE registry, 4,332 adults with chronic urticaria

> “We retrospectively analysed data from CU adult patients from the international, multicenter Chronic Urticaria Registry (CURE).”
> “Of 4332 CU patients, 61% had standalone chronic spontaneous urticaria (sCSU), 18% had ≥ 1 form of chronic inducible urticaria (CIndU), and 21% had a combination of both (CSU + CIndU).”
> “Diagnosis of CU was delayed in 24% of patients by at least 1 year.”
> “CIndU patients showed a longer DD compared to those with sCSU or CSU + CIndU (median, [IQR]: 4, [0-22] vs. 1, [0-6] vs. 2, [0-9] months, p < 0.001).”
> “In CSU patients, a DD of ≥ 6 months was associated with lower CSU activity (median weekly Urticaria Activity Score of 14 vs. 21, p = 0.02) compared to that of DD < 6 months.”

Source: [Muñoz et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41532284/)

<a id="topic-2.2.1.5-7"></a>

###### Time from symptom onset to diagnosis: 673 adults with inadequately controlled CSU

> “This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.”
> “The mean (SD) duration of disease from symptom onset to diagnosis was 24.0 (63.36) months (median 4.7 months) and from diagnosis to the time of study enrollment was 57.7 (77.79) months (median 27.7 months).”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.5-8"></a>

###### Diagnosing clinicians: physician-diagnosed CSU in a 2019 United States survey

> “Allergists (39.8%), followed by primary care physicians (36.3%) and dermatologists (16.4%), were the most frequent diagnosticians responsible for CSU diagnosis.”
> “UCT scores show that 77.0% of respondents had a score ≤11, indicating poorly controlled CSU.”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.5-9"></a>

###### Disease activity instruments: UAS7 and AAS recommendations and score ranges

> “We recommend the use of the urticaria activity score, UAS7, and/or of the angioedema activity score, AAS, for assessing disease activity in patients with chronic spontaneous urticaria.”
> “The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.”
> “For CSU patients who develop angioedema, with or without wheals, the Angioedema Activity Score (AAS) should be used to assess disease activity”
> “CSU patients who experience wheals and angioedema should use the UAS7 and the AAS in combination.”
> “For the UAS7 the sum of the score (0–3 for wheals +0–3 for pruritis) for each day is summarized over 1 week (7 days) for a maximum of 42.”
> “For the AAS, scores are summed up to an AAS day sum score (0–15), 7 AAS day sum scores to an AAS week sum score (AAS7, 0–105), and 4 ASS week sum scores may be summed up to an AAS 4‐week sum score (AAS28, 0–420).”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-10"></a>

###### Daily UAS scores for wheals and pruritus

| UAS score | Wheals | Pruritus |
| --- | --- | --- |
| 0 | “None” | “None” |
| 1 | “Mild (< 20 wheals/24 h)” | “Mild (present but not annoying or troublesome)” |
| 2 | “Moderate (20–50 wheals/24 h)” | “Moderate (troublesome but does not interfere with normal daily activity or sleep)” |
| 3 | “Intense (> 50 wheals/24 h or large confluent areas of wheals)” | “Intense (severe pruritus, which is sufficiently troublesome to interfere with normal daily activity or sleep)” |

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-11"></a>

###### UAS7 disease activity bands: pooled omalizumab trials, twice-daily UAS7

> “A weekly Urticaria Activity Score – here, the average of twice‐daily patient assessment of itch and hives scores summed over 1 week (UAS7TD) – measures severity from 0 to 42.”
> “Data from three randomized clinical trials of omalizumab in CSU were pooled.”
> “Scores were categorized into five disease states: urticaria‐free (UAS7TD = 0), well‐controlled urticaria (UAS7TD = 1–6), mild‐activity urticaria (UAS7TD = 7–15), moderate‐activity urticaria (UAS7TD = 16–27) and severe activity urticaria (UAS7TD = 28–42)”

Source: [Stull et al. (2017)](https://doi.org/10.1111/bjd.15454)

<a id="topic-2.2.1.5-12"></a>

###### UAS7 minimal important difference: omalizumab trial participants

> “Seventy-three subjects with CIU completed the UAS with enhanced instructions, other measures of disease activity including the size of the largest hive, and collateral measures during a multicenter, randomized, double-blind, placebo-controlled study of omalizumab for the treatment of CIU.”
> “The MID ranged from 9.5 to 10.5 for the UAS7, 5.0 to 5.5 for number of hives (weekly average), and 4.5 to 5.0 for pruritus and size of largest hive (weekly average).”

Source: [Mathias et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22192960/)

> “One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatGA) of disease activity, the Urticaria Control Test (UCT), the Chronic Urticaria Quality of Life Questionnaire, and the Dermatology Life Quality Index before and after the initiation of omalizumab therapy.”
> “The MID was 11 for the UAS7 (SDC = 12) and 12 for the UAS7TD (SDC = 11).”

Source: [Hawro et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29128337/)

<a id="topic-2.2.1.5-13"></a>

###### Disease control instruments: UCT and AECT recommendations and cutoffs

> “We recommend the use of the urticaria control test, UCT, and/or the angioedema control test, AECT, for assessing disease control in patients with CSU.”
> “The UCT cutoff value for well‐controlled disease is 12 out of 16 possible points.”
> “Two versions of the AECT exist, one with a 4‐week recall period and one with a 3‐month recall period.”
> “The AECT consists, like the UCT, of only four questions. Its cut off for well controlled disease is 10 points.”
> “In patients who are in the range of UCT 12–15, therefore a step up might also be required.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-14"></a>

###### Treatment goal of complete control: UAS of 0 and UCT of 16

> “The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-15"></a>

###### UCT development, score range, and cutoff of 12 for controlled disease

> “A 4-item UCT with a recall period of 4 weeks was developed based on 25 potential UCT items tested in 508 patients with chronic urticaria.”
> “Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.”
> “Taken together, we recommend a UCT cutoff value of 12 for controlled disease (ie, all patients exhibiting UCT values of ≤11 are considered to have poorly controlled disease).”

Source: [Weller et al. (2014)](https://doi.org/10.1016/j.jaci.2013.12.1076)

<a id="topic-2.2.1.5-16"></a>

###### UCT minimal important difference: 65 adults with difficult-to-treat CSU

> “We investigated 65 consecutive adult patients with difficult-to-treat CSU (ie, patients with insufficient responses to regular and increased doses of second-generation H1-antihistamines).”
> “Accordingly, we regard a MID of 3 points as most appropriate for UCT score changes.”

Source: [Ohanyan et al. (2017)](https://doi.org/10.1016/j.jaci.2017.04.050)

<a id="topic-2.2.1.5-17"></a>

###### AECT development and cutoff of 10 for well-controlled recurrent angioedema

> “A 4-item AECT with recall periods of 4 weeks and 3 months was developed based on 106 potential items tested in 97 patients with mast cell mediator-induced (n = 49) or bradykinin-mediated recurrent AE (n = 48).”

Source: [Weller et al. (2020a)](https://pubmed.ncbi.nlm.nih.gov/31815297/)

> “A stratification of AECT scores into different levels of disease control together with a receiver-operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions.”

Source: [Weller et al. (2020b)](https://pubmed.ncbi.nlm.nih.gov/32173507/)

<a id="topic-2.2.1.5-18"></a>

###### AECT minimal clinically important difference

> “Patients with recurrent angioedema due to chronic spontaneous urticaria, hereditary angioedema, or acquired C1‐inhibitor deficiency were repeatedly asked to complete the AECT”
> “The MCID was found to be three points for improvement of angioedema control.”

Source: [Fijen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10472988/)

<a id="topic-2.2.1.5-19"></a>

###### AAS development and validation in recurrent angioedema

> “Recurrent angioedema (RecA) is a frequent clinical problem characterized by suddenly occurring cutaneous and/or mucosal swellings.”
> “In total, data from 110 and 80 RecA patients were used during the AAS item evaluation and validation phase, respectively.”
> “The resulting AAS consisted of five items and was found to have a one-dimensional structure and excellent internal consistency.”

Source: [Weller et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23919330/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf); [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Wheals: definition in the 2026 international guideline

> “Urticaria is a condition characterized by the development of wheals (hives), angioedema or both. A wheal has three typical features: a sharply circumscribed superficial central swelling of variable size and shape, almost invariably surrounded by reflex erythema, an itching or sometimes burning sensation, a fleeting nature, with the skin returning to its normal appearance, usually within 30 min to 24 h.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.6-2"></a>

###### Angioedema: definition in the 2026 international guideline

> “Angioedema is characterized by: a sudden, pronounced erythematous or skin colored deep swelling in the lower dermis and subcutis or mucous membranes, tingling, burning, tightness, and sometimes pain rather than itch, a resolution slower than that of wheals (can take up to 72 h).”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.6-3"></a>

###### Angioedema frequency and symptoms: 673 adults with inadequately controlled CSU

> “According to medical records, 58.5% (394 of 673) patients were reported to have had CSU‐associated angioedema, and 41.0% (276 of 673) had experienced CSU‐associated angioedema within the past 12 months from inclusion.”
> “According to the patient survey, 65.8% of patients (427 of 649) reported experiencing angioedema during the previous 12 months; of these, 75.2% (321 of 427) reported having experienced angioedema within the past 4 weeks.”
> “Patients with angioedema reported on a scale of 0‐10 the amount of itching (mean [SD] 7.2 [2.16]), swelling (7.3 [2.73]), and pain (5.4 [3.39]) they experienced during a typical episode over the past 12 months.”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.6-4"></a>

###### Angioedema reporting in medical records and patient reports: 673 participants

> “This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria”
> “Among evaluable patients, 259 (40.3%), 173 (26.9%) and 211 (32.8%) were in the Yes‐angioedema , No‐angioedema and Misaligned category, respectively.”

Source: [Sussman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055840/)

<a id="topic-2.2.1.6-5"></a>

###### Angioedema in the past 3 months: physician-diagnosed CSU in a 2019 United States survey

> “Approximately half (49.1%) of the respondents reported experiencing angioedema in the past 3 months, with the mean (SD) number of angioedema events in the past 3 months being 3.9 (5.7).”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.6-6"></a>

###### Itch: pruritus as a key symptom and its effect on daily life and work

> “It captures the two key signs and symptoms of urticaria—wheals and pruritus—based on daily self‐assessments by the patient”
> “Its debilitating symptoms—severe pruritus and wheals—disruption of daily activities, sleep, and emotional well‐being can create a cycle of frustration and decreased quality of life (QoL) often worsened by comorbidities such as anxiety and depression”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “The main reasons affecting capacity to work were itching (39.8%) and angioedema (28.2%).”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.6-7"></a>

###### Sleep: interference with sleep and claims for sleep-related conditions

> “Chronic spontaneous urticaria markedly interfered with sleep and daily activities.”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

> “Adults (≥18 years) with CSU in the US HealthVerity claims database were included (January 2016-October 2023).”
> “Overall, 224,958 patients were included (mean follow-up: 2.4 years). The proportion of patients with claims for sleep-related conditions increased from baseline to follow-up (8.8% vs 15.4%)”
> “a higher proportion of patients with uncontrolled vs controlled disease had ≥1 claim for sleep-related (17.3% and 13.4%) and MH conditions (60.6% and 51.9%).”

Source: [Riedl et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43003384/)

Additional sources: [Kolkhir et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/36109590/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Comorbidities and consequences of CSU: 2026 international guideline

> “In CSU, the most common comorbidities are CIndUs, autoimmune diseases, metabolic syndrome, and allergies. Mental disorders, such as depression and anxiety, sexual dysfunction and sleep disturbance are also common consequences of CSU”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.7-2"></a>

###### Autoimmune thyroid disease: systematic review

> “There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%.”
> “Thyroid dysfunction rates are increased in patients with CSU (strong evidence). Hypothyroidism and Hashimoto's thyroiditis are more common than hyperthyroidism and Graves' disease (strong evidence).”
> “Thyroid dysfunction is more common in adult patients with CSU than in children (strong evidence) and in female than in male patients with CSU (weak evidence).”

Source: [Kolkhir et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/28407273/)

<a id="topic-2.2.1.7-3"></a>

###### Thyroid and other autoimmune diseases: 12,778 participants with chronic urticaria in Israel

> “Data on 12,778 patients given a diagnosis of CU by either allergy or dermatology specialists during 17 years in a large health maintenance organization in Israel were collected.”
> “Having CU was associated with an increased odds ratio for hypothyroidism, hyperthyroidism, and antithyroid antibodies. Female patients with CU had a significantly higher incidence of rheumatoid arthritis, Sjögren syndrome, celiac disease, type I diabetes mellitus, and systemic lupus erythematosus, mostly diagnosed during the 10 years after the diagnosis of CU.”

Source: [Confino-Cohen et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22336078/)

<a id="topic-2.2.1.7-4"></a>

###### Other autoimmune diseases: systematic review of prevalence

> “The prevalence of individual AIDs in CSU is increased (≥1% in most studies vs ≤1% in the general population).”
> “The rates of comorbidity in most studies were ≥1% for insulin-dependent diabetes mellitus, rheumatoid arthritis (RA), psoriasis and celiac disease (CD), ≥2% for Graves' disease, ≥3% for vitiligo, and ≥5% for pernicious anemia and Hashimoto's thyroiditis.”
> “CSU patients have an increased risk of AIDs, especially adult female patients and those with a positive family history and a genetic predisposition for AIDs, who should be screened for signs and symptoms of AIDs.”

Source: [Kolkhir et al. (2017b)](https://pubmed.ncbi.nlm.nih.gov/29037900/)

<a id="topic-2.2.1.7-5"></a>

###### Psychiatric disorders: systematic review and meta-analysis

> “Twenty-five studies were identified. Almost one out of three CU patients have at least one underlying psychiatric disorder. None of the studies clarified whether the psychiatric disorders pre-existed the CU onset, and no association was found between CU severity and duration, and psychological functioning.”
> “After meta-analyzing these three studies, among 177,998 CU patients, 56,258 had psychiatric comorbidity (31.61%). Among 996,446 healthy individuals (control group), 45,471 were found to suffer from at least one psychiatric disorder (4.6%)”
> “The most prevalent were found to be sleep–wake disorders (36.7%), followed by anxiety disorders (30.6%), mood disorders (29.4%), trauma and stressor-related disorders (17.3%), somatic symptom and related disorders (17.2%)”

Source: [Konstantinou and Konstantinou (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6706894/)

<a id="topic-2.2.1.7-6"></a>

###### Mental health conditions: United States claims before and after CSU diagnosis

> “Adults (≥18 years) with CSU in the US HealthVerity claims database were included (January 2016-October 2023).”
> “Overall, 224,958 patients were included (mean follow-up: 2.4 years). The proportion of patients with claims for sleep-related conditions increased from baseline to follow-up (8.8% vs 15.4%), and for MH conditions (40.6% vs 56.3%).”
> “Claims for sleep-related and MH conditions increased after CSU diagnosis, particularly among patients with uncontrolled disease”

Source: [Riedl et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43003384/)

<a id="topic-2.2.1.7-7"></a>

###### Suicidal ideation and malignant neoplasms: hazard ratios compared with controls

> “Compared with controls, patients with CSU exhibited higher risk and rates of the leading causes of death in the United States, including suicidal ideations/suicide attempts (HR 3.14, 95% CI 3.00-3.28) and malignant neoplasms (HR 2.09, 95% CI 2.02-2.16).”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.7-8"></a>

###### Corticosteroid-associated adverse events: United States claims cohort of 200,298 participants

> “This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).”
> “Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.”
> “The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users. The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.”
> “When assessed according to corticosteroid user type, lipid disorders were the most common AE among patients in the ≤ 31D group (33.0%), and hypertension was the most frequent in the > 31 to ≤ 60D, > 60D, and ≥ 90Dc groups (38.0%, 44.0%, and 49.4%, respectively)”
> “The proportions of patients who reported skeletal conditions and avascular necrosis were ≥ 3 times higher in the ≥ 90Dc group versus non-users.”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.1.7-9"></a>

###### Prolonged systemic corticosteroid use: 2026 international guideline

> “If systemic corticosteroids are used, doses between 20–50 mg/day of prednisone equivalent are needed (dose is appropriate for adults and not children). Because such high doses will have side effects over the long term, we strongly recommend against the prolonged use of corticosteroids.”
> “We recommend against the long‐term use of systemic glucocorticosteroids or depot preparations in CU.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Chronic spontaneous urticaria

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Quality of life, sleep, and work impairment in adults with CSU persisting 12 months or more despite treatment, Novartis-funded

> “This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.”
> “Almost 50% of patients had moderate‐to‐severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. Chronic spontaneous urticaria markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%. These effects increased with increasing disease activity.”
> “The EQ‐5D‐3L domains for which patients most frequently reported moderate or extreme problems were pain/discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) (Figure 3C).”
> “Mean DLQI scores in this study suggest that CSU has a moderate impact on patients’ HRQoL,35 which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic.”
> “This study was funded by Novartis Pharma AG.”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.8.1-2"></a>

###### Adults with self-reported physician-diagnosed CSU, 2019 National Health and Wellness Survey: utilities, DLQI, anxiety, depression, and work impairment, Novartis-funded

> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.”
> “The mean (SD) SF-6D and EQ-5D health utility scores were 0.54 (0.14) and 0.62 (0.34), respectively. The mean (SD) DLQI score was 13.8 (11.2), with more than 74.0% of respondents reporting anxiety (GAD-7 ≥5) and depression (PHQ-9 ≥5). Mean percent (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 36.5% (26.1), 67.2% (34.9), 73.1% (34.2), and 62.6% (34.1), respectively.”
> “The mean (SD) DLQI score was 13.8 (11.2), with 54.2% of respondents having a score >10. More than one-third (36.5%) of respondents had a DLQI score between 21 and 30, indicating an extremely large effect on the patient's life (Fig. 4).”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.8.1-3"></a>

###### CSU compared with atopic dermatitis and psoriasis, 2019 US National Health and Wellness Survey

> “This retrospective, cross-sectional study used real-world data from adult respondents from the 2019 US National Health and Wellness Survey (NHWS).”
> “Mean (standard error [SE]) MCS and PCS scores were lower (worse) among respondents with physician-diagnosed CSU vs. AD and PSO, respectively: MCS: 41.3 (0.6) vs. 44.8 (0.5) vs. 45.3 (0.2); PCS: 42.1 (0.5) vs. 47.8 (0.4) vs. 47.7 (0.2); all p < 0.001.”
> “Respondents with CSU reported higher (p < 0.001) work and activity impairment and HCRU vs. respondents with AD or PSO.”

Source: [Soong et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40556432/)

<a id="topic-2.2.1.8.1-4"></a>

###### Chronic urticaria compared with psoriasis in France, Germany, Italy, Spain, and the United Kingdom, supported by Novartis and Genentech

> “This retrospective cross‐sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain and the United Kingdom.”
> “This analysis included 769 CU and 7857 PsO (26.9% moderate/severe) patients. Following adjustment for covariates, CU patients showed a greater health‐related quality of life (HRQoL) impairment vs. overall PsO (MCS: −2.4, PCS: −1.6, SF‐6D: −0.03; all P < 0.001). CU patients showed a higher risk of anxiety, depression and sleep difficulties [odds ratio (OR): 1.63, 1.34 and 1.56, respectively; all P < 0.01] and greater healthcare resource use vs. overall PsO.”
> “Burden of illness in CU is higher than PsO of all severities but similar to that observed in moderate/severe PsO.”
> “The study was supported by Novartis Pharma AG, Basel, Switzerland, and Genentech, Inc., South San Francisco, CA, USA.”

Source: [Balp et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6084337/)

<a id="topic-2.2.1.8.1-5"></a>

###### Patient-reported burden by disease control in a multinational online survey, Novartis-funded

> “A multinational, cross-sectional online survey was completed by patients with chronic urticaria (CU) and physicians treating CU.”
> “A total of 582 patients with CSU (62% women; mean [standard deviation, SD] age: 42.2 [11.9] years) completed the online survey. Patients reported a mean (SD) diagnostic delay of 2 (5.4) years and saw 6.1 (8.9) physicians. The majority (79%) of patients were on antihistamines, of which 84% were inadequately controlled (UCT score of < 12) and reported a significantly higher negative impact of CSU on the HRQoL domains than adequately controlled patients, with the highest impact on mental and emotional well-being and social life and intimate relationships. More than half (55%) of the patients experienced angioedema with a mean (SD) of 7.7 (14.0) episodes per year. In addition, sleeping problems (62%), pain (55%) and fatigue (49%) were frequently reported physical symptoms during an exacerbation.”
> “This study, and the journal’s Rapid Service and Open Access Fees, were funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Weller et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909366/)

<a id="topic-2.2.1.8.1-6"></a>

###### Sex and age differences in angioedema, sleep disturbance, and quality of life in the CURE registry

> “We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria.”
> “Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female.”
> “Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%; p < 0.001), systemic symptoms (34.6 vs. 25.4%; p < 0.001), sleep disturbance (38.9 vs. 32.5%; p < 0.001), QoL impairment (CU‐Q2oL score 32 vs. 27.7; p < 0.001) and lower rates of urticaria control than males in all medication categories (p < 0.05 for all).”
> “The disease was especially more burdensome and refractory in females aged 51–65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits (p < 0.05 for all).”

Source: [Kocatürk et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12723574/)

<a id="topic-2.2.1.8.1-7"></a>

###### Quality of life of chronic urticaria outpatients on the Nottingham health profile

> “One hundred and forty-two out-patients completed self-administered questionnaires: a disease-specific, purpose designed questionnaire, and the Nottingham health profile (NHP).”
> “The NHP part I scores showed restriction in the areas of mobility, sleep, energy, and demonstrated pain, social isolation and altered emotional reactions.”

Source: [O'Donnell et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9068731/)

<a id="topic-2.2.1.8.1-8"></a>

###### Review of the global burden of chronic urticaria: quality of life, anxiety and depression, and work

> “Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society.”
> “CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment.”
> “Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism).”

Source: [Gonçalo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32956489/)

<a id="topic-2.2.1.8.1-9"></a>

###### Narrative review of the overall burden of CSU

> “This narrative review synthesizes current evidence on the overall burden of CSU, encompassing epidemiology, clinical manifestations, humanistic impact, cumulative life course impairment, and economic costs.”
> “CSU markedly disrupts quality of life through sleep disturbance, pruritus, emotional distress, psychiatric comorbidity, impaired social and occupational functioning, and stigma, with effects extending to children, caregivers, and family members.”

Source: [Kocatürk et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41913980/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Annual healthcare costs and resource use in a commercially insured US population, research paid by Genentech

> “The prevalence of chronic idiopathic or spontaneous urticaria is 0.11 % in a commercially insured US population.”
> “Oral corticosteroids were the most commonly prescribed medication, used in 54.7 % of patients. Patients accumulated a mean of 15.1 office visits per year (standard deviation 12.6). The mean all-cause healthcare cost totaled over US$9000 per year.”
> “Mean all-cause healthcare costs were US$9142 (SD US$21,835, median US$3659) (Fig. 1).”
> “Mean urticaria-related costs were US$997 (SD US$2322, median US$612).”
> “M.S. Broder and E. Chang are employed by Partnership for Health Analytic Research, LLC, a health services research company paid by Genentech, Inc. to conduct this research.”

Source: [Broder et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4529877/)

<a id="topic-2.2.1.8.2-2"></a>

###### Uncontrolled CSU, resource use, and costs in US HealthVerity claims

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.”
> “Corticosteroids were the most prescribed treatment during follow-up among the 166,195 patients prescribed at least 1 treatment (94.3%). Proxy events were observed in 59.1% of the patients. HCRU and health care costs increased from baseline in patients with uncontrolled CSU during follow-up.”
> “Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.1.8.2-3"></a>

###### Systemic corticosteroid use, adverse events, and resource use in US HealthVerity claims, Novartis-funded

> “This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).”
> “Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.”
> “More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.”
> “More frequent HCRU may also have additional implications for health care costs, which are not discussed here.”
> “This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.1.8.2-4"></a>

###### Annual direct and indirect costs in 50 adults at allergy and dermatology clinics

> “The Johns Hopkins University allergy and dermatology ambulatory clinics.”
> “Fifty adults with active CIU were recruited in sequential order.”
> “Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5% ($1280) of the total annual cost. Indirect costs accounted for 15.7% ($322) of the total costs.”

Source: [DeLong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18209166/)

<a id="topic-2.2.1.8.2-5"></a>

###### ASSURE-CSU: direct, indirect, and out-of-pocket costs by country and resource use

> “Total average (SD) annual direct costs per patient per year, as captured in the retrospective medical record review, ranged from PPP$907.1 ($2431.14) in Italy to PPP$2984.2 ($8969.46) in France. The major drivers of these costs were therapies (range, PPP$426.4‐$1788.7) and inpatient visits (range, PPP$250.7‐$1074.4) (Tables S5 and S6 in Appendix S5 and S6).”
> “Average indirect costs, or costs of patient‐reported total work productivity loss over 4 weeks, were driven primarily by the cost of presenteeism (range, PPP$544.5‐$1180.0); the mean (SD) cost of work productivity loss ranged from PPP$544.8 ($603.22) in France to PPP$1287.4 ($1123.80) in Germany (Table S7 in Appendix S7).”
> “Moreover, in ASSURE‐CSU, CSU‐related out‐of‐pocket expenses to patients averaged nearly PPP$500 per year and approached PPP$1000 in Canada.”
> “Among the 97 patients (14.4%) with at least one CSU‐related ED visit in the past 12 months, the annual mean (SD) number of visits was 1.8 (1.26). Hospitalization for CSU was recorded for 55 patients (8.2%), with a mean (SD) length of stay per hospitalization of 3.7 (2.67) days”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.8.2-6"></a>

###### Self-reported all-cause resource use over 6 months, 2019 National Health and Wellness Survey

> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “In terms of all-cause HCRU, 96.5% of the respondents had visited any healthcare provider in the past 6 months, and 60.2% reported visiting an emergency department a mean (SD) of 8.6 (11.9) and 3.7 (5.0) times, respectively. Meanwhile, 55.9% of respondents had been hospitalized in the past 6 months, with the mean (SD) number of hospitalizations being 4.4 (9.8).”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.8.2-7"></a>

###### Review of the global burden of chronic urticaria: treatment and total cost ranges

> “Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society.”
> “Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.”

Source: [Gonçalo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32956489/)

<a id="topic-2.2.1.8.2-8"></a>

###### Omalizumab spending in Oregon all-payer claims, all indications, 2024

> “Xolair (omalizumab) is an anti-immunoglobulin E (IgE) monoclonal antibody used to treat several allergic and inflammatory conditions, including moderate-to-severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.”
> “In the 2024 Oregon All Payer All Claims (APAC) data, 901 enrollees had 8,833 Xolair claims, with approximately $19.5 million in total gross payer spending.”
> “annual gross payer spending was approximately $21,618 per enrollee.”
> “APAC data showed approximately $1.8 million in total enrollee out-of-pocket spending, with an average annual cost of approximately $2,023 per enrollee and a median annual cost of $150.”

Source: [Oregon PDAB Xolair affordability review (2026)](https://dfr.oregon.gov/pdab/Documents/Xolair-2026.pdf)

<a id="topic-2.2.1.8.2-9"></a>

###### Cost of routine laboratory screening in adults with CSU: US simulation

> “Average laboratory costs per simulated patient with CSU were $573 (standard deviation [SD], $41), with only 0.16% (SD, 3.99%) of tests resulting in improved clinical outcomes.”
> “From a simulated US population perspective, nation-wide screening costs could reach $941,750,741 to $1,833,501,483.”

Source: [Shaker et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31751758/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Chronic spontaneous urticaria on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Family quality of life and household expenses by disease activity and control, international UCARE study

> “This international cross‐sectional study was conducted in 12 countries across three continents, from January to December 2024 at Urticaria Centres of Reference and Excellence (UCARE).”
> “A total of 1187 CSU patients and their respective family members completed questionnaires, including the Family Dermatology Life Quality Index (FDLQI), and physicians also provided clinical data on disease severity and control.”
> “FDLQI had a mean total score of 9.6 and mean scores varied across countries (Figure 1, Table S1).”
> “When stratified by UAS7 severity (minimal activity, mild, moderate, severe), family members of patients with higher disease activity reported significantly greater emotional distress, physical burden, social limitations and financial strain (Figure 3, Table S2).”
> “Household expenses showed no statistically significant association with either severity (β = 0.27; CI95% –0.47 to 1.00) or control (β = −0.23; CI95% –0.53 to 0.06).”

Source: [Abdalla et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13425259/)

<a id="topic-2.2.1.8.3-2"></a>

###### Healthcare costs in Medicaid-enrolled children younger than 12 years

> “Medicaid claims from four states (09/01/2013–03/31/2016) were used to identify patients less than 12 years old.”
> “A total of 548 CIU/CSU patients (mean [SD] age 4.5 [3.3] years; 51.3% male) were matched 1:1 with controls.”
> “Moreover, CIU/CSU patients also had significantly higher PPPY healthcare costs (mean cost difference [MCD] $1853), driven by incremental outpatient (MCD $1286) costs (all p values < 0.01).”
> “CIU/CSU adversely affects lives of pediatric patients and their caregivers, leading to school absenteeism, reduced school performance, and more days off work [9].”

Source: [Williams et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5825330/)

<a id="topic-2.2.1.8.3-3"></a>

###### Healthcare costs in commercially insured children younger than 12 years

> “To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (<12 years old) and to compare these with pediatric patients without CIU/CSU.”
> “A commercial administrative claims data base (September 2013 to June 2016) was used.”
> “A total of 6109 pediatric patients with CIU/CSU were selected, and 6107 were 1:1 matched with controls.”
> “Relative to the controls, the patients with CIU/CSU had higher rates of HRU (incidence rate ratios of 1.71, 2.39, and 2.07 for inpatient, emergency department, and outpatient visits, respectively; all p < 0.01), and higher all-cause per patient per year costs (mean cost differences of $2090, $1606, and $483 for total, medical, and pharmacy costs, respectively; all p < 0.01).”

Source: [Williams et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29514728/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Second-generation H1 Antihistamines

<a id="topic-2.2.2.1.1-1"></a>

###### First-line standard-dose second-generation H1-antihistamine: 2026 international guideline

> “We recommend a 2nd generation H1‐antihistamine as first‐line treatment for all types of urticaria.”
> “Most, but not all 2nd generation H1‐antihistamines have been tested specifically in urticaria, and evidence supports the use of bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine”
> “We recommend the use of a standard‐dosed modern 2nd generation H1‐antihistamines as the first‐line symptomatic treatment for urticaria. However, no recommendation can be made on which to choose because, to date, well‐designed clinical trials directly comparing the efficacy and safety of all modern 2nd generation H1‐antihistamines in urticaria are largely lacking.”
> “We suggest 2nd generation H1‐antihistamines to be taken regularly for the treatment of patients with chronic spontaneous urticaria.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-2"></a>

###### Updosing up to four-fold as second-line treatment: 2026 international guideline

> “We recommend updosing of a 2nd generation H1‐antihistamine up to 4‐fold in patients with chronic urticaria unresponsive to a standard‐dosed 2nd generation H1‐antihistamines as second‐line treatment before other treatments are considered.”
> “We recommend against using higher than 4‐fold standard dosed H1‐antihistamines in chronic urticaria”
> “Patients need to be informed that 2nd generation H1‐antihistamine updosing is off‐label and higher than fourfold is not recommended as it has not been tested.”
> “For updosing, also the time of onset needs to be considered, for example, for treatment with an antihistamine, further improvement cannot be expected after 1–2 weeks of treatment as receptor saturation is complete after 1 week.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-3"></a>

###### First-generation H1-antihistamines and combinations of antihistamines: 2026 international guideline

> “The older 1st generation H1‐antihistamines have pronounced anticholinergic and sedative effects and many interactions with alcohol and other drugs such as analgesics, hypnotics, sedatives, and mood elevating drugs, have been described.”
> “we recommend against their use for the routine management of CU as first‐line agents”
> “We suggest against using different H1‐antihistamines at the same time (against an updosing of a single H1‐antihistamine if not legally restricted in country)”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-4"></a>

###### Leukotriene receptor antagonists as add-on therapy: 2026 international guideline

> “In general, the level of evidence for the efficacy of leukotriene receptor antagonists in urticaria is low, but the most so far for montelukast.”
> “A recent, systematic review and meta‐analysis found that adding leukotriene receptor antagonists to H1 antihistamines provides modest reductions in urticaria activity without significantly increasing overall adverse events, though the risk of neuropsychiatric effects remains uncertain”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-5"></a>

###### Draft 2026 AAAAI/ACAAI Joint Task Force guideline: review invitation and scope

> “ACAAI President Cherie Zachary, MD, FACAAI invites you to review the draft of Chronic Urticaria Guidelines: 2026 AAAAI/ACAAI Joint Task Force (JTF) on Practice Parameters GRADE- and Institute of Medicine-based recommendations.”
> “The 2026 guideline focuses in greater depth on CU in children and adults, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), angioedema associated with CU, disease monitoring, comorbidities, health disparities, special populations, patient and caregiver experience, and sequencing of conventional and advanced therapies.”

Source: [ACAAI JTF chronic urticaria guideline announcement (2026)](https://college.acaai.org/new-chronic-urticaria-practice-parameter-update-puts-greater-emphasis-on-core-concepts-patient-centered-implementation/)

<a id="topic-2.2.2.1.1-6"></a>

###### Dose-response network meta-analysis of 211 randomized trials for the Joint Task Force guideline update

> “As part of updating the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma & Immunology Joint Task Force on Practice Parameters Chronic Urticaria guidelines, we searched MEDLINE, EMBASE, CENTRAL, and regulatory databases from inception to March 17, 2025, for randomized trials addressing antihistamines or their adjuncts for chronic urticaria.”
> “Random effects network and dose–response meta-analyses addressed urticaria activity, angioedema activity, urticaria-related quality of life, and harms including sedation.”
> “A total of 211 trials (22,187 participants) evaluated 55 unique treatments. Bilastine, desloratadine, and fexofenadine are among the most effective in overall improvement. Cetirizine and loratadine are among the most effective in reducing overall urticaria activity and its subcomponents, with cetirizine also effective in improving urticaria-related quality of life.”
> “Dose–response meta-analyses suggest that there may be diminishing additional benefits beyond standard dosing (Fig 3, A; RD to improve by a minimal important difference with double dose: RD 8 more per 100 participants [95% CI, 7 to 9 more]; quadruple dose: RD 16 more [95% CI, 11 to 20 more]).”
> “Second-generation agents may result in a greater reduction compared to first-generation agents (MD −2.51 [95% CrI, −5.01 to −0.02]; RD 10 more [95% CrI, 0 to 19 more]; low certainty).”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-7"></a>

###### Montelukast and H2 blocker adjuncts to a second-generation antihistamine: urticaria activity

> “Adding montelukast likely results in a greater reduction compared to a second-generation agent alone (MD −3.28 [95% CrI, −5.87 to −0.68]; RD 11 more [95% CrI, 3 to 17 more]; moderate certainty). The impact of the addition of an H2 blocker compared to a second-generation agent alone is very uncertain (MD −3.83 [95% CrI, −10.41 to 2.77]; very low certainty).”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-8"></a>

###### Sedation by agent and dose

> “Sedation risk likely increases with higher doses, with first-generation agents like diphenhydramine among the most sedating, while sedation risk differs among second-generation agents.”
> “Cetirizine (OR = 2.71 [95% CrI, 1.80 to 4.07]; RD 5 more [95% CrI, 3 to 9 more]), levocetirizine (OR = 3.20 [95% CrI, 1.69 to 6.06]; RD 7 more [95% CrI, 2 to 14 more]), and rupatadine (OR = 2.05 [95% CrI, 1.10 to 3.81]; RD 3 more [95% CrI, 0 to 8 more]) are among the intermediate sedating.”
> “High-certainty evidence demonstrates that bepotastine (OR = 0.53 [95% CrI, 0.22 to 1.31]; RD 2 fewer [95% CrI, 3 fewer to 1 more]) and loratadine (OR = 1.04 [95% CrI, 0.62 to 1.72]; RD 0 more [95% CrI, 1 fewer to 2 more]) are not more sedating than placebo”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-9"></a>

###### Implications for guidelines and payers of diminishing benefit beyond a standard dose

> “Our findings show a diminishing benefit beyond a standard dose”
> “This contrasts with current guidelines that strongly recommend increasing to 4-fold dosing for almost all patients with disease that does not respond to a standard dose.”
> “These findings underscore the need to update guidelines, refine the definition of antihistamine refractoriness, and consider alternatives to dose escalation, such as the timely initiation of biologics and systemic immunomodulators, especially when most systemic therapy trials did not require participants’ disease to be refractory to 4-fold dosing.”
> “Payors should support and enable these decisions rather than create barriers such as rigid criteria, cumbersome preauthorization, or exceptional access processes.”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-10"></a>

###### Response to updosing among standard-dose nonresponders: systematic review and meta-analysis

> “The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.”
> “We identified 1042 articles and 15 articles were included in the final evaluation. We performed two meta-analyses, one that included studies that analysed treatment response among groups receiving different antihistamine dosages vs. placebo, and another that analysed antihistamine updosing in those patients who did not respond to standard dosages.”
> “Only five articles obtained a high quality level score. We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.”
> “The estimated relative risk for improvement by increasing the antihistamine dosage was 2·27 [95% confidence interval (CI) 1·68-3·06]; however, there was significant heterogeneity. The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).”

Source: [Guillén-Aguinaga et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27237730/)

<a id="topic-2.2.2.1.1-11"></a>

###### Uncontrolled disease at Month 24 on non-sedating and updosed antihistamines: AWARE real-world study, sponsored by the omalizumab manufacturer

> “AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.”
> “Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.”

Source: [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Anti-IgE Monoclonal Antibodies

<a id="topic-2.2.2.1.2-1"></a>

###### Omalizumab as add-on treatment after high-dose antihistamines: 2026 international guideline

> “We recommend adding on omalizumab”
> “for the treatment of patients with CU unresponsive to high doses of 2nd generation H1‐antihistamines.”
> “The recommended initial dose in CSU is 300 mg every 4 weeks as add on to antihistamine treatment. Dosing is independent of total serum IgE and bodyweight”
> “Studies support the use of omalizumab treatment at doses up to 600 mg and intervals of 2 weeks, in patients with insufficient response to standard dosed omalizumab”
> “Patients need to be informed that omalizumab updosing is off‐label.”
> “Drug survival studies, or time to discontinuation, for omalizumab show that the main reason for discontinuation is due to well‐controlled disease and far less due to ineffectiveness or adverse effects”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.2-2"></a>

###### FDA-approved indication and dosage in chronic spontaneous urticaria: omalizumab

> “XOLAIR is indicated for the treatment of adults and adolescents 12 years of age and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.”
> “XOLAIR is not indicated for treatment of other forms of urticaria.”
> “The recommended dosage for chronic spontaneous urticaria (CSU) is XOLAIR 150 mg or 300 mg by subcutaneous injection every 4 weeks.”
> “Dosing of XOLAIR in CSU patients is not dependent on serum IgE (free or total) level or body weight.”
> “The appropriate duration of therapy for CSU has not been evaluated. Periodically reassess the need for continued therapy.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### Anaphylaxis warning: omalizumab

> “Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment.”
> “In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006.”
> “Approximately 60% to 70% of anaphylaxis cases have been reported to occur within the first three doses of XOLAIR, with additional cases occurring sporadically beyond the third dose.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

###### Adverse reactions in pooled CSU trials, Day 1 to Week 12: omalizumab

| Adverse reaction | Omalizumab 150 mg (n=175) | Omalizumab 300 mg (n=412) | Placebo (n=242) |
| --- | --- | --- | --- |
| Nausea | “2 (1.1%)” | “11 (2.7%)” | “6 (2.5%)” |
| Nasopharyngitis | “16 (9.1%)” | “27 (6.6%)” | “17 (7.0%)” |
| Sinusitis | “2 (1.1%)” | “20 (4.9%)” | “5 (2.1%)” |
| Upper respiratory tract infection | “2 (1.1%)” | “14 (3.4%)” | “5 (2.1%)” |
| Arthralgia | “5 (2.9%)” | “12 (2.9%)” | “1 (0.4%)” |
| Headache | “21 (12.0%)” | “25 (6.1%)” | “7 (2.9%)” |
| Cough | “2 (1.1%)” | “9 (2.2%)” | “3 (1.2%)” |

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

> “Adverse reactions are pooled from CSU Trial 2 and the first 12 weeks of CSU Trials 1 and 3.”
> “Injection site reactions of any severity occurred during the studies in more XOLAIR-treated patients [11 patients (2.7%) at 300 mg, 1 patient (0.6%) at 150 mg] compared with 2 placebo-treated patients (0.8%).”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### Week 12 itch severity, hive count, and UAS7=0 in CSU Trial 1: omalizumab label

| Week 12 outcome | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo |
| --- | --- | --- | --- | --- |
| N | “77” | “80” | “81” | “80” |
| Weekly itch severity score, mean change (SD) | “−6.46 (6.14)” | “−6.66 (6.28)” | “−9.40 (5.73)” | “−3.63 (5.22)” |
| Weekly itch severity score, difference in LS means vs placebo | “−2.96” | “−2.95” | “−5.80” | Not applicable |
| Weekly hive count score, mean change (SD) | “−7.36 (7.52)” | “−7.78 (7.08)” | “−11.35 (7.25)” | “−4.37 (6.60)” |

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

> “All patients were required to have a UAS7 of ≥16, and a weekly itch severity score of ≥8 for the 7 days prior to randomization, despite having used an H1 antihistamine for at least 2 weeks.”
> “In CSU Trial 1, a larger proportion of patients treated with XOLAIR 300 mg (36%) reported no itch and no hives (UAS7=0) at Week 12 compared to patients treated with XOLAIR 150 mg (15%), XOLAIR 75 mg (12%), and placebo group (9%). Similar results were observed in CSU Trial 2.”
> “The 75-mg dose did not demonstrate consistent evidence of efficacy and is not approved for use.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

###### ASTERIA I: well-controlled UAS7 ⩽6 and complete response UAS7=0 with omalizumab 300 mg

> “ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment at licensed doses.”
> “The omalizumab 300-mg group met all nine secondary end points, including a significant decrease in the duration of time to reach minimally important difference response (⩾5-point decrease) in weekly ISS ( P <0.0001) and higher percentages of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) ⩽6: 51.9% vs. 11.3% P <0.0001) and complete response (UAS7=0: 35.8% vs. 8.8% P <0.0001) versus placebo.”

Source: [Saini et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4269803/)

<a id="topic-2.2.2.1.2-7"></a>

###### Week 12 itch severity by omalizumab dose: phase 3 randomized trial

> “In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite”
> “We randomly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omalizumab at doses of 75 mg, 150 mg, or 300 mg or placebo, followed by a 16-week observation period.”
> “At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was -5.1±5.6 in the placebo group, -5.9±6.5 in the 75-mg group (P=0.46), -8.1±6.4 in the 150-mg group (P=0.001), and -9.8±6.0 in the 300-mg group (P<0.001).”
> “The frequency of serious adverse events was low, although the rate was higher in the 300-mg group (6%) than in the placebo group (3%) or in either the 75-mg or 150-mg group (1% for each).”

Source: [Maurer et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23432142/)

<a id="topic-2.2.2.1.2-8"></a>

###### Week 12 results with omalizumab 300 mg after antihistamines up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists

> “We sought to evaluate the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent CIU/CSU despite treatment with H1-antihistamines at up to 4 times the approved dose plus H2-antihistamines, leukotriene receptor antagonists, or both.”
> “In this phase III study patients were randomized to receive 6 subcutaneous injections at 4-week intervals of either 300 mg of omalizumab or placebo, followed by a 16-week observation period.”
> “At week 12, the mean change from baseline in weekly itch severity score was −8.6 (95% CI, −9.3 to −7.8) in the omalizumab group compared with −4.0 (95% CI, −5.3 to −2.7) in the placebo group (P < .001).”
> “This study shows that approximately half of the patients who received add-on omalizumab achieved UAS7s of 6 or less, and one third were completely itch and hive free (UAS7 = 0).”

Source: [Kaplan et al. (2013)](https://doi.org/10.1016/j.jaci.2013.05.013)

| Week 12 outcome | Omalizumab 300 mg (n = 252) | Placebo (n = 83) |
| --- | --- | --- |
| Change from baseline in UAS7, mean (95% CI) | “−19.0 (−20.6 to −17.4)” | “−8.5 (−11.1 to −5.9)” |
| UAS7 ≤6, no. (%) | “132 (52.4)” | “10 (12.0)” |
| UAS7 = 0, no. (%) | “85 (33.7)” | “4 (4.8)” |

Source: [Kaplan et al. (2013)](https://doi.org/10.1016/j.jaci.2013.05.013)

<a id="topic-2.2.2.1.2-9"></a>

###### Pooled randomized trial effects of omalizumab 150 mg and 300 mg: systematic review

> “This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU).”
> “Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated.”
> “Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5)”
> “Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25)”

Source: [Agache et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767573/)

<a id="topic-2.2.2.1.2-10"></a>

###### Real-world effectiveness and adverse events: meta-analysis of 67 observational studies

> “Included studies were observational in design and included at least 1 outcome in common with other studies and at a concurrent time point of exposure to omalizumab. A total of 67 articles (35.2% of those screened) were included in the analysis.”
> “Random-effects meta-analyses were performed.”
> “Omalizumab therapy was associated with an improvement in UAS7 scores (−25.6 points, 95% CI, −28.2 to −23.0; P < .001; 15 studies, 294 patients), an improvement in UAS scores (−4.7 points, 95% CI, −5.0 to −4.4, P < .001; 10 studies, 1158 patients), an average complete response rate of 72.2% (95% CI, 66.1%-78.3%; P < .001; 45 studies, 1158 patients) with an additional average partial response rate of 17.8% (95% CI, 11.7%-23.9%; P < .001; 37 studies, 908 patients), and an average adverse event rate of 4.0% (95% CI, 1.0%-7.0%; P < .001; any level of severity, 47 studies, 1314 patients).”

Source: [Tharp et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439579/)

<a id="topic-2.2.2.1.2-11"></a>

###### Drug survival and reasons for discontinuation: meta-analysis of 8 observational studies

> “Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included.”
> “Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).”
> “Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon.”
> “Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)”
> “The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events.”

Source: [Altayf et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42714921/)

<a id="topic-2.2.2.1.2-12"></a>

###### Omalizumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update

> “We systematically synthesized the comparative benefits and harms of systemic treatments for chronic urticaria.”
> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “We included 93 studies (n = 11,398; mostly adult and adolescent participants across 83 randomized trials and 10 nonrandomized studies) that evaluated 42 interventions. With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes.”
> “Standard-dose omalizumab (MD −8.37 [95% CrI −10.28 to −6.46]; high certainty), and remibrutinib (MD −7.65 [95% CrI −11.75 to −3.54]; high certainty) are among the most effective, while low-dose omalizumab (MD −5.25 [95% CrI −7.83 to −2.68]; high certainty) is among the intermediate effective.”
> “Standard-dose omalizumab (MD 8.75% more [95% CrI 1.93% to 15.56% more]; high certainty) and remibrutinib (MD 15.00% more [95% CrI 3.16% to 26.84% more]; high certainty) are among the most effective.”
> “Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients with disease refractory to standard-dose omalizumab may experience response (ie, UAS7 ≤ 6 or Urticaria Control Test [UCT] ≥ 12) with higher doses or more frequent administration.”
> “High-certainty evidence demonstrates that omalizumab (OR 0.92 [95% CrI 0.58 to 1.45]; RD 0.2% less [95% CrI 1% less to 1% more]) is not different from placebo”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.1.2-13"></a>

###### Omalizumab 300 mg compared with dupilumab and remibrutinib: network meta-analysis of 15 studies

> “This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.”
> “Frequentist random-effects network meta-analysis were conducted in R.”
> “Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints.”
> “Lower omalizumab doses lacked durability at 24 weeks.”

Source: [Xiong et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41186128/)

<a id="topic-2.2.2.1.2-14"></a>

###### Ligelizumab not superior to omalizumab: PEARL-1 and PEARL-2 phase 3 trials

> “PEARL-1 and PEARL-2 were identically designed randomised, double-blind, active-controlled and placebo-controlled parallel-group studies.”
> “Between Oct 17, 2018, and Oct 26, 2021, 2057 adult patients were randomly allocated across both studies (72 mg ligelizumab n=614; 120 mg ligelizumab n=616; 300 mg omalizumab n=618, and placebo n=209).”
> “Both doses of ligelizumab were superior to placebo (p<0·0001), but not to omalizumab, in both studies.”
> “In the phase 3 PEARL studies, ligelizumab demonstrated superior efficacy versus placebo but not versus omalizumab.”

Source: [Maurer et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38008109/)

<a id="topic-2.2.2.1.2-15"></a>

###### Omalizumab biosimilar omalizumab-igec: FDA-approved indication in chronic spontaneous urticaria

> “OMLYCLO® (omalizumab-igec) injection, for subcutaneous use Initial U.S. Approval: 2025 OMLYCLO® (omalizumab-igec) is biosimilar”
> “to XOLAIR® (omalizumab)”
> “Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment (1.4)”
> “Chronic Spontaneous Urticaria: OMLYCLO 150 or 300 mg SC every 4 weeks. Dosing in CSU is not dependent on serum IgE level or body weight. (2.5)”

Source: [Omlyclo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761399s004lbl.pdf)

<a id="topic-2.2.2.1.2-16"></a>

###### Biosimilar CT-P39 compared with reference omalizumab: randomized active-controlled phase 3 equivalence trial

> “This double‐blind, randomized, active‐controlled Phase 3 study ( NCT04426890 ) included two 12‐week treatment periods (TPs).”
> “In TP1, 619 patients were randomized (CT‐P39 300 mg, n = 204; ref‐OMA 300 mg, n = 205; CT‐P39 150 mg, n = 107; ref‐OMA 150 mg, n = 103). Equivalence was demonstrated between CT‐P39 300 mg and ref‐OMA 300 mg for mean change from baseline in ISS7 at week 12”
> “Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching.”

Source: [Saini et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368742/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Anti-IL-4 Receptor Alpha Monoclonal Antibodies

<a id="topic-2.2.2.1.3-1"></a>

###### Dupilumab as add-on treatment after high-dose antihistamines: 2026 international guideline

> “We suggest using dupilumab”
> “as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.”
> “Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab”
> “Currently, urticaria‐specific long‐term safety data are lacking, but existent studies in various diseases reflect a generally favorable safety profile”
> “Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.3-2"></a>

###### FDA-approved indication in chronic spontaneous urticaria, ages 2 years and older: dupilumab

> “Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. (1.7) Limitations of Use: Not indicated for other forms of urticaria. (1.7)”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-3"></a>

###### Dosage in chronic spontaneous urticaria by age and body weight: dupilumab

> “2.9 Recommended Dosage for Chronic Spontaneous Urticaria Dosage in Adults The recommended dosage of DUPIXENT for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).”
> “For pediatric patients 2 years to 5 years of age with CSU, no initial loading dose is recommended.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Age and body weight | Initial loading dose | Subsequent dosage |
| --- | --- | --- |
| 2 to 5 years, 5 to less than 15 kg | Not applicable | “200 mg (one 200 mg injection) every 4 weeks (Q4W)” |
| 2 to 5 years, 15 to less than 30 kg | Not applicable | “300 mg (one 300 mg injection) every 4 weeks (Q4W)” |
| 6 to 17 years, 15 to less than 30 kg | “600 mg (two 300 mg injections)” | “300 mg every 4 weeks (Q4W)” |
| 6 to 17 years, 30 to less than 60 kg | “400 mg (two 200 mg injections)” | “200 mg every 2 weeks (Q2W)” |
| 6 to 17 years, 60 kg or more | “600 mg (two 300 mg injections)” | “300 mg every 2 weeks (Q2W)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### CUPID Study A and Study C in anti-IgE-naive participants: Week 24 efficacy in the label

> “CUPID Study A and Study C included subjects who remained symptomatic despite H1 antihistamine treatment and were anti-IgE treatment naïve, while CUPID Study B included patients who remained symptomatic despite H1 antihistamine and anti-IgE treatments. The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.”
> “The primary endpoint was change from baseline in itch severity score over 7 days (ISS7) at Week 24.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Week 24 outcome | Study A dupilumab (N=68) | Study A placebo (N=68) | Study A difference or odds ratio (95% CI) | Study C dupilumab (N=73) | Study C placebo (N=75) | Study C difference or odds ratio (95% CI) |
| --- | --- | --- | --- | --- | --- | --- |
| ISS7, LS mean change (SE) | “-10.44 (0.92)” | “-6.02 (0.94)” | “-4.42 (-6.84, -2.01)” | “-8.50 (1.39)” | “-6.13 (1.38)” | “-2.37 (-4.48, -0.27)” |
| UAS7, LS mean change (SE) | “-20.99 (1.77)” | “-11.95 (1.81)” | “-9.04 (-13.68, -4.40)” | “-15.61 (2.62)” | “-11.27 (2.61)” | “-4.34 (-8.31, -0.36)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “3.23 (1.43, 7.27)” | “29 (39.7)” | “17 (22.7)” | “3.05 (1.32, 7.02)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “3.09 (1.24, 7.69)” | “22 (30.1)” | “13 (17.3)” | “2.73 (1.15, 6.50)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### CUPID Study A: Week 12 results in the label

> “CUPID Study A showed significant improvement in ISS7 and UAS7 from baseline at Week 12 in the DUPIXENT group (LS mean difference DUPIXENT versus placebo of -2.53 [95% CI: (-4.79, -0.27)] for ISS7 and -5.44 [95% CI: (-9.77, -1.11)] for UAS7). The proportion of patients with UAS7 ≤6 at Week 12 in CUPID Study A was 35.3% in the DUPIXENT group and 17.6% in the placebo group (Odds Ratio: 2.79 [95% CI: (1.22, 6.40)]).”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

###### CUPID Study B in anti-IgE inadequate responders or intolerant participants: primary endpoint not met

> “CUPID Study B enrolled 108 adult and pediatric patients 12 years of age and older with CSU who were inadequate responders (N=104) to H1 antihistamines and anti-IgE treatments or intolerant (N=4) to anti-IgE therapy.”
> “The DUPIXENT group in CUPID Study B did not meet statistical significance for reduction in the primary endpoint ISS7 at Week 24.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

###### LIBERTY-CSU CUPID Study A and Study B: phase 3 publication

> “In LIBERTY-CSU CUPID Study A, patients were omalizumab-naive (n = 138, aged ≥6 years). In Study B, patients were omalizumab-intolerant/incomplete responders (n = 108, aged ≥12 years).”
> “In Study A, UAS7 and ISS7 improved with dupilumab versus placebo (difference -8.5 [95% CI, -13.2 to -3.9; P = .0003] and -4.2 [95% CI, -6.6 to -1.8; P = .0005]). In Study B, tested at α = 0.043 after interim analysis, UAS7 improved (difference -5.8 [95% CI, -11.4 to -0.3; P = .0390]), with a numerical trend in ISS7 (difference -2.9 [95% CI, -5.7 to -0.07; nominal P = .0449, not significant]).”
> “Although the primary end point for Study B was not met, dupilumab effects were small in patients who were omalizumab-intolerant/incomplete responders.”

Source: [Maurer et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38431226/)

<a id="topic-2.2.2.1.3-8"></a>

###### Adverse reactions in pooled CUPID Studies A, B, and C and immunogenicity in CSU: dupilumab

> “A total of 392 adult and pediatric subjects 12 years of age and older with CSU were evaluated for safety in three randomized, double-blind, parallel-group, multicenter, placebo-controlled, studies, Study A, B, and C, conducted under a master protocol (CUPID) for 36 weeks”
> “No new adverse reactions were identified in pediatric subjects aged 2 to 11 years who received DUPIXENT.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Pooled CUPID Study A, B, and C | Dupilumab 200 mg or 300 mg Q2W (N=195) | Placebo (N=197) |
| --- | --- | --- |
| Injection site reactions, n (%) | “20 (10.3)” | “16 (8.1)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| CSU population and regimen | Positive anti-drug antibody | Persistent anti-drug antibody | Neutralizing antibody |
| --- | --- | --- | --- |
| Adults and 12 years or older, 200 mg Q2W or 300 mg Q2W through 24 weeks | “9/193 (5%)” | “1/193 (1%)” | “2/9 (22%)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.3-9"></a>

###### Efficacy by baseline serum IgE level: dupilumab

> “Improvements in ISS7 and UAS7 at Week 24 were consistent regardless of the patients’ baseline IgE level.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

> “Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons), with weak correlations ( r < 0.2) observed between IgE level changes and ISS7, UAS7, and HSS7 outcomes.”
> “In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.”

Source: [Maurer et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11393262/)

<a id="topic-2.2.2.1.3-10"></a>

###### Dupilumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update

> “We systematically synthesized the comparative benefits and harms of systemic treatments for chronic urticaria.”
> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “Dupilumab improved urticaria activity, but its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity.”
> “Dupilumab (MD −6.01 [95% CrI −10.57 to −1.46]; moderate certainty) is likely among the most effective”
> “Cyclosporine (MD −8.25 [95% CrI −18.11 to 1.61]; low certainty) and dupilumab (MD −9.73 [95% CrI −21.51 to 2.05]; low certainty) may be better than placebo.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.1.3-11"></a>

###### Dupilumab compared with omalizumab and remibrutinib: network meta-analysis of 15 studies

> “This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.”
> “Frequentist random-effects network meta-analysis were conducted in R.”
> “Fifteen studies (4,913 patients) were included.”
> “Dupilumab provided sustained itch relief but delayed efficacy.”

Source: [Xiong et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41186128/)

<a id="topic-2.2.2.1.3-12"></a>

###### Matching-adjusted indirect comparison of omalizumab with dupilumab: analysis with Genentech involvement

> “To overcome this limitation, we used matching-adjusted indirect comparison to assess the efficacy of omalizumab versus dupilumab in primary phase 3 trials.”
> “Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial ( NCT04180488 ).”
> “Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).”
> “Genentech Inc was involved in the study design, data analysis, and preparation of the report.”

Source: [Mosnaim et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990347/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Bruton Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Remibrutinib: FDA-approved indication, dosage, and surgical interruption

> “RHAPSIDO® is a kinase inhibitor indicated for adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of:”
> “chronic spontaneous urticaria (1)”
> “The recommended dosage is 25 mg taken orally twice daily with or without food.”
> “Interrupt treatment with RHAPSIDO for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### Remibrutinib: mechanism of action

> “Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton’s tyrosine kinase (BTK).”
> “Remibrutinib inhibits mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators, mediated by pathogenic IgE or IgG directed against the FcεR1 or IgE.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### REMIX-1 and REMIX-2: design and Week 12 efficacy in the prescribing information

> “The efficacy of RHAPSIDO for chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment was evaluated in two identical, 52-week, multi-center, randomized, double-blind, placebo- controlled clinical trials (REMIX-1 [NCT05030311] and REMIX-2 [NCT05032157]).”
> “The co-primary endpoints were absolute change from baseline in ISS7 and HSS7 at Week 12.”
> “Secondary endpoints included proportion of patients who achieved UAS7 ≤6 at Weeks 2 and 12, and the proportion of patients who achieved complete absence of itch and hives (UAS7 = 0) at Week 12.”
> “In both REMIX-1 and REMIX-2 studies, the co-primary and all secondary endpoints showed statistically significant improvement in itch and hives symptoms in patients treated with RHAPSIDO compared to patients treated with placebo.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
| --- | --- | --- | --- | --- |
| LS mean (SE) change in ISS7 | “-9.52 (0.34)” | “-6.89 (0.47)” | “-8.95 (0.34)” | “-5.72 (0.45)” |
| LS mean (SE) change in HSS7 | “-10.47 (0.40)” | “-6.86 (0.55)” | “-10.47 (0.39)” | “-6.00 (0.53)” |
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

| Treatment difference versus placebo at Week 12 | REMIX-1 | REMIX-2 |
| --- | --- | --- |
| UAS7 difference in LS mean (SE) | “-6.22 (1.14)” | “-7.68 (1.14)” |
| UAS7 95% CI for difference | “-8.45, -4.00” | “-9.91, -5.46” |
| UAS7 ≤6 treatment difference (95% CI) | “25.44” “16.48, 34.39” | “27.61” “19.14, 36.08” |
| UAS7 = 0 treatment difference (95% CI) | “20.55” “13.35, 27.75” | “21.60” “15.10, 28.10” |

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

> “Multiple imputation techniques were implemented for missing data.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-4"></a>

###### REMIX-1 and REMIX-2: Week 12 UAS7 outcomes and adverse events

> “A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive either remibrutinib (313 and 300 patients, respectively) or placebo (157 and 155 patients, respectively).”
> “The remibrutinib group had a significantly greater decrease in the UAS7 at week 12 than the placebo group (least-squares mean [±SE] change, -20.0±0.7 vs. -13.8±1.0 [P<0.001] in REMIX-1 and -19.4±0.7 vs. -11.7±0.9 [P<0.001] in REMIX-2), which appeared to be sustained through week 24.”
> “At week 12, significantly more patients in the remibrutinib group than in the placebo group had a UAS7 of 6 or lower (REMIX-1, 49.8% vs. 24.8% [P<0.001]; REMIX-2, 46.8% vs. 19.6% [P<0.001]) and a UAS7 of 0 (REMIX-1, 31.1% vs. 10.5% [P<0.001]; REMIX-2, 27.9% vs. 6.5% [P<0.001]).”
> “The percentages of patients with any adverse event and with serious adverse events were similar in the remibrutinib group and the placebo group, although a higher percentage of patients in the remibrutinib group than in the placebo group had petechiae (3.8% vs. 0.3% in the combined groups).”
> “Funded by Novartis Pharmaceuticals;”

Source: [Metz et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40043237/)

<a id="topic-2.2.2.1.4-5"></a>

###### REMIX-1 and REMIX-2: Week 52 efficacy and safety

> “Patients were randomized 2:1 to receive oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks).”
> “At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score (mean [95% confidence interval], REMIX-1: -23.22 [-24.78, -21.66]; REMIX-2: -22.98 [-24.51, -21.44]), with similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning).”
> “Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis.”

Source: [Giménez-Arnau et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41115533/)

<a id="topic-2.2.2.1.4-6"></a>

###### Pooled REMIX-1 and REMIX-2: disease control, sleep, and quality of life through Week 52

> “To evaluate the impact of remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, on disease control, sleep, and QoL in CSU.”
> “REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were phase 3, double-blind, placebo-controlled studies in adults with CSU who remained symptomatic despite receiving second-generation H1-antihistamines.”
> “The pooled analysis included 606 and 306 patients receiving remibrutinib and placebo, respectively.”
> “Within 1 week of starting remibrutinib, greater improvements in mean (SD) change from baseline (CFB) compared with placebo were noted in urticaria activity (CFB-Urticaria Activity Score: -11.8 [9.9] and -3.6 [7.6]) and sleep (CFB-Sleep Interference Score: -4.9 [4.9] and -1.9 [4.1]).”
> “Across assessments, responses were sustained through week 52 with remibrutinib, and comparable improvements were observed in those who transitioned to remibrutinib.”

Source: [Mosnaim et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42297099/)

<a id="topic-2.2.2.1.4-7"></a>

###### Remibrutinib: bleeding risk, live vaccines, and adverse reactions in the prescribing information

> “In clinical trials, mucocutaneous-related bleeding occurred in 9% of patients who received RHAPSIDO”
> “Use of antithrombotic agents concomitantly with RHAPSIDO may further increase the risk of bleeding”
> “The use of live and live-attenuated vaccines should be avoided in patients receiving RHAPSIDO.”
> “The most common adverse reactions (incidence >3%) were nasopharyngitis, bleeding, headache, nausea and abdominal pain.”
> “In the pooled safety population (REMIX-1 and REMIX-2), bleeding occurred in 9% of patients treated with RHAPSIDO compared to 2% in the placebo group during the 24-week controlled treatment period [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Drug Interactions (7.2)]. Petechiae (4%) and contusion (2%) were the most commonly reported reactions in patients treated with RHAPSIDO. No severe bleeding reactions occurred.”
> “Similar safety findings were observed through Week 52”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-8"></a>

###### Pooled REMIX-1 and REMIX-2 safety: bleeding, infections, cytopenia, and hepatic disorders

> “This was a pooled analysis of REMIX-1 and REMIX-2 consisting of a 24-week, randomized, double-blind, placebo-controlled period, followed by a 28-week open-label treatment period.”
> “AE frequencies and risk differences (95% CI) for remibrutinib (n = 606) versus placebo (n = 306) were as follows: any AE 64.9% versus 64.7%, difference 0.1% (-6.4% to 6.7%); bleeding (including laboratory abnormalities) 10.6% versus 5.2%, difference 5.3% (1.6% to 8.7%); infections 33.5% versus 34.3%, difference -0.8% (-7.4% to 5.6%); cytopenia AEs 3.6% versus 2.0%, difference 1.7% (-0.7% to 3.8%); hepatic disorders 3.3% versus 4.9%, difference -1.6% (-4.6% to 1.1%).”
> “Imbalance in bleeding was due to petechia and similar mucocutaneous events (predominantly mild, none severe) occurring in 9.1% of patients on remibrutinib versus 2.0% of patients on placebo.”
> “Findings during the entire study period were consistent with those in the controlled period.”

Source: [Giménez-Arnau et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42242425/)

<a id="topic-2.2.2.1.4-9"></a>

###### Remibrutinib: drug interactions and hepatic impairment in the prescribing information

> “Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors.”
> “Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers.”
> “No data are available on concomitant use of RHAPSIDO with anticoagulants. The concomitant use of RHAPSIDO and anticoagulants was not allowed in clinical studies. Use of the antiplatelet agents, acetyl salicylic acid at doses up to 100 mg daily or clopidogrel up to 75 mg daily, was allowed in the RHAPSIDO clinical studies.”
> “Avoid use of RHAPSIDO in patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B, and C)”
> “The safety and effectiveness of RHAPSIDO have not been established in pediatric patients.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.4-10"></a>

###### International guideline: remibrutinib suggested as add-on after high-dose H1-antihistamines

> “We suggest using remibrutinib”
> “as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.”
> “The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high‐dose antihistamine and omalizumab treatment.”
> “25 mg twice daily will most likely be recommended as the treatment dose”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.4-11"></a>

###### Rilzabrutinib: RILECSU phase 2 Week 12 results in antihistamine-refractory CSU

> “What is the efficacy and risk profile of rilzabrutinib, an oral reversible covalent Bruton tyrosine kinase inhibitor, in adults with antihistamine-refractory chronic spontaneous urticaria (CSU)?”
> “The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension.”
> “Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo.”
> “The primary analysis population included only the 143 omalizumab-naive patients.”
> “Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, −9.21 vs −5.77; difference, −3.44 [95% CI, −6.25 to −0.62]; P  = .02) and UAS7 (LS mean, −16.89 vs −10.14; difference, −6.75 [95% CI, −12.23 to −1.26]; P  = .02).”
> “Further research is needed to determine long-term efficacy and potential harms.”

Source: [Giménez-Arnau et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019677/)

<a id="topic-2.2.2.1.4-12"></a>

###### Rilzabrutinib adverse events: diarrhea, nausea, and headache

> “adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache.”
> “The most frequent treatment-emergent AEs with rilzabrutinib, 800 mg/d, and rilzabrutinib, 1200 mg/d, were diarrhea and nausea, with most events reported as mild, and none reported as severe.”

Source: [Giménez-Arnau et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019677/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Calcineurin Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

###### International guideline: ciclosporin for CSU unresponsive to licensed treatments, off-label

> “Patients with CSU who do not show sufficient benefit from treatment with H1‐antihistamines, especially if they are also unresponsive to omalizumab, can alternatively be treated with ciclosporin 3–5 mg/kg per day.”
> “Ciclosporin is off‐label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.”
> “We suggest using ciclosporin”
> “for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.”
> “currently not licensed for CU”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.5-2"></a>

###### International guideline: ciclosporin adverse effects, embryotoxicity, and comparison with long-term corticosteroids

> “but this drug cannot be recommended as standard treatment due to a higher incidence of adverse effects, especially with long‐term use”
> “However, ciclosporin has a far better risk/benefit ratio compared to long‐term use of steroids.”
> “ciclosporin, although not teratogenic, is embryotoxic in animal models and is associated with preterm delivery and low birth weight in human infants.”
> “Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.5-3"></a>

###### Draft joint task force guideline: calcineurin inhibitor after advanced systemic therapy

> “advanced systemic therapy, the panel suggests adding a calcineurin inhibitor rather than not adding one.”
> “rather than adding an oral calcineurin inhibitor such as cyclosporine or”
> “Calcineurin inhibitors may also serve as a longer bridge or later-line control strategy when”

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="topic-2.2.2.1.5-4"></a>

###### Cyclosporine meta-analysis: response rates and dose-dependent adverse events

> “Eighteen studies (909 participants) including 2 randomized controlled trials were included, with 125, 363, and 266 patients with CSU receiving very low (<2 mg/kg/d), low (from 2 to< 4 mg/kg/d), and moderate (4-5 mg/kg/d) doses of CsA, respectively.”
> “The overall response rate to CsA treatment with low to moderate doses at 4, 8, and 12 weeks was 54%, 66%, and 73%, respectively.”
> “Among patients treated with very low, low, and moderate doses of CsA, 6%, 23%, and 57% experienced 1 or more adverse event, respectively.”
> “Given the limited number and quality of studies, our results should be interpreted with caution.”
> “We suggest that the appropriate dosage of CsA for CSU may range from 1 to 5 mg/kg/d, and 3 mg/kg/d is a reasonable starting dose for most patients.”

Source: [Kulthanan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916431/)

<a id="topic-2.2.2.1.5-5"></a>

###### Network meta-analysis for the joint task force guideline: cyclosporine effective but among the most harmful

> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Cyclosporine may be among the most effective for improving urticaria activity but may be among the most harmful in increasing the frequency of any adverse events.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.1.5-6"></a>

###### Predictors of response to cyclosporine: systematic review

> “This study aimed to systemically review literature relating to factors that could potentially predict a favorable response to cyclosporine A (CsA) treatment for chronic spontaneous urticaria (CSU).”
> “A total of 13 studies (404 patients with CSU and 200 healthy patients) were included.”
> “Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.”

Source: [Kulthanan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658402/)

<a id="topic-2.2.2.1.5-7"></a>

###### Type IIb autoimmune CSU: good response to cyclosporine

> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti–thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab, and a good response to cyclosporine.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Systemic Corticosteroids for Acute Exacerbations

<a id="topic-2.2.2.1.6-1"></a>

###### International guideline: short rescue course for acute exacerbations and against long-term use

> “We recommend against the long‐term use of systemic glucocorticosteroids or depot preparations in CU.”
> “We suggest considering a short course of rescue systemic glucocorticosteroids in patients with an acute exacerbation of CU.”
> “For acute urticaria and acute exacerbations of CSU, a short course of oral corticosteroids, that is, treatment of a maximum of up to 10 days, may, however, be helpful to reduce disease duration/activity”
> “Nevertheless, well‐designed randomized clinical trials are lacking.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.6-2"></a>

###### International guideline: prednisone-equivalent dose, licensing, and use in children

> “If systemic corticosteroids are used, doses between 20–50 mg/day of prednisone equivalent are needed (dose is appropriate for adults and not children).”
> “Because such high doses will have side effects over the long term, we strongly recommend against the prolonged use of corticosteroids.”
> “Depending on the country it must be noted that steroids are also not licensed for CU”
> “a short course of corticosteroids as advised in the algorithm should be used only as a very restricted measure in children.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.6-3"></a>

###### Corticosteroid use, adverse events, and health care resource use in a Novartis-funded US claims study

> “This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).”
> “Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.”
> “The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users.”
> “The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.”
> “More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.”
> “This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.2.1.6-4"></a>

###### Corticosteroids as the most prescribed treatment in a US claims cohort with diagnosed CSU

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Corticosteroids were the most prescribed treatment during follow-up among the 166,195 patients prescribed at least 1 treatment (94.3%).”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary: antihistamine-refractory and uncontrolled disease

- Updosing: in a meta-analysis, 63·2% (95% CI 57 to 69·6) of participants with CSU who did not respond to a standard antihistamine dose responded to updosing; the authors state that study weakness and heterogeneity made a final conclusion difficult. A dose-response network meta-analysis of 211 trials (22,187 participants) suggested that there may be diminishing additional benefit beyond standard dosing (8 more per 100 participants improving by a minimal important difference with a double dose and 16 more with a quadruple dose).
- Real-world control: in the AWARE study, sponsored by the manufacturer of omalizumab, uncontrolled CSU (UCT below 12) at Month 24 was reported in 23.2% (26 of 112) of participants on non-sedating H1-antihistamines, 41.9% (44 of 105) on updosed non-sedating H1-antihistamines, and 27.1% (78 of 288) on omalizumab.
- US claims: proxy events for uncontrolled CSU (prescriptions for corticosteroids, biologics, or immunosuppressants, or CSU-related inpatient, emergency department, or urgent care visits) occurred in 59.1% of adults with diagnosed CSU, and, excluding over-the-counter medication and antihistamines, corticosteroids were the most prescribed treatment after diagnosis (78.3% of 200,298 adults; 68.2% systemic).

Source: [Guillén-Aguinaga et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27237730/); [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030); [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/); [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/); [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.2.1.7-2"></a>

###### Summary: response and nonresponse to omalizumab

- Week 12 response: in CSU Trial 1 of the label, UAS7=0 was reported in 36% with omalizumab 300 mg and 9% with placebo. In participants symptomatic despite H1-antihistamines at up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists, UAS7 of 6 or less was reached by 132 (52.4%) with omalizumab 300 mg and 10 (12.0%) with placebo, and UAS7 = 0 by 85 (33.7%) and 4 (4.8%).
- Insufficient response: the international guideline states that omalizumab at higher doses, shorter intervals, or both is off-label. Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients refractory to standard-dose omalizumab may respond with higher doses or more frequent administration. Type IIb autoimmune CSU is characterized by poor response to antihistamines and to omalizumab.
- Persistence: in a meta-analysis of 8 observational studies (4516 participants), median omalizumab drug survival was 3.1 years, 7-year survival was 30% in CSU alone, and autoimmune comorbidity was associated with discontinuation for lack of efficacy (HR 2.03; 95% CI 1.20 to 3.41).
- Safety: the label estimates anaphylaxis in at least 0.2% of patients from postmarketing reports and directs that omalizumab be initiated only in a healthcare setting equipped to manage anaphylaxis.

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf); [Kaplan et al. (2013)](https://doi.org/10.1016/j.jaci.2013.05.013); [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004); [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010); [Altayf et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42714921/)

<a id="topic-2.2.2.1.7-3"></a>

###### Summary: response and nonresponse to dupilumab and remibrutinib

- Dupilumab: in anti-IgE-naive participants, UAS7 = 0 at Week 24 was reported in 22 (32.4%) with dupilumab and 9 (13.2%) with placebo in CUPID Study A, and in 22 (30.1%) and 13 (17.3%) in Study C. CUPID Study B, in 108 participants who were inadequate responders to or intolerant of anti-IgE treatment, did not meet its primary endpoint (ISS7 at Week 24). The international guideline states that dupilumab efficacy is likely to be less pronounced than that of omalizumab, and a network meta-analysis states that its impact on quality of life is uncertain and that no dupilumab trial addressed angioedema activity.
- Remibrutinib: at Week 12, UAS7 = 0 was reported in 96 (31.1%) with remibrutinib and 16 (10.5%) with placebo in REMIX-1, and in 83 (27.9%) and 10 (6.5%) in REMIX-2. The label reports bleeding in 9% of patients treated with remibrutinib and 2% with placebo over the 24-week controlled period, requires interruption for 3 to 7 days before and after surgery, and advises avoiding use with strong or moderate CYP3A4 inhibitors or inducers and in hepatic impairment (Child-Pugh A, B, and C); safety and effectiveness have not been established in pediatric patients. The network meta-analysis commissioned for the US guideline states that the safety profile of remibrutinib is less certain.

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf); [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004); [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

###### Summary: ciclosporin and systemic corticosteroid harms, cost, and preferences

- Ciclosporin is off-label for urticaria and the international guideline recommends it only for severe disease refractory to licensed treatments. In a meta-analysis of 18 studies (909 participants), response to low to moderate doses was 54%, 66%, and 73% at 4, 8, and 12 weeks, and 6%, 23%, and 57% of participants on very low, low, and moderate doses had 1 or more adverse events. The guideline states that ciclosporin is embryotoxic in animal models and associated with preterm delivery and low birth weight.
- The international guideline recommends against long-term systemic corticosteroids and suggests a rescue course of up to 10 days for acute exacerbations. In US claims, the 10 most common adverse events after systemic corticosteroid initiation, including hypertension, lipid disorders, diabetes, and cataracts, occurred in higher proportions of corticosteroid users than non-users, and the proportion with adverse events generally increased with longer use.
- The international guideline acknowledges that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost and that ciclosporin is restricted by its safety profile. Across 18 studies of patient values and preferences (28,497 participants), oral or topical treatments were favored over injections and infusions were least favored (moderate certainty).

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [Kulthanan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916431/); [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/); [Chu et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/41060663/)

<a id="topic-2.2.2.1.7-5"></a>

###### Response to updosed antihistamines in non-responders to standard doses: meta-analysis

> “We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.”
> “The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).”
> “However, the relative weakness of the studies and the significant heterogeneity among them made it difficult to reach a final conclusion.”

Source: [Guillén-Aguinaga et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27237730/)

<a id="topic-2.2.2.1.7-6"></a>

###### Uncontrolled CSU at Month 24 on antihistamines and on omalizumab: AWARE, sponsored by the manufacturer of omalizumab

> “AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.”
> “The proportion of patients with uncontrolled CSU (UCT score <12) dropped from 78% (n/N = 1641/2104) at baseline to 28.7% (n/N = 269/936) after two years of participation in the AWARE study.”
> “Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.”
> “Further studies are needed to understand the differences between guideline recommendations and reported management.”

Source: [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/)

<a id="topic-2.2.2.1.7-7"></a>

###### Uncontrolled CSU among treated participants in a US claims cohort

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Proxy events representing uncontrolled CSU (any record of prescriptions for corticosteroids, biologics, or immunosuppressants [excluding all antihistamines and over-the-counter medication] or any CSU-related inpatient admissions or emergency department or urgent care visits) were used to identify patients with uncontrolled CSU.”
> “Proxy events were observed in 59.1% of the patients.”
> “Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.2.1.7-8"></a>

###### Insufficient response to licensed-dose omalizumab and off-label updosing

> “Patients with urticaria who do not show sufficient benefit from treatment with omalizumab at the licensed dose of 300 mg every 4 weeks can be treated with omalizumab at higher doses, shorter intervals, or both.”
> “Patients need to be informed that omalizumab updosing is off‐label.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.7-9"></a>

###### Type IIb autoimmune CSU: poor response to antihistamines and omalizumab

> “Despite omalizumab’s high efficacy, a significant proportion of patients require third-line treatment, which, at present, is limited to cyclosporine”
> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti–thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.2.1.7-10"></a>

###### Dupilumab in participants symptomatic despite anti-IgE treatment: CUPID Study B did not meet the primary endpoint

> “while CUPID Study B included patients who remained symptomatic despite H1 antihistamine and anti-IgE treatments.”
> “The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.7-11"></a>

###### Omalizumab: anaphylaxis boxed warning and initiation in a healthcare setting

> “Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR.”
> “In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006.”
> “Initiate XOLAIR only in a healthcare setting equipped to manage anaphylaxis”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.7-12"></a>

###### Remibrutinib: bleeding and interruption around surgery

> “In clinical trials, mucocutaneous-related bleeding occurred in 9% of patients who received RHAPSIDO”
> “Interrupt treatment with RHAPSIDO for 3 to 7 days pre- and post-surgery or invasive procedures”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.7-13"></a>

###### Cost and safety restrictions on advanced therapies and ciclosporin in the international guideline

> “alternative treatments are needed for the remaining unresponsive patients.”
> “but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost, and that ciclosporin restricted due to its safety profile.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.7-14"></a>

###### Ciclosporin and systemic corticosteroid harms

> “Adverse events appear to be dose dependent and occur in more than half the patients treated with moderate doses of CsA.”

Source: [Kulthanan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916431/)

> “The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.2.1.7-15"></a>

###### Patient values and preferences: oral treatments favored over injections

> “The search resulted in 18 studies addressing the values and preferences among 28 497 participants.”
> “Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage-oral or topical treatments were favored over injections, with the least favored being infusions.”

Source: [Chu et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/41060663/)

<a id="topic-2.2.2.1.7-16"></a>

###### Omalizumab drug survival and discontinuation for lack of efficacy

> “The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).”
> “Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%).”
> “Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)”

Source: [Altayf et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42714921/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The 2026 international guideline sequences treatment as a standard-dose second-generation H1-antihistamine first line, updosing up to 4-fold second line, then add-on omalizumab (recommended), dupilumab, or remibrutinib (both suggested) for CSU unresponsive to high-dose antihistamines, and off-label ciclosporin for CU unresponsive to licensed treatments. The guideline states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges cost restrictions on the three advanced therapies, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A US Joint Task Force guideline that addresses the sequencing of conventional and advanced therapies was in draft for member review in 2026; the network meta-analysis commissioned for it rated standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib among the most effective with high certainty. In a primary care pathway, patients who remain symptomatic and adherent after up to four times the standard antihistamine dose should be referred for specialist evaluation, where total IgE and IgG-anti-TPO may be tested to indicate the likelihood of response to omalizumab. The barzolvolimab phase 3 trials, which study adults with CSU who remain symptomatic despite H1 antihistamine treatment, enrolled 1,939 participants, including advanced therapy-experienced or refractory participants, and are designed to detect a difference in an omalizumab-refractory subpopulation. The manufacturer describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.” It is supplied for the trials in 1 mL pre-filled syringes for subcutaneous injection, which the manufacturer states allows potential self-administration at home.

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [ACAAI JTF chronic urticaria guideline announcement (2026)](https://college.acaai.org/new-chronic-urticaria-practice-parameter-update-puts-greater-emphasis-on-core-concepts-patient-centered-implementation/); [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004); [Ryan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9533216/); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm); [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.2.2.2-2"></a>

###### International guideline update: development method

> “This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-3"></a>

###### Proposed population: adults symptomatic despite H1 antihistamine treatment

> “The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.2.2.2-4"></a>

###### Manufacturer positioning: first-line therapy in severe disease or angioedema and second-line advanced therapy

> “We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.2.2.2-5"></a>

###### Enrollment of advanced therapy-experienced participants and design for an omalizumab-refractory subpopulation

> “1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU.”
> “The studies are designed to detect a clinically meaningful difference between each of the active arms versus placebo in the overall population as well as in the subpopulation of omalizumab refractory participants.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.2-6"></a>

###### Care setting: subcutaneous pre-filled syringe with potential self-administration at home

> “The subcutaneous formulation allows for potential self-administration at home, eliminating the need for intravenous dosing in a hospital or clinic setting.”
> “Drug product manufacturing into 1 mL pre-filled syringes has been completed and pre-filled syringes are actively being used in Phase 3 trials.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.2.2.2-7"></a>

###### International guideline treatment algorithm: antihistamines, then omalizumab, dupilumab, or remibrutinib, then ciclosporin

> “We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.”
> “We recommend updosing of a 2nd generation H1-antihistamine up to 4-fold in patients with chronic urticaria unresponsive to a standard-dosed 2nd generation H1-antihistamines as second-line treatment before other treatments are considered.”
> “We recommend adding on omalizumab* for the treatment of patients with CU unresponsive to high doses of 2nd generation H1-antihistamines.”
> “We suggest using dupilumab* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.”
> “We suggest using remibrutinib* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.”
> “We suggest using ciclosporin* for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-8"></a>

###### International guideline: positioning of remibrutinib and ciclosporin after omalizumab

> “The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high-dose antihistamine and omalizumab treatment.”
> “Ciclosporin is off-label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-9"></a>

###### International guideline: cost and safety restrictions on advanced therapies

> “It is strongly recommended to stick to the treatment algorithm, but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost, and that ciclosporin restricted due to its safety profile.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-10"></a>

###### International guideline: treatments under development that reduce mast cell numbers

> “Novel treatments currently under development aim to better regulate Type 2 immunity, or silence mast cells via inhibitory receptors, or to reduce mast cell numbers.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-11"></a>

###### Specialist care: biomarker testing and referral for comorbidities

> “In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “Therefore, any findings from the patient's medical history, physical examination, or basic testing that suggest the presence of a comorbidity or consequence of CSU should prompt further investigations.”
> “These may include screening for specific diseases by questionnaires, provocation tests, further laboratory tests, or a referral to a specialist.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-12"></a>

###### Primary care pathway: specialist referral after up to fourfold antihistamine dosing

> “Urticaria is a common condition presenting both as acute and chronic disease within primary care.”
> “If symptoms are controlled on any dose of a long-acting non-sedating antihistamine up to a maximum of four times the standard dose or if the symptoms have spontaneously remitted, no referral is necessary.”
> “The corollary of this is that all patients who remain symptomatic and who have been adherent to medication, should be referred for specialist evaluation.”

Source: [Ryan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9533216/)

<a id="topic-2.2.2.2-13"></a>

###### Draft US joint task force guideline: member review and scope, including sequencing of advanced therapies

> “When draft clinical guidelines or practice parameters are developed by the Joint Task Force on Practice Parameters (JTFPP), ACAAI and AAAAI have the opportunity to ask members to review and comment on the drafts.”
> “The 2026 guideline focuses in greater depth on CU in children and adults, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), angioedema associated with CU, disease monitoring, comorbidities, health disparities, special populations, patient and caregiver experience, and sequencing of conventional and advanced therapies.”

Source: [ACAAI JTF chronic urticaria guideline announcement (2026)](https://college.acaai.org/new-chronic-urticaria-practice-parameter-update-puts-greater-emphasis-on-core-concepts-patient-centered-implementation/)

<a id="topic-2.2.2.2-14"></a>

###### Network meta-analysis commissioned for the draft US guideline: comparative effectiveness of systemic treatments

> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “This study was commissioned by the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology through the Joint Task Force on Practice Parameters for Chronic Urticaria.”
> “With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes.”
> “The safety profile of remibrutinib, however, is less certain.”
> “Dupilumab improved urticaria activity, but its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity.”
> “Cyclosporine may be among the most effective for improving urticaria activity but may be among the most harmful in increasing the frequency of any adverse events.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Barzolvolimab phase 2: efficacy at Week 12 and Week 52 by baseline total IgE

> “Barzolvolimab treatment demonstrated rapid and strong efficacy in a Phase 2 study in CSU and was well tolerated.”
> “Patients receiving placebo, or barzolvolimab at 150 mg Q4W or 300 mg Q8W were subgrouped according to baseline IgE levels as previously defined”
> “Analysis was conducted in patients with observable data Weeks 12 and 52.”
> “Similarly strong efficacy was observed in patients with normal/high (≥ 40 IU/mL) or low (< 40 IU/mL) IgE levels for both dosing regimens”
> “Adjusted p-value was non-significant for all comparisons between normal/high vs IgE low subgroups in indicated analyses.”
> “The rate ratio (95% CI) of achieving a complete response in patients with low compared to normal/high baseline IgE was 1.37 (0.74-2.55) and 1.24 (0.71-2.16) in the 150 mg Q4W and 300 mg Q8W groups, respectively.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

<a id="topic-2.2.2.3-2"></a>

###### Barzolvolimab phase 2: Week 12 response with and without prior omalizumab

> “Adults with antihistamine-refractory CSU (urticaria activity score over 7 days [UAS7] ≥ 16) in a phase 2 double-blind placebo-controlled trial were randomized 1:1:1:1”
> “The disease of patients with and without prior omalizumab treatment responded similarly.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

> “Barzolvolimab demonstrated strong improvement in UAS7 independent of omalizumab status at Week 12. Approximately 20% (n=41) of enrolled patients received prior treatment with omalizumab and more than half of these patients had omalizumab-refractory disease. These patients experienced a similar clinical benefit as the overall treated population within their individual dosing groups consistent with the barzolvolimab mechanism of action.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.3-3"></a>

###### Barzolvolimab phase 3: complete response (UAS7=0) at Week 12, overall and in omalizumab-refractory participants

> “Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Population and arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
| --- | --- | --- |
| Overall, placebo | “9.3%” | “12.6%” |
| Overall, 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| Overall, 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |
| Omalizumab-refractory, placebo | “9.3%” | “15.1%” |
| Omalizumab-refractory, 150 mg Q4W | “55.3% (p<.00001)” | “41.7% (p=.0089)” |
| Omalizumab-refractory, 300 mg Q8W | “44.3% (p=.00017)” | “46.4% (p=.0036)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “P-values are based on adjusted odds ratio of logistic regression models.”
> “A higher proportion of patients achieved Complete Response (UAS7=0) vs placebo at Week 12 in the sub-population of patients with CSU refractory to omalizumab.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Patients treated with omalizumab at approved doses for at least 3 months and whose symptoms never responded or who responded initially but symptoms subsequently returned, or who discontinued omalizumab due to intolerance”
> “Adjusted proportions are based on logistic regression model with multiple imputation method.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.2.2.3-4"></a>

###### Barzolvolimab phase 2: efficacy by baseline serum tryptase

> “In a Phase 2 study in patients with H1-antihistamine-refractory CSU (NCT05368285)”
> “Baseline serum tryptase was not associated with baseline disease severity nor was predictive of barzolvolimab response”
> “Barzolvolimab demonstrated clinical benefits for patients with CSU regardless of their baseline serum tryptase levels”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-2.2.2.3-5"></a>

###### International guideline: biomarkers of response to omalizumab, dupilumab, ciclosporin, and antihistamines

> “In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited”
> “Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response”
> “Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity”
> “For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.3-6"></a>

###### Systematic review of predictors of response to antihistamines, omalizumab, and cyclosporine

> “A systematic search was performed by two independent researchers using the MEDLINE/PubMed database with specific keywords and 73 studies included in the review.”
> “High disease activity, high levels of C-reactive protein and D-dimer are robust predictors for a poor or no response to sgAHs.”
> “Poor or no response to omalizumab is robustly predicted by low serum levels of total IgE.”
> “A good response to cyclosporine is robustly predicted by a positive basophil histamine release assay, whereas low total IgE is an emerging predictor.”

Source: [Fok et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33539587/)

<a id="topic-2.2.2.3-7"></a>

###### Omalizumab: response by baseline total IgE and its change after 4 weeks

> “Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE).”
> “Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032).”
> “Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016).”

Source: [Ertas et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29083482/)

<a id="topic-2.2.2.3-8"></a>

###### Type IIb autoimmune endotype: low total IgE and poor response to antihistamines and omalizumab

> “Type IIb autoimmune CSU is mediated by autoantibodies that activate mast cells, for example, via IgE and FcεRI, and is present in less than 10% of patients with CSU when strict criteria are used, that is, triple positivity of autologous serum skin test, immunoassays for IgG autoantibodies, and basophil activation tests.”
> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti-thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab, and a good response to cyclosporine.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.2.3-9"></a>

###### Dupilumab: response by baseline total IgE in omalizumab-naive participants

> “Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons)”
> “In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.”
> “Dupilumab is an effective treatment in H1-antihistamine (H1-AH)-resistant, omalizumab-naïve patients with CSU, regardless of their baseline serum total IgE levels.”

Source: [Maurer et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11393262/)

<a id="topic-2.2.2.3-10"></a>

###### Dupilumab: label statements on baseline IgE and on anti-IgE inadequate responders

> “Improvements in ISS7 and UAS7 at Week 24 were consistent regardless of the patients’ baseline IgE level.”
> “CUPID Study B enrolled 108 adult and pediatric patients 12 years of age and older with CSU who were inadequate responders (N=104) to H1 antihistamines and anti-IgE treatments or intolerant (N=4) to anti-IgE therapy.”
> “The DUPIXENT group in CUPID Study B did not meet statistical significance for reduction in the primary endpoint ISS7 at Week 24.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.3-11"></a>

###### Remibrutinib and dupilumab by prior biologic or omalizumab exposure

> “Dupilumab, a monoclonal antibody that blocks IL-4Ra, significantly reduced urticaria activity in omalizumab-naive patients and showed smaller effects in patients who were omalizumab-intolerant/incomplete responders”
> “Remibrutinib, a Bruton's tyrosine kinase inhibitor, has shown efficacy in reducing disease symptoms in patients remaining symptomatic despite treatment with sgH1-AH in clinical trials, without a notable drop in efficacy in biologic-experienced patients”

Source: [Kolkhir et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466147/)

<a id="topic-2.2.2.3-12"></a>

###### Cyclosporine: candidate predictors of response, systematic review

> “Our systematic review showed that positive autologous serum skin test results, positive baseline basophil histamine release assays, positive baseline basophil activation test responses, elevated baseline plasma D-dimer levels, elevated baseline serum interleukin (IL)-2, IL-5, and tumor necrosis factor-alpha (TNF-α) levels, and low baseline serum IgE levels might assist in predicting favorable CsA responses in CSU patients.”
> “Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.”

Source: [Kulthanan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658402/)

<a id="topic-2.2.2.3-13"></a>

###### Comparative network meta-analysis: consistency across age groups and baseline severity

> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “Findings were consistent across age groups and baseline severity, and were robust to subgroup analyses.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.3-14"></a>

###### Sex: poorer urticaria control in women across treatment categories, CURE registry

> “Specifically, a higher number of females had UCT < 12 compared to males when treated with standard-dose second-generation anti-histamines (sgAH; 70.5% vs. 66.9%, p = 0.02), high-dose sgAH (76.5% vs. 73.9%, p = 0.02), omalizumab (53% vs. 44.5%, p = 0.03) and cyclosporine (81% vs. 71.4%, p = 0.02; Table 4).”
> “We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria.”

Source: [Kocatürk et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12723574/)

Additional sources: [Gericke et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27838346/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Patient-reported outcome measures at every visit

> “Patients should be assessed for disease activity, impact, and control at all visits.”
> “The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.”
> “It is important to highlight that patients need good counseling regarding continuous treatment and using PROMs, especially about using the UAS.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.4-2"></a>

###### Stepping treatment up or down: assess, act and adjust, and reassess

> “Treatment should follow the basic principles of treating as much as needed and as little as possible, taking into consideration that the activity of the disease may vary”
> “This implies stepping up or stepping down in the treatment algorithm according to the course of disease following the principle assess, act & adjust, and reassess”
> “In order to constantly ensure the right level of treatment, patients need to be seen at regular intervals and adjustments are recommended based on the level of symptoms.”
> “For a stepdown, different options exist but costs are especially relevant for choosing which step to take first.”
> “In patients who are in the range of UCT 12–15, therefore a step up might also be required.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.4-3"></a>

###### Omalizumab interval prolongation after 3 months of complete control

> “After 3 months of complete control, the interval can be prolonged until long as first wheals reappear, as there is no tachyphylaxis nor have relevant levels of blocking antibodies been described.”
> “But also, the prolongation of the interval is strictly off label.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.4-4"></a>

###### Omalizumab step-down: relapse after gradual de-escalation versus abrupt discontinuation, meta-analysis

> “Random-effects proportion meta-analysis (DerSimonian-Laird logit transformation) determined pooled relapse rates.”
> “The overall pooled post-discontinuation relapse rate was 39.5% (95% CI: 30.1%-49.7%; I2 = 91.5%).”
> “Gradual de-escalation achieved a significantly lower pooled relapse rate compared with abrupt discontinuation (31.2% [95% CI: 20.3%-44.7%] vs. 48.9% [95% CI: 37.0%-61.0%], Qb = 8.12, df = 1, p = 0.004).”
> “Concomitant angioedema was an independent risk factor for relapse (multivariate OR = 2.399, p = 0.004), whereas gradual de-escalation was protective (multivariate OR = 0.373, p = 0.005).”

Source: [Doğan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42886609/)

<a id="topic-2.2.2.4-5"></a>

###### Omalizumab cessation: pooled relapse across 41 stopping risk sets and uncertainty about stopping strategies

> “Forty-one stopping risk sets (2,643 patients; 1,209 source-reported events) yielded a pooled proportion of 46.6% (95% CI 40.1-53.2%; I2 = 87.7%; prediction interval 16.0-79.9%).”
> “Relapse is common after cessation, but high heterogeneity limits individualized prediction. The evidence cannot establish a causal advantage of any stopping strategy or an immune endotype for recurrence.”

Source: [Yücel and Ünal (2026)](https://pubmed.ncbi.nlm.nih.gov/43019004/)

<a id="topic-2.2.2.4-6"></a>

###### Primary care: periodic antihistamine withdrawal to test for remission

> “Urticaria is a common condition presenting both as acute and chronic disease within primary care.”
> “However, when remission is achieved, therapy should be withdrawn every 3–6 months to discover whether natural remission has occurred.”

Source: [Ryan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9533216/)

<a id="topic-2.2.2.4-7"></a>

###### Barzolvolimab phase 3b extension: observation of controlled disease and retreatment on flare

> “In addition, a global Phase 3b long term extension (LTE) study has been established for patient entry after completion of the EMBARQ - CSU Phase 3 trials.”
> “The study will consist of 2 Groups: Group 1 (Observation Group), containing patients whose disease remains well controlled (UAS7<16) and Group 2 (Barzolvolimab Retreatment Group) containing patients whose disease is currently moderate to severe (UAS7≥16).”
> “Patients in the observation group (Group 1) whose CSU flares to a UAS7>/=16 in the first 6 months of the LTE will also be able to receive treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.4-8"></a>

###### Treatment escalation in practice: CURE registry

> “This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.”
> “About one-third (28.6%) of patients clinically eligible for escalation at BL (UCT < 12) did not receive step-up treatment (18.0%) or were even stepped down (10.6%) and remained poorly controlled at FU.”
> “Many patients with poorly controlled CSU do not receive guideline-recommended treatment escalation and remain symptomatic on their current treatments, which deserves further attention.”

Source: [Kolkhir et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466147/)

<a id="topic-2.2.2.4-9"></a>

###### Mobile app symptom monitoring: adherence to CRUSE

> “We analysed data from 2085 patients (66,114 days). Median adherence to the CRUSE app was of 22 days (24.4% of 90 days).”
> “Our findings suggest that age, male sex, residence in Europe, and the use of monoclonal antibodies are significant factors associated with increased adherence to the CRUSE app.”

Source: [Viegas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12619656/)

<a id="topic-2.2.2.4-10"></a>

###### Quality-improvement study of guideline-based care: planned steps

> “Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU”
> “Step 3 (quality improvement): Recommendations to improve quality of care for patients with CSU will be developed, pilot tested, and published.”

Source: [Mosnaim et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12814061/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Treatment goal: continuous complete control and normal quality of life

> “The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life”
> “The overall aim of the management in urticaria is to achieve complete control of symptoms and maintain effective and safe treatment until the disease is gone.”
> “The UCT cutoff value for well-controlled disease is 12 out of 16 possible points.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.7-2"></a>

###### Manufacturer statement of complete response as the treatment goal

> “Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment and achieving complete response is directly correlated to the greatest improvements in quality of life for patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.7-3"></a>

###### Complete control and complete response rates in practice, CURE registry

> “We report real-world data from the global Chronic Urticaria Registry (CURE)”
> “At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2.”
> “Few patients had CR/CC of their CSU at baseline entry. Disease control strongly related to good sleep and better HRQoL; therefore, it is important to aim for CR in CSU treatment.”

Source: [Kolkhir et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36481420/)

<a id="topic-2.2.2.7-4"></a>

###### Complete response after treatment escalation, CURE registry

> “This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.”
> “Complete response was defined as UCT = 16 with a ≥ 3-point increase.”
> “After treatment escalation from BL to FU, 5.3% (no treatment to licensed-dose sgH1-AH), 6.0% (licensed-dose sgH1-AH to up-dosed sgH1-AH), and 28.4% (any dose sgH1-AH to omalizumab) achieved complete response.”
> “Appropriate treatment escalation improves CSU control, although only about a quarter of patients achieve a complete response, indicating the need for novel treatments.”

Source: [Kolkhir et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466147/)

<a id="topic-2.2.2.7-5"></a>

###### Uncontrolled disease at Month 24 in antihistamine-refractory CSU, AWARE study sponsored by the manufacturer of omalizumab

> “AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.”
> “Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.”

Source: [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/)

<a id="topic-2.2.2.7-6"></a>

###### Real-world omalizumab complete response rate, meta-analysis supported by Novartis

> “In this meta-analysis of 67 published reports on real-world effectiveness, omalizumab therapy was associated with an average 25.6-point improvement in weekly Urticaria Activity Score (vs a 14.9 to 22.1 point improvement reported in clinical trials), a 4.7 point improvement in Urticaria Activity Score, a complete response rate of 72.2%, a partial response rate of 17.8%, and an average adverse event rate of 4.0% (vs 2.9%-8.0% reported in clinical trials).”
> “This study was supported by Novartis.”

Source: [Tharp et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439579/)

<a id="topic-2.2.2.7-7"></a>

###### Barzolvolimab phase 3: complete response (UAS7=0) at Week 12

> “Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.”
> “Significantly more patients achieved Complete Response (UAS7=0) with both barzolvolimab doses vs. placebo at Weeks 12 and 24.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
| --- | --- | --- |
| Placebo | “9.3%” | “12.6%” |
| 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.2.2.7-8"></a>

###### Barzolvolimab phase 2: complete response at Week 52 and at Week 76, seven months after the last dose

> “In Phase 2, the primary endpoint was met at Week 12 and patients on study continued to receive barzolvolimab for a total of 52 weeks of treatment.”
> “71% of patients treated with barzolvolimab 150 mg Q4W and 52% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 52.”
> “41% of patients treated with barzolvolimab 150 mg Q4W and 35% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 76.”
> “At Week 76, seven months after receiving their final dose of barzolvolimab, patients continued to experience profound clinical benefit on study.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
